IND_ID,IND_CODE,INDICATOR_NAME,YEAR,COUNTRY,DISAGGR_1,UNIT,VALUE,VALUE_LO,VALUE_HI
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cyprus,Previously treated,Percentage,7,1.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cyprus,Previously treated,Percentage,6.8,1.3,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cyprus,Previously treated,Percentage,6.6,1.1,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Czechia,Previously treated,Percentage,12,7.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Czechia,Previously treated,Percentage,12,7.2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Czechia,Previously treated,Percentage,13,7,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Czechia,Previously treated,Percentage,13,6.8,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Czechia,Previously treated,Percentage,13,6.6,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Czechia,Previously treated,Percentage,13,6.2,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Czechia,Previously treated,Percentage,13,5.9,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Czechia,Previously treated,Percentage,13,5.7,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Czechia,Previously treated,Percentage,14,5.4,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Democratic People's Republic of Korea,Previously treated,Percentage,16,9.8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Democratic People's Republic of Korea,Previously treated,Percentage,15,9,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Democratic People's Republic of Korea,Previously treated,Percentage,15,8.2,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Democratic People's Republic of Korea,Previously treated,Percentage,14,7.1,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Democratic People's Republic of Korea,Previously treated,Percentage,14,6.2,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Democratic People's Republic of Korea,Previously treated,Percentage,13,5.3,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Democratic People's Republic of Korea,Previously treated,Percentage,13,4.5,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cabo Verde,Previously treated,Percentage,15,2.6,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cabo Verde,Previously treated,Percentage,14,2.9,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cabo Verde,Previously treated,Percentage,13,3.5,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cabo Verde,Previously treated,Percentage,13,3.7,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cabo Verde,Previously treated,Percentage,12,3.7,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cabo Verde,Previously treated,Percentage,12,3.6,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cabo Verde,Previously treated,Percentage,11,3.4,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cabo Verde,Previously treated,Percentage,11,3.1,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cambodia,Previously treated,Percentage,12,7,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cambodia,Previously treated,Percentage,12,7.1,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Democratic People's Republic of Korea,Previously treated,Percentage,12,3.9,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Democratic People's Republic of Korea,Previously treated,Percentage,12,3.4,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Democratic Republic of the Congo,Previously treated,Percentage,6.9,6.2,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Democratic Republic of the Congo,Previously treated,Percentage,8,7.4,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Democratic Republic of the Congo,Previously treated,Percentage,9.2,8.7,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Democratic Republic of the Congo,Previously treated,Percentage,11,10,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Democratic Republic of the Congo,Previously treated,Percentage,12,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Democratic Republic of the Congo,Previously treated,Percentage,14,14,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Democratic Republic of the Congo,Previously treated,Percentage,16,16,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cambodia,Previously treated,Percentage,11,6.9,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cambodia,Previously treated,Percentage,11,6.9,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cambodia,Previously treated,Percentage,11,6.7,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cambodia,Previously treated,Percentage,11,6.4,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cambodia,Previously treated,Percentage,11,6.1,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cambodia,Previously treated,Percentage,11,5.6,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cambodia,Previously treated,Percentage,11,5.4,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cameroon,Previously treated,Percentage,15,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cameroon,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cameroon,Previously treated,Percentage,11,9.8,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Democratic Republic of the Congo,Previously treated,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Democratic Republic of the Congo,Previously treated,Percentage,21,20,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Denmark,Previously treated,Percentage,2.1,0.81,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Denmark,Previously treated,Percentage,2.3,0.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Denmark,Previously treated,Percentage,2.5,0.97,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Denmark,Previously treated,Percentage,2.7,1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Denmark,Previously treated,Percentage,2.9,1.1,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Denmark,Previously treated,Percentage,3.1,1.1,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Denmark,Previously treated,Percentage,3.4,1.1,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Denmark,Previously treated,Percentage,3.7,1.2,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Austria,Previously treated,Percentage,38,26,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Austria,Previously treated,Percentage,41,27,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Austria,Previously treated,Percentage,43,28,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Austria,Previously treated,Percentage,46,30,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Austria,Previously treated,Percentage,49,31,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Azerbaijan,Previously treated,Percentage,30,29,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Azerbaijan,Previously treated,Percentage,30,28,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Azerbaijan,Previously treated,Percentage,29,28,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Azerbaijan,Previously treated,Percentage,28,28,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Azerbaijan,Previously treated,Percentage,28,27,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cameroon,Previously treated,Percentage,9.9,8.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cameroon,Previously treated,Percentage,8.7,8,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cameroon,Previously treated,Percentage,7.6,7,8.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cameroon,Previously treated,Percentage,6.7,6.1,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cameroon,Previously treated,Percentage,5.8,5.2,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cameroon,Previously treated,Percentage,5.1,4.4,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Canada,Previously treated,Percentage,3.7,2.1,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Canada,Previously treated,Percentage,4,2.3,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Canada,Previously treated,Percentage,4.4,2.4,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Canada,Previously treated,Percentage,4.7,2.5,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Denmark,Previously treated,Percentage,4,1.2,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Djibouti,Previously treated,Percentage,27,21,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Djibouti,Previously treated,Percentage,24,18,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Djibouti,Previously treated,Percentage,21,15,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Djibouti,Previously treated,Percentage,18,12,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Djibouti,Previously treated,Percentage,16,9.6,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Djibouti,Previously treated,Percentage,14,7.7,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Djibouti,Previously treated,Percentage,12,5.8,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Djibouti,Previously treated,Percentage,10,4.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Djibouti,Previously treated,Percentage,8.8,3.4,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Azerbaijan,Previously treated,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Azerbaijan,Previously treated,Percentage,26,26,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Azerbaijan,Previously treated,Percentage,26,25,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Azerbaijan,Previously treated,Percentage,25,24,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bahamas,Previously treated,Percentage,15,3.2,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bahamas,Previously treated,Percentage,14,3.3,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bahamas,Previously treated,Percentage,14,3.3,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bahamas,Previously treated,Percentage,13,3.4,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bahamas,Previously treated,Percentage,13,3.4,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bahamas,Previously treated,Percentage,13,3.3,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Canada,Previously treated,Percentage,5.1,2.7,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Canada,Previously treated,Percentage,5.5,2.8,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Canada,Previously treated,Percentage,6,2.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Canada,Previously treated,Percentage,6.5,3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Canada,Previously treated,Percentage,7.1,3.1,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cayman Islands,Previously treated,Percentage,16,1.2,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cayman Islands,Previously treated,Percentage,15,1.4,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cayman Islands,Previously treated,Percentage,14,1.4,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cayman Islands,Previously treated,Percentage,14,1.5,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cayman Islands,Previously treated,Percentage,13,1.5,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Dominica,Previously treated,Percentage,9.4,0.82,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Dominica,Previously treated,Percentage,9.1,0.88,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Dominica,Previously treated,Percentage,8.9,0.91,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Dominica,Previously treated,Percentage,8.7,0.93,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Dominica,Previously treated,Percentage,8.5,0.92,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Dominica,Previously treated,Percentage,8.4,0.87,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Dominica,Previously treated,Percentage,8.3,0.88,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Dominica,Previously treated,Percentage,8.2,0.86,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Dominica,Previously treated,Percentage,8.2,0.77,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Dominican Republic,Previously treated,Percentage,36,30,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Afghanistan,Previously treated,Percentage,23,19,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Afghanistan,Previously treated,Percentage,21,18,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Afghanistan,Previously treated,Percentage,19,17,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Afghanistan,Previously treated,Percentage,18,16,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Afghanistan,Previously treated,Percentage,16,15,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Afghanistan,Previously treated,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Afghanistan,Previously treated,Percentage,13,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Afghanistan,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Afghanistan,Previously treated,Percentage,11,9.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Albania,Previously treated,Percentage,16,9.2,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nicaragua,Previously treated,Percentage,7.8,5.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nicaragua,Previously treated,Percentage,7.4,5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nicaragua,Previously treated,Percentage,7.1,4.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nicaragua,Previously treated,Percentage,6.8,4.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nicaragua,Previously treated,Percentage,6.5,3.8,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nicaragua,Previously treated,Percentage,6.2,3.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nicaragua,Previously treated,Percentage,5.9,3.2,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nicaragua,Previously treated,Percentage,5.6,2.8,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nicaragua,Previously treated,Percentage,5.4,2.5,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Niger,Previously treated,Percentage,19,16,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Maldives,Previously treated,Percentage,5.7,0.55,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Maldives,Previously treated,Percentage,5.4,0.54,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Maldives,Previously treated,Percentage,5.2,0.52,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Maldives,Previously treated,Percentage,5,0.46,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Maldives,Previously treated,Percentage,4.8,0.4,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mali,Previously treated,Percentage,18,7.3,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mali,Previously treated,Percentage,16,7.5,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mali,Previously treated,Percentage,15,7.8,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mali,Previously treated,Percentage,13,8.2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mali,Previously treated,Percentage,12,8.3,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mali,Previously treated,Percentage,11,8.1,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Gambia,Previously treated,Percentage,5.7,2.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Gambia,Previously treated,Percentage,5.9,3.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Gambia,Previously treated,Percentage,6.1,3.6,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Gambia,Previously treated,Percentage,6.4,4.1,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Gambia,Previously treated,Percentage,6.7,4.7,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Gambia,Previously treated,Percentage,7.1,4.8,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Georgia,Previously treated,Percentage,33,32,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Georgia,Previously treated,Percentage,33,31,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Georgia,Previously treated,Percentage,32,30,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Georgia,Previously treated,Percentage,31,30,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Georgia,Previously treated,Percentage,30,28,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Georgia,Previously treated,Percentage,29,27,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Georgia,Previously treated,Percentage,27,25,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Georgia,Previously treated,Percentage,26,23,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Georgia,Previously treated,Percentage,24,21,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Germany,Previously treated,Percentage,18,15,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Germany,Previously treated,Percentage,19,16,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Germany,Previously treated,Percentage,20,16,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Germany,Previously treated,Percentage,21,17,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Germany,Previously treated,Percentage,22,17,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Germany,Previously treated,Percentage,23,18,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Israel,Previously treated,Percentage,13,5.5,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Israel,Previously treated,Percentage,12,4.5,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Israel,Previously treated,Percentage,11,3.7,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Israel,Previously treated,Percentage,9.8,3,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Israel,Previously treated,Percentage,9,2.4,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Italy,Previously treated,Percentage,7.7,6.1,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Italy,Previously treated,Percentage,6.9,5.4,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Italy,Previously treated,Percentage,6.2,4.7,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Italy,Previously treated,Percentage,5.5,4.1,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Italy,Previously treated,Percentage,5,3.6,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Italy,Previously treated,Percentage,4.4,3.1,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Albania,Previously treated,Percentage,16,9.2,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Albania,Previously treated,Percentage,16,9.2,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Albania,Previously treated,Percentage,16,9.1,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Albania,Previously treated,Percentage,16,8.9,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Albania,Previously treated,Percentage,16,8.5,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Albania,Previously treated,Percentage,16,8.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Albania,Previously treated,Percentage,16,8,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Albania,Previously treated,Percentage,16,7.7,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Algeria,Previously treated,Percentage,20,1.7,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Algeria,Previously treated,Percentage,19,1.7,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bahamas,Previously treated,Percentage,12,3.2,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bahamas,Previously treated,Percentage,12,3,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bahamas,Previously treated,Percentage,12,2.9,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bahrain,Previously treated,Percentage,25,3.5,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bahrain,Previously treated,Percentage,23,3.3,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bahrain,Previously treated,Percentage,21,3.3,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bahrain,Previously treated,Percentage,19,3.2,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bahrain,Previously treated,Percentage,18,2.8,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bahrain,Previously treated,Percentage,16,2.4,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bahrain,Previously treated,Percentage,15,2.1,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Niger,Previously treated,Percentage,18,15,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Niger,Previously treated,Percentage,16,14,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Niger,Previously treated,Percentage,15,13,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Niger,Previously treated,Percentage,14,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Niger,Previously treated,Percentage,12,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Niger,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Niger,Previously treated,Percentage,10,9.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Niger,Previously treated,Percentage,9.5,8.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nigeria,Previously treated,Percentage,17,9.8,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nigeria,Previously treated,Percentage,16,8.2,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nigeria,Previously treated,Percentage,15,6.8,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Dominican Republic,Previously treated,Percentage,31,26,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Dominican Republic,Previously treated,Percentage,26,23,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Dominican Republic,Previously treated,Percentage,22,19,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Dominican Republic,Previously treated,Percentage,18,16,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Dominican Republic,Previously treated,Percentage,15,13,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Dominican Republic,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Dominican Republic,Previously treated,Percentage,10,8.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Dominican Republic,Previously treated,Percentage,8.2,6.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ecuador,Previously treated,Percentage,25,23,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ecuador,Previously treated,Percentage,24,22,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Algeria,Previously treated,Percentage,18,1.7,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Algeria,Previously treated,Percentage,17,1.7,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Algeria,Previously treated,Percentage,16,1.6,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Algeria,Previously treated,Percentage,15,1.6,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Algeria,Previously treated,Percentage,14,1.6,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Algeria,Previously treated,Percentage,14,1.6,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Algeria,Previously treated,Percentage,13,1.5,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,American Samoa,Previously treated,Percentage,37,5.6,82
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,American Samoa,Previously treated,Percentage,36,5.8,80
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,American Samoa,Previously treated,Percentage,34,6,77
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cayman Islands,Previously treated,Percentage,12,1.4,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cayman Islands,Previously treated,Percentage,12,1.4,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cayman Islands,Previously treated,Percentage,11,1.3,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cayman Islands,Previously treated,Percentage,11,1.2,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Central African Republic,Previously treated,Percentage,15,0.83,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Central African Republic,Previously treated,Percentage,15,0.9,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Central African Republic,Previously treated,Percentage,14,1,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Central African Republic,Previously treated,Percentage,14,1.2,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Central African Republic,Previously treated,Percentage,13,1.3,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Central African Republic,Previously treated,Percentage,13,1.2,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nigeria,Previously treated,Percentage,14,5.6,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nigeria,Previously treated,Percentage,13,4.7,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nigeria,Previously treated,Percentage,12,3.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nigeria,Previously treated,Percentage,11,3.2,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nigeria,Previously treated,Percentage,10,2.6,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nigeria,Previously treated,Percentage,9.8,2.1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Niue,Previously treated,Percentage,24,2,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Niue,Previously treated,Percentage,23,1.9,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Niue,Previously treated,Percentage,22,1.9,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Niue,Previously treated,Percentage,21,1.9,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Niue,Previously treated,Percentage,20,2,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bahrain,Previously treated,Percentage,14,1.8,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bahrain,Previously treated,Percentage,12,1.6,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bangladesh,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bangladesh,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bangladesh,Previously treated,Percentage,11,10,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bangladesh,Previously treated,Percentage,9.4,9,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bangladesh,Previously treated,Percentage,8.4,8.1,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bangladesh,Previously treated,Percentage,7.5,7.2,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bangladesh,Previously treated,Percentage,6.6,6.4,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bangladesh,Previously treated,Percentage,5.9,5.6,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,American Samoa,Previously treated,Percentage,33,5.9,74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,American Samoa,Previously treated,Percentage,32,5.8,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,American Samoa,Previously treated,Percentage,30,5.1,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,American Samoa,Previously treated,Percentage,29,4.5,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,American Samoa,Previously treated,Percentage,28,4,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,American Samoa,Previously treated,Percentage,27,3.4,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Andorra,Previously treated,Percentage,15,1.9,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Andorra,Previously treated,Percentage,15,2,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Andorra,Previously treated,Percentage,15,2.1,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Andorra,Previously treated,Percentage,15,2.1,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Central African Republic,Previously treated,Percentage,13,1.2,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Central African Republic,Previously treated,Percentage,12,1.3,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Central African Republic,Previously treated,Percentage,12,1.2,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Chad,Previously treated,Percentage,3,1.1,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Chad,Previously treated,Percentage,3,1.4,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Chad,Previously treated,Percentage,3.1,1.6,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Chad,Previously treated,Percentage,3.2,1.9,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Chad,Previously treated,Percentage,3.3,2.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Chad,Previously treated,Percentage,3.4,2.6,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Chad,Previously treated,Percentage,3.5,2.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bangladesh,Previously treated,Percentage,5.2,4.9,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Barbados,Previously treated,Percentage,14,1.4,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Barbados,Previously treated,Percentage,13,1.4,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Barbados,Previously treated,Percentage,13,1.4,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Barbados,Previously treated,Percentage,12,1.3,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Barbados,Previously treated,Percentage,11,1.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Barbados,Previously treated,Percentage,11,1.3,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Barbados,Previously treated,Percentage,10,1.2,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Barbados,Previously treated,Percentage,9.9,1.1,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Barbados,Previously treated,Percentage,9.6,0.98,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Chad,Previously treated,Percentage,3.6,3.1,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Chad,Previously treated,Percentage,3.8,3,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Chile,Previously treated,Percentage,6.2,5.2,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Chile,Previously treated,Percentage,6.1,5.1,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Chile,Previously treated,Percentage,6.1,5,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Chile,Previously treated,Percentage,6,4.8,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Chile,Previously treated,Percentage,6,4.7,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Chile,Previously treated,Percentage,5.9,4.5,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Chile,Previously treated,Percentage,5.9,4.3,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Chile,Previously treated,Percentage,5.8,4.2,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Chile,Previously treated,Percentage,5.8,4,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Italy,Previously treated,Percentage,4,2.7,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Italy,Previously treated,Percentage,3.6,2.4,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Italy,Previously treated,Percentage,3.2,2,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Jamaica,Previously treated,Percentage,11,0.92,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Jamaica,Previously treated,Percentage,11,0.94,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Jamaica,Previously treated,Percentage,10,0.97,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Jamaica,Previously treated,Percentage,9.7,0.99,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Jamaica,Previously treated,Percentage,9.3,1.1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Jamaica,Previously treated,Percentage,9,1.2,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Jamaica,Previously treated,Percentage,8.7,1.2,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belarus,Previously treated,Percentage,67,66,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belarus,Previously treated,Percentage,67,66,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belarus,Previously treated,Percentage,66,65,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belarus,Previously treated,Percentage,66,64,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belarus,Previously treated,Percentage,65,64,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belarus,Previously treated,Percentage,64,63,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belarus,Previously treated,Percentage,64,62,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belarus,Previously treated,Percentage,63,61,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belarus,Previously treated,Percentage,63,61,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belgium,Previously treated,Percentage,10,6.6,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belgium,Previously treated,Percentage,10,6.5,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Jamaica,Previously treated,Percentage,8.5,1.3,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Jamaica,Previously treated,Percentage,8.2,1.2,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Japan,Previously treated,Percentage,10,2.7,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Japan,Previously treated,Percentage,10,2.4,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Japan,Previously treated,Percentage,10,2.2,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Japan,Previously treated,Percentage,10,1.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Japan,Previously treated,Percentage,10,1.7,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Japan,Previously treated,Percentage,10,1.6,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Japan,Previously treated,Percentage,10,1.4,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Japan,Previously treated,Percentage,11,1.3,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Japan,Previously treated,Percentage,11,1.1,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,China,Previously treated,Percentage,24,23,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,China,Previously treated,Percentage,23,23,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,China,Previously treated,Percentage,23,22,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,China,Previously treated,Percentage,22,22,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,China,Previously treated,Percentage,21,21,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,China,Previously treated,Percentage,21,20,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,China,Previously treated,Percentage,20,20,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,China,Previously treated,Percentage,19,19,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,China,Previously treated,Percentage,19,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"China, Hong Kong SAR",Previously treated,Percentage,3.9,3.1,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"China, Hong Kong SAR",Previously treated,Percentage,3.8,2.9,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belgium,Previously treated,Percentage,11,6.4,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belgium,Previously treated,Percentage,11,6.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belgium,Previously treated,Percentage,12,6.4,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belgium,Previously treated,Percentage,12,6.4,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belgium,Previously treated,Percentage,13,6.3,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belgium,Previously treated,Percentage,13,6.3,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belgium,Previously treated,Percentage,14,6.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belize,Previously treated,Percentage,27,11,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belize,Previously treated,Percentage,25,11,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belize,Previously treated,Percentage,23,10,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Andorra,Previously treated,Percentage,15,2.1,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Andorra,Previously treated,Percentage,15,2.1,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Andorra,Previously treated,Percentage,16,2.2,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Andorra,Previously treated,Percentage,16,2.2,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Andorra,Previously treated,Percentage,16,2.1,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Angola,Previously treated,Percentage,17,0.95,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Angola,Previously treated,Percentage,17,1.1,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Angola,Previously treated,Percentage,17,1.2,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Angola,Previously treated,Percentage,16,1.2,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Angola,Previously treated,Percentage,16,1.3,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"China, Hong Kong SAR",Previously treated,Percentage,3.7,2.8,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"China, Hong Kong SAR",Previously treated,Percentage,3.5,2.6,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"China, Hong Kong SAR",Previously treated,Percentage,3.4,2.5,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"China, Hong Kong SAR",Previously treated,Percentage,3.3,2.4,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"China, Hong Kong SAR",Previously treated,Percentage,3.2,2.2,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"China, Hong Kong SAR",Previously treated,Percentage,3.1,2.1,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"China, Hong Kong SAR",Previously treated,Percentage,3,2,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"China, Macao SAR",Previously treated,Percentage,9.7,7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"China, Macao SAR",Previously treated,Percentage,9.4,6.8,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"China, Macao SAR",Previously treated,Percentage,9.2,6.5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Jordan,Previously treated,Percentage,21,9.6,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Jordan,Previously treated,Percentage,20,8.3,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Jordan,Previously treated,Percentage,19,7.2,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Jordan,Previously treated,Percentage,17,6,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Jordan,Previously treated,Percentage,16,5,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Jordan,Previously treated,Percentage,15,4.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Jordan,Previously treated,Percentage,14,3.7,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Jordan,Previously treated,Percentage,13,3.1,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Jordan,Previously treated,Percentage,12,2.5,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kazakhstan,Previously treated,Percentage,54,53,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kazakhstan,Previously treated,Percentage,54,53,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Angola,Previously treated,Percentage,16,1.4,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Angola,Previously treated,Percentage,16,1.4,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Angola,Previously treated,Percentage,16,1.4,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Angola,Previously treated,Percentage,16,1.4,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Anguilla,Previously treated,Percentage,20,1.6,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Anguilla,Previously treated,Percentage,19,1.6,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Anguilla,Previously treated,Percentage,18,1.6,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Anguilla,Previously treated,Percentage,18,1.6,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Anguilla,Previously treated,Percentage,17,1.6,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Anguilla,Previously treated,Percentage,16,1.5,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belize,Previously treated,Percentage,22,9.8,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belize,Previously treated,Percentage,20,9.1,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belize,Previously treated,Percentage,18,8.3,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belize,Previously treated,Percentage,17,7.4,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belize,Previously treated,Percentage,16,6.7,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belize,Previously treated,Percentage,15,5.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Benin,Previously treated,Percentage,10,8.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Benin,Previously treated,Percentage,9.2,8,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Benin,Previously treated,Percentage,8.4,7.3,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Benin,Previously treated,Percentage,7.7,6.6,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Benin,Previously treated,Percentage,7,6,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"China, Macao SAR",Previously treated,Percentage,9,6.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"China, Macao SAR",Previously treated,Percentage,8.7,5.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"China, Macao SAR",Previously treated,Percentage,8.5,5.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"China, Macao SAR",Previously treated,Percentage,8.3,5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"China, Macao SAR",Previously treated,Percentage,8.1,4.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"China, Macao SAR",Previously treated,Percentage,8,4.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Colombia,Previously treated,Percentage,7.4,5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Colombia,Previously treated,Percentage,6.3,3.9,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Colombia,Previously treated,Percentage,5.3,3,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Colombia,Previously treated,Percentage,4.5,2.3,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Benin,Previously treated,Percentage,6.4,5.4,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Benin,Previously treated,Percentage,5.8,4.8,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Benin,Previously treated,Percentage,5.3,4.2,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Benin,Previously treated,Percentage,4.8,3.7,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bermuda,Previously treated,Percentage,22,1.3,77
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bermuda,Previously treated,Percentage,21,1.4,74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bermuda,Previously treated,Percentage,20,1.4,71
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bermuda,Previously treated,Percentage,19,1.5,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bermuda,Previously treated,Percentage,19,1.5,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bermuda,Previously treated,Percentage,18,1.5,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Anguilla,Previously treated,Percentage,15,1.4,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Anguilla,Previously treated,Percentage,15,1.4,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Anguilla,Previously treated,Percentage,14,1.3,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Antigua and Barbuda,Previously treated,Percentage,16,0.57,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Antigua and Barbuda,Previously treated,Percentage,16,0.61,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Antigua and Barbuda,Previously treated,Percentage,15,0.72,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Antigua and Barbuda,Previously treated,Percentage,15,0.84,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Antigua and Barbuda,Previously treated,Percentage,15,0.96,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Antigua and Barbuda,Previously treated,Percentage,15,0.98,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Antigua and Barbuda,Previously treated,Percentage,15,1,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Colombia,Previously treated,Percentage,3.8,1.8,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Colombia,Previously treated,Percentage,3.2,1.3,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Colombia,Previously treated,Percentage,2.7,1,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Colombia,Previously treated,Percentage,2.3,0.79,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Colombia,Previously treated,Percentage,2,0.6,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Comoros,Previously treated,Percentage,9.9,0.84,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Comoros,Previously treated,Percentage,9.4,0.85,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Comoros,Previously treated,Percentage,9,0.84,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Comoros,Previously treated,Percentage,8.6,0.83,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Comoros,Previously treated,Percentage,8.3,0.83,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kazakhstan,Previously treated,Percentage,54,53,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kazakhstan,Previously treated,Percentage,53,53,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kazakhstan,Previously treated,Percentage,53,53,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kazakhstan,Previously treated,Percentage,53,52,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kazakhstan,Previously treated,Percentage,53,52,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kazakhstan,Previously treated,Percentage,53,52,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kazakhstan,Previously treated,Percentage,53,52,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kenya,Previously treated,Percentage,5.5,4.4,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kenya,Previously treated,Percentage,5.2,4.4,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kenya,Previously treated,Percentage,5,4.5,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Niue,Previously treated,Percentage,19,1.8,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Niue,Previously treated,Percentage,18,1.6,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Niue,Previously treated,Percentage,17,1.5,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Niue,Previously treated,Percentage,16,1.3,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,North Macedonia,Previously treated,Percentage,8,5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,North Macedonia,Previously treated,Percentage,7.6,4.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,North Macedonia,Previously treated,Percentage,7.3,4.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,North Macedonia,Previously treated,Percentage,7,3.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,North Macedonia,Previously treated,Percentage,6.8,3.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,North Macedonia,Previously treated,Percentage,6.5,3.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Comoros,Previously treated,Percentage,8,0.84,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Comoros,Previously treated,Percentage,7.7,0.9,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Comoros,Previously treated,Percentage,7.5,0.94,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Comoros,Previously treated,Percentage,7.3,0.91,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Congo,Previously treated,Percentage,21,14,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Congo,Previously treated,Percentage,19,14,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Congo,Previously treated,Percentage,17,14,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Congo,Previously treated,Percentage,15,13,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Congo,Previously treated,Percentage,14,11,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Congo,Previously treated,Percentage,13,8.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Congo,Previously treated,Percentage,12,6.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Antigua and Barbuda,Previously treated,Percentage,15,1.1,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Antigua and Barbuda,Previously treated,Percentage,15,1.1,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Argentina,Previously treated,Percentage,12,4.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Argentina,Previously treated,Percentage,12,3.7,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Argentina,Previously treated,Percentage,11,3.2,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Argentina,Previously treated,Percentage,11,2.7,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Argentina,Previously treated,Percentage,10,2.3,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Argentina,Previously treated,Percentage,10,2,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Argentina,Previously treated,Percentage,9.9,1.7,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Argentina,Previously treated,Percentage,9.6,1.5,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Argentina,Previously treated,Percentage,9.4,1.3,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Armenia,Previously treated,Percentage,48,44,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Armenia,Previously treated,Percentage,48,44,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Armenia,Previously treated,Percentage,47,43,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Armenia,Previously treated,Percentage,47,43,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Armenia,Previously treated,Percentage,47,42,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Armenia,Previously treated,Percentage,47,42,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Armenia,Previously treated,Percentage,47,41,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Armenia,Previously treated,Percentage,46,40,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Armenia,Previously treated,Percentage,46,40,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Aruba,Previously treated,Percentage,21,1.7,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,North Macedonia,Previously treated,Percentage,6.3,2.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,North Macedonia,Previously treated,Percentage,6.1,2.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,North Macedonia,Previously treated,Percentage,5.9,2.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Northern Mariana Islands,Previously treated,Percentage,5.7,0.61,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Northern Mariana Islands,Previously treated,Percentage,5.5,0.63,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Northern Mariana Islands,Previously treated,Percentage,5.4,0.61,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Northern Mariana Islands,Previously treated,Percentage,5.4,0.58,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Northern Mariana Islands,Previously treated,Percentage,5.3,0.56,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Northern Mariana Islands,Previously treated,Percentage,5.3,0.56,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Northern Mariana Islands,Previously treated,Percentage,5.3,0.56,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kenya,Previously treated,Percentage,4.8,4.4,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kenya,Previously treated,Percentage,4.6,4.2,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kenya,Previously treated,Percentage,4.4,3.9,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kenya,Previously treated,Percentage,4.3,3.6,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kenya,Previously treated,Percentage,4.1,3.3,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kenya,Previously treated,Percentage,3.9,3,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kiribati,Previously treated,Percentage,23,5.9,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kiribati,Previously treated,Percentage,21,5.8,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kiribati,Previously treated,Percentage,20,6.1,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kiribati,Previously treated,Percentage,18,6.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ecuador,Previously treated,Percentage,23,22,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ecuador,Previously treated,Percentage,22,21,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ecuador,Previously treated,Percentage,21,20,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ecuador,Previously treated,Percentage,20,19,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ecuador,Previously treated,Percentage,19,18,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ecuador,Previously treated,Percentage,19,17,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ecuador,Previously treated,Percentage,18,16,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Egypt,Previously treated,Percentage,24,22,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Egypt,Previously treated,Percentage,22,21,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Egypt,Previously treated,Percentage,20,19,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Egypt,Previously treated,Percentage,19,17,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kiribati,Previously treated,Percentage,17,6.2,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kiribati,Previously treated,Percentage,16,5.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kiribati,Previously treated,Percentage,15,5.5,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kiribati,Previously treated,Percentage,14,5.1,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kiribati,Previously treated,Percentage,13,4.6,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kuwait,Previously treated,Percentage,14,1,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kuwait,Previously treated,Percentage,13,1.1,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kuwait,Previously treated,Percentage,13,1.1,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kuwait,Previously treated,Percentage,12,1.2,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kuwait,Previously treated,Percentage,12,1.2,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kuwait,Previously treated,Percentage,12,1.2,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Egypt,Previously treated,Percentage,17,16,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Egypt,Previously treated,Percentage,16,14,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Egypt,Previously treated,Percentage,14,13,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Egypt,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Egypt,Previously treated,Percentage,12,10,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,El Salvador,Previously treated,Percentage,6.3,3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,El Salvador,Previously treated,Percentage,6.1,2.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,El Salvador,Previously treated,Percentage,6,2.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,El Salvador,Previously treated,Percentage,5.8,2.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,El Salvador,Previously treated,Percentage,5.6,2.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Northern Mariana Islands,Previously treated,Percentage,5.3,0.55,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Northern Mariana Islands,Previously treated,Percentage,5.3,0.49,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Norway,Previously treated,Percentage,7.9,4.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Norway,Previously treated,Percentage,8.2,4.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Norway,Previously treated,Percentage,8.5,4.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Norway,Previously treated,Percentage,8.8,4.7,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Norway,Previously treated,Percentage,9.1,4.6,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Norway,Previously treated,Percentage,9.5,4.5,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Norway,Previously treated,Percentage,9.8,4.4,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Norway,Previously treated,Percentage,10,4.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,El Salvador,Previously treated,Percentage,5.5,2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,El Salvador,Previously treated,Percentage,5.4,1.8,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,El Salvador,Previously treated,Percentage,5.2,1.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,El Salvador,Previously treated,Percentage,5.1,1.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Equatorial Guinea,Previously treated,Percentage,36,23,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Equatorial Guinea,Previously treated,Percentage,33,23,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Equatorial Guinea,Previously treated,Percentage,30,22,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Equatorial Guinea,Previously treated,Percentage,27,21,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Equatorial Guinea,Previously treated,Percentage,25,20,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Equatorial Guinea,Previously treated,Percentage,22,19,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Aruba,Previously treated,Percentage,20,1.7,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Aruba,Previously treated,Percentage,18,1.6,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Aruba,Previously treated,Percentage,17,1.5,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Aruba,Previously treated,Percentage,16,1.5,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Aruba,Previously treated,Percentage,14,1.3,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Aruba,Previously treated,Percentage,13,1.2,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Aruba,Previously treated,Percentage,12,1.1,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Aruba,Previously treated,Percentage,12,0.95,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Australia,Previously treated,Percentage,15,11,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Australia,Previously treated,Percentage,14,9.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Australia,Previously treated,Percentage,13,9.1,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Norway,Previously treated,Percentage,11,4.3,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,23,2.1,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,22,2.1,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,20,2,62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,18,1.9,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,17,1.9,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,15,1.8,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,14,1.6,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kuwait,Previously treated,Percentage,12,1.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kuwait,Previously treated,Percentage,11,1.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kuwait,Previously treated,Percentage,11,1.3,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kyrgyzstan,Previously treated,Percentage,60,58,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kyrgyzstan,Previously treated,Percentage,59,58,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kyrgyzstan,Previously treated,Percentage,58,57,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kyrgyzstan,Previously treated,Percentage,57,55,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kyrgyzstan,Previously treated,Percentage,55,54,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kyrgyzstan,Previously treated,Percentage,54,53,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kyrgyzstan,Previously treated,Percentage,53,52,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bermuda,Previously treated,Percentage,17,1.5,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bermuda,Previously treated,Percentage,16,1.4,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bermuda,Previously treated,Percentage,16,1.2,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bhutan,Previously treated,Percentage,26,20,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bhutan,Previously treated,Percentage,24,19,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bhutan,Previously treated,Percentage,22,18,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bhutan,Previously treated,Percentage,21,16,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bhutan,Previously treated,Percentage,19,15,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bhutan,Previously treated,Percentage,18,14,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bhutan,Previously treated,Percentage,16,12,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bhutan,Previously treated,Percentage,15,11,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Congo,Previously treated,Percentage,11,5.6,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Congo,Previously treated,Percentage,9.9,4.4,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cook Islands,Previously treated,Percentage,37,5.9,80
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cook Islands,Previously treated,Percentage,35,5.5,79
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cook Islands,Previously treated,Percentage,34,5.1,76
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cook Islands,Previously treated,Percentage,32,4.9,74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cook Islands,Previously treated,Percentage,30,4.6,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cook Islands,Previously treated,Percentage,29,4.3,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cook Islands,Previously treated,Percentage,27,4,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cook Islands,Previously treated,Percentage,26,3.7,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,13,1.5,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"occupied Palestinian territory, including east Jerusalem",Previously treated,Percentage,11,1.4,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Oman,Previously treated,Percentage,8,4.2,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Oman,Previously treated,Percentage,6.6,3.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Oman,Previously treated,Percentage,5.5,2.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Oman,Previously treated,Percentage,4.5,1.9,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Oman,Previously treated,Percentage,3.8,1.4,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Oman,Previously treated,Percentage,3.1,1.1,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Oman,Previously treated,Percentage,2.6,0.82,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Oman,Previously treated,Percentage,2.1,0.62,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Equatorial Guinea,Previously treated,Percentage,20,16,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Equatorial Guinea,Previously treated,Percentage,18,13,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Equatorial Guinea,Previously treated,Percentage,16,11,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Eritrea,Previously treated,Percentage,7.1,3.3,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Eritrea,Previously treated,Percentage,7.2,3.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Eritrea,Previously treated,Percentage,7.4,4.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Eritrea,Previously treated,Percentage,7.5,4.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Eritrea,Previously treated,Percentage,7.7,5.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Eritrea,Previously treated,Percentage,7.9,5.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Eritrea,Previously treated,Percentage,8.2,6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bhutan,Previously treated,Percentage,14,9.6,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bolivia (Plurinational State of),Previously treated,Percentage,11,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bolivia (Plurinational State of),Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bolivia (Plurinational State of),Previously treated,Percentage,10,9.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bolivia (Plurinational State of),Previously treated,Percentage,9.7,8.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bolivia (Plurinational State of),Previously treated,Percentage,9.2,8.3,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bolivia (Plurinational State of),Previously treated,Percentage,8.8,7.8,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bolivia (Plurinational State of),Previously treated,Percentage,8.3,7.3,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bolivia (Plurinational State of),Previously treated,Percentage,7.9,6.8,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kyrgyzstan,Previously treated,Percentage,52,51,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kyrgyzstan,Previously treated,Percentage,51,49,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lao People's Democratic Republic,Previously treated,Percentage,15,7.3,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lao People's Democratic Republic,Previously treated,Percentage,14,7.6,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lao People's Democratic Republic,Previously treated,Percentage,13,7.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lao People's Democratic Republic,Previously treated,Percentage,12,8,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lao People's Democratic Republic,Previously treated,Percentage,11,8.1,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lao People's Democratic Republic,Previously treated,Percentage,10,8.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lao People's Democratic Republic,Previously treated,Percentage,9.3,7.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Australia,Previously treated,Percentage,13,8.2,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Australia,Previously treated,Percentage,12,7.3,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Australia,Previously treated,Percentage,11,6.6,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Australia,Previously treated,Percentage,11,5.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Australia,Previously treated,Percentage,11,5.1,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Australia,Previously treated,Percentage,10,4.5,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Austria,Previously treated,Percentage,29,21,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Austria,Previously treated,Percentage,31,22,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Austria,Previously treated,Percentage,33,23,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Austria,Previously treated,Percentage,36,25,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Eritrea,Previously treated,Percentage,8.4,5.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Eritrea,Previously treated,Percentage,8.8,5.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Estonia,Previously treated,Percentage,52,47,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Estonia,Previously treated,Percentage,52,47,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Estonia,Previously treated,Percentage,52,47,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Estonia,Previously treated,Percentage,52,47,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Estonia,Previously treated,Percentage,53,47,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Estonia,Previously treated,Percentage,53,46,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Estonia,Previously treated,Percentage,53,46,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Estonia,Previously treated,Percentage,53,46,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Estonia,Previously treated,Percentage,53,46,62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Republic of Korea,Previously treated,Percentage,9.6,9.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Republic of Korea,Previously treated,Percentage,9.3,8.9,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Republic of Korea,Previously treated,Percentage,9,8.6,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Republic of Korea,Previously treated,Percentage,8.8,8.3,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Republic of Korea,Previously treated,Percentage,8.5,8,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Republic of Moldova,Previously treated,Percentage,57,56,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Republic of Moldova,Previously treated,Percentage,57,56,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Republic of Moldova,Previously treated,Percentage,56,55,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Republic of Moldova,Previously treated,Percentage,56,55,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Republic of Moldova,Previously treated,Percentage,55,54,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bolivia (Plurinational State of),Previously treated,Percentage,7.4,6.4,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bosnia and Herzegovina,Previously treated,Percentage,3.5,2.2,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bosnia and Herzegovina,Previously treated,Percentage,3.4,2,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bosnia and Herzegovina,Previously treated,Percentage,3.3,1.9,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bosnia and Herzegovina,Previously treated,Percentage,3.1,1.7,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bosnia and Herzegovina,Previously treated,Percentage,3,1.6,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bosnia and Herzegovina,Previously treated,Percentage,2.9,1.5,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bosnia and Herzegovina,Previously treated,Percentage,2.8,1.4,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bosnia and Herzegovina,Previously treated,Percentage,2.7,1.3,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Eswatini,Previously treated,Percentage,36,32,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Eswatini,Previously treated,Percentage,35,31,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Eswatini,Previously treated,Percentage,34,30,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Eswatini,Previously treated,Percentage,33,29,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Eswatini,Previously treated,Percentage,32,28,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Eswatini,Previously treated,Percentage,31,27,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Eswatini,Previously treated,Percentage,31,26,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Eswatini,Previously treated,Percentage,30,25,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Eswatini,Previously treated,Percentage,29,24,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ethiopia,Previously treated,Percentage,15,13,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lao People's Democratic Republic,Previously treated,Percentage,8.6,7.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lao People's Democratic Republic,Previously treated,Percentage,8,6.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Latvia,Previously treated,Percentage,29,26,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Latvia,Previously treated,Percentage,28,25,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Latvia,Previously treated,Percentage,28,24,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Latvia,Previously treated,Percentage,27,24,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Latvia,Previously treated,Percentage,27,23,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Latvia,Previously treated,Percentage,26,22,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Latvia,Previously treated,Percentage,26,21,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Latvia,Previously treated,Percentage,25,21,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Oman,Previously treated,Percentage,1.8,0.47,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Pakistan,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Pakistan,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Pakistan,Previously treated,Percentage,10,9.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Pakistan,Previously treated,Percentage,8.7,8.2,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Pakistan,Previously treated,Percentage,7.6,7.2,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Pakistan,Previously treated,Percentage,6.6,6.3,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Pakistan,Previously treated,Percentage,5.7,5.5,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Pakistan,Previously treated,Percentage,5,4.7,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Pakistan,Previously treated,Percentage,4.3,4.1,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cook Islands,Previously treated,Percentage,25,3.2,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Costa Rica,Previously treated,Percentage,4.4,1.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Costa Rica,Previously treated,Percentage,4.2,1.2,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Costa Rica,Previously treated,Percentage,4,1.2,8.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Costa Rica,Previously treated,Percentage,3.9,1.1,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Costa Rica,Previously treated,Percentage,3.8,1,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Costa Rica,Previously treated,Percentage,3.7,0.92,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Costa Rica,Previously treated,Percentage,3.6,0.84,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Costa Rica,Previously treated,Percentage,3.5,0.77,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Costa Rica,Previously treated,Percentage,3.4,0.72,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Palau,Previously treated,Percentage,14,0.66,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Palau,Previously treated,Percentage,13,0.68,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Palau,Previously treated,Percentage,12,0.67,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Palau,Previously treated,Percentage,11,0.7,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Palau,Previously treated,Percentage,11,0.7,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Palau,Previously treated,Percentage,10,0.7,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Palau,Previously treated,Percentage,9.7,0.68,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Palau,Previously treated,Percentage,9.3,0.67,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Palau,Previously treated,Percentage,8.9,0.69,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Panama,Previously treated,Percentage,18,9.5,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Panama,Previously treated,Percentage,17,9,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ethiopia,Previously treated,Percentage,14,13,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ethiopia,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ethiopia,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ethiopia,Previously treated,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ethiopia,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ethiopia,Previously treated,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ethiopia,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ethiopia,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Fiji,Previously treated,Percentage,7,1.4,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Fiji,Previously treated,Percentage,6.7,1.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Republic of Moldova,Previously treated,Percentage,55,53,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Republic of Moldova,Previously treated,Percentage,55,53,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Republic of Moldova,Previously treated,Percentage,54,52,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Republic of Moldova,Previously treated,Percentage,54,51,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Romania,Previously treated,Percentage,16,15,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Romania,Previously treated,Percentage,16,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Romania,Previously treated,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Romania,Previously treated,Percentage,14,14,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Romania,Previously treated,Percentage,14,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Romania,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Fiji,Previously treated,Percentage,6.4,1.6,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Fiji,Previously treated,Percentage,6.2,1.6,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Fiji,Previously treated,Percentage,6.1,1.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Fiji,Previously treated,Percentage,5.9,1.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Fiji,Previously treated,Percentage,5.8,1.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Fiji,Previously treated,Percentage,5.7,1.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Fiji,Previously treated,Percentage,5.7,1.5,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Finland,Previously treated,Percentage,9.2,3.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Finland,Previously treated,Percentage,10,3.9,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Finland,Previously treated,Percentage,11,4,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Finland,Previously treated,Percentage,12,4.1,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cte d'Ivoire,Previously treated,Percentage,41,38,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cte d'Ivoire,Previously treated,Percentage,36,34,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cte d'Ivoire,Previously treated,Percentage,31,30,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cte d'Ivoire,Previously treated,Percentage,27,26,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cte d'Ivoire,Previously treated,Percentage,23,22,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cte d'Ivoire,Previously treated,Percentage,20,19,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cte d'Ivoire,Previously treated,Percentage,17,16,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cte d'Ivoire,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cte d'Ivoire,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Croatia,Previously treated,Percentage,5.2,2.8,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bosnia and Herzegovina,Previously treated,Percentage,2.7,1.2,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Botswana,Previously treated,Percentage,8.1,4.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Botswana,Previously treated,Percentage,7.7,3.9,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Botswana,Previously treated,Percentage,7.4,3.5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Botswana,Previously treated,Percentage,7.1,3.1,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Botswana,Previously treated,Percentage,6.8,2.8,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Botswana,Previously treated,Percentage,6.5,2.5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Botswana,Previously treated,Percentage,6.3,2.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Botswana,Previously treated,Percentage,6,2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Botswana,Previously treated,Percentage,5.8,1.8,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Brazil,Previously treated,Percentage,8.4,3.9,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Brazil,Previously treated,Percentage,8.5,3.6,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Brazil,Previously treated,Percentage,8.6,3.2,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Brazil,Previously treated,Percentage,8.8,2.9,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Brazil,Previously treated,Percentage,9,2.6,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Brazil,Previously treated,Percentage,9.2,2.4,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Brazil,Previously treated,Percentage,9.4,2.1,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Brazil,Previously treated,Percentage,9.6,1.9,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Brazil,Previously treated,Percentage,9.8,1.7,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,British Virgin Islands,Previously treated,Percentage,23,1.8,75
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,British Virgin Islands,Previously treated,Percentage,23,1.9,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,British Virgin Islands,Previously treated,Percentage,22,2,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,British Virgin Islands,Previously treated,Percentage,21,2.2,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,British Virgin Islands,Previously treated,Percentage,20,2.1,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,British Virgin Islands,Previously treated,Percentage,20,1.9,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,British Virgin Islands,Previously treated,Percentage,19,2,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,British Virgin Islands,Previously treated,Percentage,19,2,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,British Virgin Islands,Previously treated,Percentage,18,2,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Brunei Darussalam,Previously treated,Percentage,1.1,0.21,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Brunei Darussalam,Previously treated,Percentage,1.2,0.23,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Romania,Previously treated,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Romania,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Romania,Previously treated,Percentage,11,10,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Russian Federation,Previously treated,Percentage,70,70,71
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Russian Federation,Previously treated,Percentage,70,70,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Russian Federation,Previously treated,Percentage,70,69,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Russian Federation,Previously treated,Percentage,69,69,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Russian Federation,Previously treated,Percentage,69,68,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Russian Federation,Previously treated,Percentage,68,68,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Russian Federation,Previously treated,Percentage,68,67,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Panama,Previously treated,Percentage,16,8.4,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Panama,Previously treated,Percentage,15,7.5,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Panama,Previously treated,Percentage,14,6.7,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Panama,Previously treated,Percentage,13,5.7,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Panama,Previously treated,Percentage,12,4.9,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Panama,Previously treated,Percentage,12,4.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Panama,Previously treated,Percentage,11,3.5,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Papua New Guinea,Previously treated,Percentage,21,16,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Papua New Guinea,Previously treated,Percentage,18,14,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Papua New Guinea,Previously treated,Percentage,15,12,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Finland,Previously treated,Percentage,13,4.1,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Finland,Previously treated,Percentage,14,4.2,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Finland,Previously treated,Percentage,16,4.3,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Finland,Previously treated,Percentage,17,4.3,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Finland,Previously treated,Percentage,18,4.4,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,France,Previously treated,Percentage,12,6.4,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,France,Previously treated,Percentage,12,6.2,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,France,Previously treated,Percentage,12,6,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,France,Previously treated,Percentage,12,5.8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,France,Previously treated,Percentage,13,5.6,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,France,Previously treated,Percentage,13,5.4,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Latvia,Previously treated,Percentage,25,20,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lebanon,Previously treated,Percentage,27,19,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lebanon,Previously treated,Percentage,25,17,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lebanon,Previously treated,Percentage,22,15,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lebanon,Previously treated,Percentage,20,13,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lebanon,Previously treated,Percentage,18,11,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lebanon,Previously treated,Percentage,16,9.4,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lebanon,Previously treated,Percentage,15,8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lebanon,Previously treated,Percentage,13,6.8,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lebanon,Previously treated,Percentage,12,5.7,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lesotho,Previously treated,Percentage,12,9.8,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Brunei Darussalam,Previously treated,Percentage,1.2,0.25,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Brunei Darussalam,Previously treated,Percentage,1.3,0.28,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Brunei Darussalam,Previously treated,Percentage,1.4,0.29,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Brunei Darussalam,Previously treated,Percentage,1.4,0.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Brunei Darussalam,Previously treated,Percentage,1.5,0.3,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Brunei Darussalam,Previously treated,Percentage,1.6,0.29,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Brunei Darussalam,Previously treated,Percentage,1.8,0.29,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bulgaria,Previously treated,Percentage,22,18,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bulgaria,Previously treated,Percentage,21,17,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bulgaria,Previously treated,Percentage,20,15,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Croatia,Previously treated,Percentage,5.4,2.8,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Croatia,Previously treated,Percentage,5.6,2.7,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Croatia,Previously treated,Percentage,5.9,2.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Croatia,Previously treated,Percentage,6.1,2.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Croatia,Previously treated,Percentage,6.4,2.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Croatia,Previously treated,Percentage,6.7,2.5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Croatia,Previously treated,Percentage,7,2.5,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Croatia,Previously treated,Percentage,7.3,2.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cuba,Previously treated,Percentage,17,13,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cuba,Previously treated,Percentage,18,14,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lesotho,Previously treated,Percentage,11,9.2,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lesotho,Previously treated,Percentage,10,8.6,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lesotho,Previously treated,Percentage,9.1,7.9,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lesotho,Previously treated,Percentage,8.2,7.2,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lesotho,Previously treated,Percentage,7.3,6.4,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lesotho,Previously treated,Percentage,6.6,5.6,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lesotho,Previously treated,Percentage,5.9,4.9,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lesotho,Previously treated,Percentage,5.3,4.2,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Liberia,Previously treated,Percentage,9.9,1.4,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Liberia,Previously treated,Percentage,8.6,1.3,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bulgaria,Previously treated,Percentage,19,14,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bulgaria,Previously treated,Percentage,18,13,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bulgaria,Previously treated,Percentage,17,11,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bulgaria,Previously treated,Percentage,16,10,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bulgaria,Previously treated,Percentage,16,9.1,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bulgaria,Previously treated,Percentage,15,8.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Burkina Faso,Previously treated,Percentage,17,10,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Burkina Faso,Previously treated,Percentage,15,9.5,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Burkina Faso,Previously treated,Percentage,13,8.8,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Burkina Faso,Previously treated,Percentage,11,8.2,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Liberia,Previously treated,Percentage,7.5,1.3,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Liberia,Previously treated,Percentage,6.6,1.2,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Liberia,Previously treated,Percentage,5.8,1.1,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Liberia,Previously treated,Percentage,5.1,1.1,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Liberia,Previously treated,Percentage,4.5,0.96,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Liberia,Previously treated,Percentage,4,0.81,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Liberia,Previously treated,Percentage,3.6,0.67,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Libya,Previously treated,Percentage,17,1,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Libya,Previously treated,Percentage,16,1.1,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Libya,Previously treated,Percentage,16,1.1,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Burkina Faso,Previously treated,Percentage,9.8,7.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Burkina Faso,Previously treated,Percentage,8.5,7,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Burkina Faso,Previously treated,Percentage,7.3,6.1,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Burkina Faso,Previously treated,Percentage,6.3,5.3,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Burkina Faso,Previously treated,Percentage,5.5,4.4,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Burundi,Previously treated,Percentage,20,14,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Burundi,Previously treated,Percentage,19,15,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Burundi,Previously treated,Percentage,18,15,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Burundi,Previously treated,Percentage,17,14,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Burundi,Previously treated,Percentage,16,13,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cuba,Previously treated,Percentage,19,14,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cuba,Previously treated,Percentage,20,14,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cuba,Previously treated,Percentage,21,15,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cuba,Previously treated,Percentage,23,15,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cuba,Previously treated,Percentage,24,16,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cuba,Previously treated,Percentage,25,16,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cuba,Previously treated,Percentage,27,17,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Curaao,Previously treated,Percentage,21,1.6,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Curaao,Previously treated,Percentage,20,1.6,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Curaao,Previously treated,Percentage,18,1.5,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Curaao,Previously treated,Percentage,17,1.3,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Papua New Guinea,Previously treated,Percentage,13,10,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Papua New Guinea,Previously treated,Percentage,11,9,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Papua New Guinea,Previously treated,Percentage,9.2,7.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Papua New Guinea,Previously treated,Percentage,7.7,6.3,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Papua New Guinea,Previously treated,Percentage,6.5,5.2,8.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Papua New Guinea,Previously treated,Percentage,5.4,4.3,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Paraguay,Previously treated,Percentage,3.4,2.2,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Paraguay,Previously treated,Percentage,3.1,2.1,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Paraguay,Previously treated,Percentage,2.8,1.9,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Paraguay,Previously treated,Percentage,2.6,1.8,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Libya,Previously treated,Percentage,16,1.2,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Libya,Previously treated,Percentage,16,1.2,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Libya,Previously treated,Percentage,15,1.2,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Libya,Previously treated,Percentage,15,1.2,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Libya,Previously treated,Percentage,15,1.3,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Libya,Previously treated,Percentage,15,1.3,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lithuania,Previously treated,Percentage,45,43,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lithuania,Previously treated,Percentage,45,43,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lithuania,Previously treated,Percentage,44,42,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lithuania,Previously treated,Percentage,44,42,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lithuania,Previously treated,Percentage,44,42,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Burundi,Previously treated,Percentage,16,11,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Burundi,Previously treated,Percentage,15,9.5,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Burundi,Previously treated,Percentage,15,8.1,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Burundi,Previously treated,Percentage,14,6.8,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cabo Verde,Previously treated,Percentage,16,2.5,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Solomon Islands,Previously treated,Percentage,4.3,0.79,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Solomon Islands,Previously treated,Percentage,4.5,0.79,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Somalia,Previously treated,Percentage,83,63,96
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Somalia,Previously treated,Percentage,82,64,94
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Somalia,Previously treated,Percentage,81,66,93
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Curaao,Previously treated,Percentage,16,1.2,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Curaao,Previously treated,Percentage,15,1.2,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Curaao,Previously treated,Percentage,13,1.2,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Curaao,Previously treated,Percentage,12,1.2,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Curaao,Previously treated,Percentage,12,1.1,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cyprus,Previously treated,Percentage,8.8,2,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cyprus,Previously treated,Percentage,8.4,2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cyprus,Previously treated,Percentage,8,1.8,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cyprus,Previously treated,Percentage,7.7,1.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cyprus,Previously treated,Percentage,7.4,1.6,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Paraguay,Previously treated,Percentage,2.4,1.6,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Paraguay,Previously treated,Percentage,2.2,1.5,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Paraguay,Previously treated,Percentage,2,1.3,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Paraguay,Previously treated,Percentage,1.8,1.2,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Paraguay,Previously treated,Percentage,1.7,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Peru,Previously treated,Percentage,24,23,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Peru,Previously treated,Percentage,23,22,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Peru,Previously treated,Percentage,22,21,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Peru,Previously treated,Percentage,21,20,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Peru,Previously treated,Percentage,20,19,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Peru,Previously treated,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Russian Federation,Previously treated,Percentage,67,67,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Russian Federation,Previously treated,Percentage,67,66,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Rwanda,Previously treated,Percentage,9.8,8.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Rwanda,Previously treated,Percentage,8.6,7.5,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Rwanda,Previously treated,Percentage,7.6,6.6,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Rwanda,Previously treated,Percentage,6.6,5.8,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Rwanda,Previously treated,Percentage,5.8,5,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Rwanda,Previously treated,Percentage,5.1,4.3,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Rwanda,Previously treated,Percentage,4.4,3.7,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Rwanda,Previously treated,Percentage,3.9,3.2,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Peru,Previously treated,Percentage,18,17,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Peru,Previously treated,Percentage,17,16,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Peru,Previously treated,Percentage,17,16,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Philippines,Previously treated,Percentage,24,22,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Philippines,Previously treated,Percentage,24,22,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Philippines,Previously treated,Percentage,23,21,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Philippines,Previously treated,Percentage,23,21,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Philippines,Previously treated,Percentage,22,20,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Philippines,Previously treated,Percentage,21,20,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Philippines,Previously treated,Percentage,21,19,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,France,Previously treated,Percentage,13,5.2,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,France,Previously treated,Percentage,13,5.1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,France,Previously treated,Percentage,14,4.9,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,French Polynesia,Previously treated,Percentage,8.3,2.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,French Polynesia,Previously treated,Percentage,8.3,2.6,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,French Polynesia,Previously treated,Percentage,8.4,2.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,French Polynesia,Previously treated,Percentage,8.5,2.8,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,French Polynesia,Previously treated,Percentage,8.7,2.6,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,French Polynesia,Previously treated,Percentage,8.9,2.6,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,French Polynesia,Previously treated,Percentage,9.2,2.4,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Rwanda,Previously treated,Percentage,3.4,2.7,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Kitts and Nevis,Previously treated,Percentage,24,1.4,73
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Kitts and Nevis,Previously treated,Percentage,23,1.4,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Kitts and Nevis,Previously treated,Percentage,22,1.4,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Kitts and Nevis,Previously treated,Percentage,20,1.4,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Kitts and Nevis,Previously treated,Percentage,19,1.4,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Kitts and Nevis,Previously treated,Percentage,18,1.4,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Kitts and Nevis,Previously treated,Percentage,17,1.5,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Kitts and Nevis,Previously treated,Percentage,16,1.4,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Kitts and Nevis,Previously treated,Percentage,15,1.2,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Somalia,Previously treated,Percentage,79,67,90
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Somalia,Previously treated,Percentage,78,68,88
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Somalia,Previously treated,Percentage,76,69,84
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Somalia,Previously treated,Percentage,74,68,80
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Somalia,Previously treated,Percentage,72,67,77
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Somalia,Previously treated,Percentage,70,64,76
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,South Africa,Previously treated,Percentage,10,9.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,South Africa,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,South Africa,Previously treated,Percentage,11,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,South Africa,Previously treated,Percentage,12,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Lucia,Previously treated,Percentage,18,0.75,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Lucia,Previously treated,Percentage,17,0.84,62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Lucia,Previously treated,Percentage,16,0.92,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Lucia,Previously treated,Percentage,16,1,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Lucia,Previously treated,Percentage,15,1,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Lucia,Previously treated,Percentage,14,1.1,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Lucia,Previously treated,Percentage,14,1,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Lucia,Previously treated,Percentage,14,0.97,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Lucia,Previously treated,Percentage,13,0.95,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Vincent and the Grenadines,Previously treated,Percentage,15,0.95,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,French Polynesia,Previously treated,Percentage,9.5,2.3,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,French Polynesia,Previously treated,Percentage,9.8,2.1,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Gabon,Previously treated,Percentage,17,10,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Gabon,Previously treated,Percentage,18,12,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Gabon,Previously treated,Percentage,18,14,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Gabon,Previously treated,Percentage,19,16,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Gabon,Previously treated,Percentage,20,17,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Gabon,Previously treated,Percentage,21,18,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Gabon,Previously treated,Percentage,22,18,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Gabon,Previously treated,Percentage,24,17,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Gabon,Previously treated,Percentage,25,16,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,South Africa,Previously treated,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,South Africa,Previously treated,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,South Africa,Previously treated,Percentage,14,14,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,South Africa,Previously treated,Percentage,15,15,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,South Africa,Previously treated,Percentage,16,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,South Sudan,Previously treated,Percentage,12,3.1,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,South Sudan,Previously treated,Percentage,11,3.4,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,South Sudan,Previously treated,Percentage,10,3.9,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,South Sudan,Previously treated,Percentage,9.7,4.4,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,South Sudan,Previously treated,Percentage,9,5,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Gambia,Previously treated,Percentage,5.4,1.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Gambia,Previously treated,Percentage,5.5,1.8,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Gambia,Previously treated,Percentage,5.6,2.2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Andorra,New,Percentage,2,0.41,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Andorra,New,Percentage,2.1,0.43,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Andorra,New,Percentage,2.1,0.43,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Andorra,New,Percentage,2.2,0.42,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Andorra,New,Percentage,2.2,0.41,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Andorra,New,Percentage,2.3,0.41,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Andorra,New,Percentage,2.3,0.39,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Andorra,New,Percentage,2.4,0.39,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Andorra,New,Percentage,2.5,0.42,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Angola,New,Percentage,8.6,5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Angola,New,Percentage,7.6,4.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Angola,New,Percentage,6.8,4.6,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Angola,New,Percentage,6.1,4.4,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Angola,New,Percentage,5.4,4.2,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Angola,New,Percentage,4.9,4.1,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Angola,New,Percentage,4.3,3.9,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Angola,New,Percentage,3.9,3.7,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Angola,New,Percentage,3.5,3.3,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Anguilla,New,Percentage,2.6,0.25,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Vincent and the Grenadines,Previously treated,Percentage,14,1,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Vincent and the Grenadines,Previously treated,Percentage,13,1,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Vincent and the Grenadines,Previously treated,Percentage,13,1.1,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Vincent and the Grenadines,Previously treated,Percentage,12,1.2,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Vincent and the Grenadines,Previously treated,Percentage,12,1.3,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Vincent and the Grenadines,Previously treated,Percentage,11,1.3,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Vincent and the Grenadines,Previously treated,Percentage,11,1.3,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Vincent and the Grenadines,Previously treated,Percentage,11,1.2,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Samoa,Previously treated,Percentage,24,1.9,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Samoa,Previously treated,Percentage,23,2.1,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Samoa,Previously treated,Percentage,21,2.1,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Samoa,Previously treated,Percentage,20,2.1,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Samoa,Previously treated,Percentage,20,2,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Samoa,Previously treated,Percentage,19,2,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Samoa,Previously treated,Percentage,18,2,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Samoa,Previously treated,Percentage,17,1.9,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Samoa,Previously treated,Percentage,16,1.9,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,San Marino,Previously treated,Percentage,14,1.2,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,San Marino,Previously treated,Percentage,14,1.3,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,San Marino,Previously treated,Percentage,14,1.5,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,South Sudan,Previously treated,Percentage,8.5,5.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,South Sudan,Previously treated,Percentage,8,5.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,South Sudan,Previously treated,Percentage,7.6,5.8,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,South Sudan,Previously treated,Percentage,7.2,5.3,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Spain,Previously treated,Percentage,11,5.3,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Spain,Previously treated,Percentage,9.1,4.9,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Spain,Previously treated,Percentage,7.5,4.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Spain,Previously treated,Percentage,6.2,3.8,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Spain,Previously treated,Percentage,5.1,3.4,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Spain,Previously treated,Percentage,4.2,2.7,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Anguilla,New,Percentage,2.5,0.25,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Anguilla,New,Percentage,2.5,0.25,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Anguilla,New,Percentage,2.5,0.26,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Anguilla,New,Percentage,2.4,0.27,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Anguilla,New,Percentage,2.4,0.27,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Anguilla,New,Percentage,2.4,0.27,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Anguilla,New,Percentage,2.4,0.28,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Anguilla,New,Percentage,2.4,0.29,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Antigua and Barbuda,New,Percentage,4,0.2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Antigua and Barbuda,New,Percentage,3.9,0.2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Antigua and Barbuda,New,Percentage,3.8,0.2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Philippines,Previously treated,Percentage,20,18,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Philippines,Previously treated,Percentage,20,17,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Poland,Previously treated,Percentage,4.9,4.4,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Poland,Previously treated,Percentage,4.7,4.2,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Poland,Previously treated,Percentage,4.6,4,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Poland,Previously treated,Percentage,4.4,3.8,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Poland,Previously treated,Percentage,4.3,3.6,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Poland,Previously treated,Percentage,4.1,3.5,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Poland,Previously treated,Percentage,4,3.3,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Poland,Previously treated,Percentage,3.8,3.2,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lithuania,Previously treated,Percentage,43,41,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lithuania,Previously treated,Percentage,43,41,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lithuania,Previously treated,Percentage,43,40,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lithuania,Previously treated,Percentage,42,40,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Luxembourg,Previously treated,Percentage,6.1,1.2,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Luxembourg,Previously treated,Percentage,6.5,1.2,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Luxembourg,Previously treated,Percentage,7,1.3,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Luxembourg,Previously treated,Percentage,7.5,1.4,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Luxembourg,Previously treated,Percentage,8,1.5,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Luxembourg,Previously treated,Percentage,8.6,1.5,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,San Marino,Previously treated,Percentage,14,1.5,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,San Marino,Previously treated,Percentage,14,1.6,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,San Marino,Previously treated,Percentage,14,1.8,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,San Marino,Previously treated,Percentage,14,1.9,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,San Marino,Previously treated,Percentage,14,2.1,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,San Marino,Previously treated,Percentage,14,2.1,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sao Tome and Principe,Previously treated,Percentage,55,29,79
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sao Tome and Principe,Previously treated,Percentage,51,26,74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sao Tome and Principe,Previously treated,Percentage,46,23,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sao Tome and Principe,Previously treated,Percentage,41,19,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cyprus,Previously treated,Percentage,7.2,1.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Turks and Caicos Islands,Previously treated,Percentage,17,1.9,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Turks and Caicos Islands,Previously treated,Percentage,17,1.8,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Turks and Caicos Islands,Previously treated,Percentage,16,1.8,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Turks and Caicos Islands,Previously treated,Percentage,16,1.6,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Turks and Caicos Islands,Previously treated,Percentage,15,1.5,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tuvalu,Previously treated,Percentage,18,3.1,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tuvalu,Previously treated,Percentage,17,3.2,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tuvalu,Previously treated,Percentage,17,3.3,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tuvalu,Previously treated,Percentage,17,3.5,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tuvalu,Previously treated,Percentage,16,3.5,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tuvalu,Previously treated,Percentage,16,3.6,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tuvalu,Previously treated,Percentage,16,3.5,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tuvalu,Previously treated,Percentage,16,3.4,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tuvalu,Previously treated,Percentage,16,3.5,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uganda,Previously treated,Percentage,6.3,1.4,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uganda,Previously treated,Percentage,5.7,1.5,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uganda,Previously treated,Percentage,5.1,1.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uganda,Previously treated,Percentage,4.6,1.8,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uganda,Previously treated,Percentage,4.2,2,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uganda,Previously treated,Percentage,3.8,2.2,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uganda,Previously treated,Percentage,3.5,2.3,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uganda,Previously treated,Percentage,3.3,2.5,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uganda,Previously treated,Percentage,3,2.4,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ukraine,Previously treated,Percentage,44,43,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ukraine,Previously treated,Percentage,44,43,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ukraine,Previously treated,Percentage,43,43,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ukraine,Previously treated,Percentage,43,42,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ukraine,Previously treated,Percentage,42,42,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ukraine,Previously treated,Percentage,42,41,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ukraine,Previously treated,Percentage,42,41,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ukraine,Previously treated,Percentage,41,40,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ukraine,Previously treated,Percentage,41,40,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Arab Emirates,Previously treated,Percentage,14,3.1,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Arab Emirates,Previously treated,Percentage,13,3.1,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Arab Emirates,Previously treated,Percentage,12,2.9,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Arab Emirates,Previously treated,Percentage,11,2.7,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Arab Emirates,Previously treated,Percentage,10,2.5,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Arab Emirates,Previously treated,Percentage,9.8,2.2,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Arab Emirates,Previously treated,Percentage,9.3,1.9,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Arab Emirates,Previously treated,Percentage,8.8,1.9,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Arab Emirates,Previously treated,Percentage,8.4,1.6,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sao Tome and Principe,Previously treated,Percentage,37,16,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sao Tome and Principe,Previously treated,Percentage,33,13,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sao Tome and Principe,Previously treated,Percentage,29,11,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sao Tome and Principe,Previously treated,Percentage,26,8.5,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sao Tome and Principe,Previously treated,Percentage,23,6.6,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saudi Arabia,Previously treated,Percentage,16,13,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saudi Arabia,Previously treated,Percentage,16,12,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saudi Arabia,Previously treated,Percentage,15,12,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saudi Arabia,Previously treated,Percentage,15,11,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saudi Arabia,Previously treated,Percentage,14,10,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Poland,Previously treated,Percentage,3.7,3,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Portugal,Previously treated,Percentage,7,4.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Portugal,Previously treated,Percentage,7,4.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Portugal,Previously treated,Percentage,6.9,4.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Portugal,Previously treated,Percentage,6.9,3.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Portugal,Previously treated,Percentage,6.8,3.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Portugal,Previously treated,Percentage,6.8,3.6,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Portugal,Previously treated,Percentage,6.7,3.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Portugal,Previously treated,Percentage,6.7,3.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Portugal,Previously treated,Percentage,6.7,3.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Luxembourg,Previously treated,Percentage,9.3,1.6,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Luxembourg,Previously treated,Percentage,10,1.6,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Luxembourg,Previously treated,Percentage,11,1.7,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Madagascar,Previously treated,Percentage,7.3,1.8,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Madagascar,Previously treated,Percentage,7.5,1.7,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Madagascar,Previously treated,Percentage,7.6,1.6,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Madagascar,Previously treated,Percentage,7.8,1.5,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Madagascar,Previously treated,Percentage,8,1.4,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Madagascar,Previously treated,Percentage,8.2,1.3,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Madagascar,Previously treated,Percentage,8.5,1.2,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Puerto Rico,Previously treated,Percentage,23,9.2,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Puerto Rico,Previously treated,Percentage,23,8.8,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Puerto Rico,Previously treated,Percentage,22,8.4,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Puerto Rico,Previously treated,Percentage,21,8.2,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Puerto Rico,Previously treated,Percentage,21,7.8,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Puerto Rico,Previously treated,Percentage,20,7.4,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Puerto Rico,Previously treated,Percentage,20,6.7,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Puerto Rico,Previously treated,Percentage,19,6.1,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Puerto Rico,Previously treated,Percentage,19,5.5,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Qatar,Previously treated,Percentage,22,3.6,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Madagascar,Previously treated,Percentage,8.7,1.1,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Madagascar,Previously treated,Percentage,9,1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malawi,Previously treated,Percentage,6.2,4.8,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malawi,Previously treated,Percentage,6.2,4.8,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malawi,Previously treated,Percentage,6.2,4.7,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malawi,Previously treated,Percentage,6.1,4.6,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malawi,Previously treated,Percentage,6.1,4.5,8.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malawi,Previously treated,Percentage,6.1,4.3,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malawi,Previously treated,Percentage,6,4.1,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malawi,Previously treated,Percentage,6,3.9,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Qatar,Previously treated,Percentage,21,3.6,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Qatar,Previously treated,Percentage,19,3.6,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Qatar,Previously treated,Percentage,18,3.5,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Qatar,Previously treated,Percentage,17,3.5,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Qatar,Previously treated,Percentage,16,3.3,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Qatar,Previously treated,Percentage,15,3.1,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Qatar,Previously treated,Percentage,14,2.8,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Qatar,Previously treated,Percentage,13,2.6,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Republic of Korea,Previously treated,Percentage,11,10,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Republic of Korea,Previously treated,Percentage,10,10,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malawi,Previously treated,Percentage,6,3.7,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malaysia,Previously treated,Percentage,7.4,5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malaysia,Previously treated,Percentage,7.8,5.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malaysia,Previously treated,Percentage,8.2,6.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malaysia,Previously treated,Percentage,8.6,6.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malaysia,Previously treated,Percentage,9.1,7.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malaysia,Previously treated,Percentage,9.5,8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malaysia,Previously treated,Percentage,10,8.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malaysia,Previously treated,Percentage,11,9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malaysia,Previously treated,Percentage,11,9.4,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Maldives,Previously treated,Percentage,7.3,0.52,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Maldives,Previously treated,Percentage,6.8,0.54,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Maldives,Previously treated,Percentage,6.4,0.53,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Maldives,Previously treated,Percentage,6,0.55,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cook Islands,New,Percentage,2.7,0.32,8.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cook Islands,New,Percentage,2.8,0.35,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Costa Rica,New,Percentage,1.4,0.85,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Costa Rica,New,Percentage,1.3,0.83,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Costa Rica,New,Percentage,1.3,0.82,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Costa Rica,New,Percentage,1.3,0.8,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Costa Rica,New,Percentage,1.2,0.76,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Republic of Korea,Previously treated,Percentage,10,9.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Republic of Korea,Previously treated,Percentage,9.8,9.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Indonesia,New,Percentage,2.1,2,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Indonesia,New,Percentage,2.1,2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iran (Islamic Republic of),New,Percentage,1.4,0.82,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iran (Islamic Republic of),New,Percentage,1.4,0.83,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iran (Islamic Republic of),New,Percentage,1.4,0.83,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iran (Islamic Republic of),New,Percentage,1.5,0.83,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iran (Islamic Republic of),New,Percentage,1.5,0.8,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iran (Islamic Republic of),New,Percentage,1.5,0.79,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iran (Islamic Republic of),New,Percentage,1.6,0.76,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iran (Islamic Republic of),New,Percentage,1.6,0.72,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iran (Islamic Republic of),New,Percentage,1.6,0.68,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iraq,New,Percentage,5.4,4.2,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iraq,New,Percentage,5.1,4.1,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iraq,New,Percentage,4.9,4,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iraq,New,Percentage,4.6,3.8,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iraq,New,Percentage,4.4,3.7,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iraq,New,Percentage,4.2,3.5,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iraq,New,Percentage,4,3.3,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iraq,New,Percentage,3.8,3.2,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iraq,New,Percentage,3.6,2.9,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ireland,New,Percentage,1.1,0.58,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ireland,New,Percentage,1.1,0.57,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ireland,New,Percentage,1.2,0.57,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ireland,New,Percentage,1.2,0.56,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ireland,New,Percentage,1.3,0.54,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ireland,New,Percentage,1.3,0.53,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ireland,New,Percentage,1.4,0.52,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ireland,New,Percentage,1.5,0.5,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ireland,New,Percentage,1.5,0.49,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Israel,New,Percentage,6,5.2,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Israel,New,Percentage,6.2,5.4,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Israel,New,Percentage,6.5,5.6,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Israel,New,Percentage,6.7,5.7,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Israel,New,Percentage,7,5.8,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Israel,New,Percentage,7.3,5.9,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Israel,New,Percentage,7.6,6,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Israel,New,Percentage,7.9,6.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Israel,New,Percentage,8.2,6.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Italy,New,Percentage,2.8,2.4,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Italy,New,Percentage,2.8,2.4,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Italy,New,Percentage,2.8,2.3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Italy,New,Percentage,2.8,2.3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Italy,New,Percentage,2.8,2.3,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Italy,New,Percentage,2.8,2.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Italy,New,Percentage,2.8,2.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Italy,New,Percentage,2.8,2.1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Italy,New,Percentage,2.8,2.1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Jamaica,New,Percentage,0.74,0.16,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Jamaica,New,Percentage,0.72,0.16,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Jamaica,New,Percentage,0.71,0.17,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Jamaica,New,Percentage,0.69,0.17,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Jamaica,New,Percentage,0.68,0.17,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Jamaica,New,Percentage,0.67,0.17,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Jamaica,New,Percentage,0.67,0.16,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Jamaica,New,Percentage,0.66,0.16,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Jamaica,New,Percentage,0.66,0.16,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Japan,New,Percentage,1.8,0.73,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Japan,New,Percentage,1.9,0.71,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Japan,New,Percentage,2,0.7,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Japan,New,Percentage,2.1,0.69,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Japan,New,Percentage,2.2,0.67,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Japan,New,Percentage,2.3,0.65,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Japan,New,Percentage,2.5,0.64,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Japan,New,Percentage,2.6,0.62,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Japan,New,Percentage,2.8,0.6,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Jordan,New,Percentage,4.4,2.7,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Jordan,New,Percentage,4.1,2.5,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Jordan,New,Percentage,3.8,2.2,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Jordan,New,Percentage,3.6,2,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Jordan,New,Percentage,3.3,1.8,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Jordan,New,Percentage,3.1,1.6,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Jordan,New,Percentage,2.9,1.4,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Jordan,New,Percentage,2.7,1.2,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Jordan,New,Percentage,2.6,1.1,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kazakhstan,New,Percentage,29,29,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kazakhstan,New,Percentage,30,29,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kazakhstan,New,Percentage,30,30,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kazakhstan,New,Percentage,31,30,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kazakhstan,New,Percentage,31,31,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kazakhstan,New,Percentage,32,31,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kazakhstan,New,Percentage,32,32,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kazakhstan,New,Percentage,33,32,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kazakhstan,New,Percentage,33,33,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kenya,New,Percentage,1,0.76,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kenya,New,Percentage,1,0.78,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kenya,New,Percentage,0.97,0.8,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kenya,New,Percentage,0.94,0.81,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kenya,New,Percentage,0.91,0.81,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kenya,New,Percentage,0.89,0.8,0.99
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kenya,New,Percentage,0.86,0.76,0.99
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kenya,New,Percentage,0.84,0.71,0.99
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kenya,New,Percentage,0.82,0.66,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kiribati,New,Percentage,1.1,0.42,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kiribati,New,Percentage,1.1,0.47,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kiribati,New,Percentage,1,0.5,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kiribati,New,Percentage,1,0.54,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kiribati,New,Percentage,1,0.58,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kiribati,New,Percentage,1,0.59,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kiribati,New,Percentage,1,0.58,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kiribati,New,Percentage,1,0.58,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kiribati,New,Percentage,1,0.57,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kuwait,New,Percentage,1.6,1.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kuwait,New,Percentage,1.7,1.4,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kuwait,New,Percentage,1.7,1.4,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kuwait,New,Percentage,1.8,1.4,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kuwait,New,Percentage,1.8,1.4,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kuwait,New,Percentage,1.9,1.5,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kuwait,New,Percentage,1.9,1.5,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kuwait,New,Percentage,2,1.5,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kuwait,New,Percentage,2,1.4,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Kyrgyzstan,New,Percentage,30,28,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Kyrgyzstan,New,Percentage,29,28,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Kyrgyzstan,New,Percentage,28,27,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Kyrgyzstan,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Kyrgyzstan,New,Percentage,26,26,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Kyrgyzstan,New,Percentage,26,25,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Kyrgyzstan,New,Percentage,25,24,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Kyrgyzstan,New,Percentage,24,23,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Kyrgyzstan,New,Percentage,24,22,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lao People's Democratic Republic,New,Percentage,1.1,0.71,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lao People's Democratic Republic,New,Percentage,0.97,0.68,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lao People's Democratic Republic,New,Percentage,0.88,0.66,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lao People's Democratic Republic,New,Percentage,0.8,0.63,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lao People's Democratic Republic,New,Percentage,0.73,0.6,0.89
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lao People's Democratic Republic,New,Percentage,0.66,0.56,0.78
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lao People's Democratic Republic,New,Percentage,0.6,0.51,0.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lao People's Democratic Republic,New,Percentage,0.55,0.45,0.66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lao People's Democratic Republic,New,Percentage,0.5,0.4,0.62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Latvia,New,Percentage,9.9,9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saudi Arabia,Previously treated,Percentage,14,9.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saudi Arabia,Previously treated,Percentage,13,9.2,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saudi Arabia,Previously treated,Percentage,13,8.6,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saudi Arabia,Previously treated,Percentage,13,8,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Senegal,Previously treated,Percentage,9.4,8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Senegal,Previously treated,Percentage,8.5,7.3,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Senegal,Previously treated,Percentage,7.6,6.7,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Senegal,Previously treated,Percentage,6.8,6.1,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Senegal,Previously treated,Percentage,6.1,5.4,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Senegal,Previously treated,Percentage,5.4,4.8,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,4.6,3.7,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,4.7,3.7,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,4.8,3.7,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,4.9,3.6,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,5,3.6,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,5.1,3.7,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,5.2,3.6,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,5.3,3.6,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Antigua and Barbuda,New,Percentage,3.8,0.22,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Antigua and Barbuda,New,Percentage,3.7,0.23,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Antigua and Barbuda,New,Percentage,3.6,0.23,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Antigua and Barbuda,New,Percentage,3.6,0.24,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Antigua and Barbuda,New,Percentage,3.5,0.25,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Antigua and Barbuda,New,Percentage,3.5,0.25,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Argentina,New,Percentage,1.9,0.73,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Argentina,New,Percentage,1.8,0.66,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Argentina,New,Percentage,1.8,0.61,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Argentina,New,Percentage,1.8,0.55,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Argentina,New,Percentage,1.8,0.5,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Argentina,New,Percentage,1.8,0.45,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Argentina,New,Percentage,1.8,0.41,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Argentina,New,Percentage,1.8,0.37,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Argentina,New,Percentage,1.8,0.33,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Armenia,New,Percentage,15,14,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Armenia,New,Percentage,15,14,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Armenia,New,Percentage,16,15,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Armenia,New,Percentage,16,15,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Armenia,New,Percentage,17,15,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Armenia,New,Percentage,17,15,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Armenia,New,Percentage,17,16,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Kingdom of Great Britain and Northern Ireland,Previously treated,Percentage,5.4,3.6,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Republic of Tanzania,Previously treated,Percentage,14,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Republic of Tanzania,Previously treated,Percentage,13,11,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Republic of Tanzania,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Republic of Tanzania,Previously treated,Percentage,12,10,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Republic of Tanzania,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Republic of Tanzania,Previously treated,Percentage,10,9.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Republic of Tanzania,Previously treated,Percentage,9.6,8.8,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Republic of Tanzania,Previously treated,Percentage,9,8.2,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Armenia,New,Percentage,18,16,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Armenia,New,Percentage,18,16,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Aruba,New,Percentage,3.8,0.51,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Aruba,New,Percentage,3.7,0.51,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Aruba,New,Percentage,3.6,0.49,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Aruba,New,Percentage,3.6,0.46,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Aruba,New,Percentage,3.5,0.44,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Aruba,New,Percentage,3.4,0.43,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Aruba,New,Percentage,3.4,0.44,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Aruba,New,Percentage,3.4,0.44,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Aruba,New,Percentage,3.3,0.42,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Australia,New,Percentage,2.4,2.1,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Australia,New,Percentage,2.4,2.1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Australia,New,Percentage,2.4,2.1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Australia,New,Percentage,2.4,2.1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Australia,New,Percentage,2.4,2.1,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Australia,New,Percentage,2.4,2,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Australia,New,Percentage,2.4,2,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Australia,New,Percentage,2.4,1.9,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Australia,New,Percentage,2.4,1.9,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Austria,New,Percentage,3.2,2.3,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Austria,New,Percentage,3.2,2.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Austria,New,Percentage,3.1,2.1,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Austria,New,Percentage,3,1.9,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Austria,New,Percentage,2.9,1.7,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Austria,New,Percentage,2.8,1.5,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Austria,New,Percentage,2.7,1.3,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Austria,New,Percentage,2.6,1.1,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Austria,New,Percentage,2.5,0.9,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Azerbaijan,New,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Azerbaijan,New,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bahamas,New,Percentage,8.2,5.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bahamas,New,Percentage,7.5,4.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bahamas,New,Percentage,6.9,4.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bahamas,New,Percentage,6.3,3.7,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bahamas,New,Percentage,5.8,3.2,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bahamas,New,Percentage,5.3,2.8,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bahamas,New,Percentage,4.9,2.4,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Costa Rica,New,Percentage,1.2,0.72,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Costa Rica,New,Percentage,1.2,0.7,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Costa Rica,New,Percentage,1.1,0.65,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Costa Rica,New,Percentage,1.1,0.61,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cte d'Ivoire,New,Percentage,3.3,2.4,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cte d'Ivoire,New,Percentage,3.2,2.4,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cte d'Ivoire,New,Percentage,3.1,2.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cte d'Ivoire,New,Percentage,3,2.3,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cte d'Ivoire,New,Percentage,2.9,2.2,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cte d'Ivoire,New,Percentage,2.8,2.1,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cte d'Ivoire,New,Percentage,2.7,2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cte d'Ivoire,New,Percentage,2.6,1.9,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cte d'Ivoire,New,Percentage,2.6,1.9,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Croatia,New,Percentage,0.52,0.31,0.82
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Croatia,New,Percentage,0.52,0.29,0.85
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Croatia,New,Percentage,0.53,0.28,0.88
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Croatia,New,Percentage,0.53,0.27,0.91
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Croatia,New,Percentage,0.53,0.26,0.95
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Croatia,New,Percentage,0.53,0.24,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Croatia,New,Percentage,0.54,0.23,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Croatia,New,Percentage,0.54,0.22,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Croatia,New,Percentage,0.55,0.21,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cuba,New,Percentage,1.7,0.84,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cuba,New,Percentage,1.8,0.86,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cuba,New,Percentage,1.9,0.88,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cuba,New,Percentage,2,0.87,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cuba,New,Percentage,2.1,0.85,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cuba,New,Percentage,2.2,0.85,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cuba,New,Percentage,2.4,0.84,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cuba,New,Percentage,2.5,0.82,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cuba,New,Percentage,2.7,0.81,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Curaao,New,Percentage,3.9,0.56,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Curaao,New,Percentage,3.8,0.56,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Curaao,New,Percentage,3.7,0.55,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Curaao,New,Percentage,3.7,0.55,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Curaao,New,Percentage,3.6,0.55,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Curaao,New,Percentage,3.6,0.54,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Curaao,New,Percentage,3.6,0.53,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Curaao,New,Percentage,3.6,0.52,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Curaao,New,Percentage,3.5,0.51,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cyprus,New,Percentage,2.5,1.2,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cyprus,New,Percentage,2.4,1.1,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cyprus,New,Percentage,2.3,1.1,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cyprus,New,Percentage,2.3,1,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cyprus,New,Percentage,2.2,1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cyprus,New,Percentage,2.1,0.98,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cyprus,New,Percentage,2.1,0.92,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cyprus,New,Percentage,2,0.87,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cyprus,New,Percentage,2,0.79,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Czechia,New,Percentage,2.9,2.5,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Czechia,New,Percentage,3.1,2.6,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Czechia,New,Percentage,3.3,2.8,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Czechia,New,Percentage,3.5,2.9,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Czechia,New,Percentage,3.8,3.1,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Czechia,New,Percentage,4,3.2,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Czechia,New,Percentage,4.3,3.4,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Czechia,New,Percentage,4.6,3.5,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Czechia,New,Percentage,4.9,3.7,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Democratic People's Republic of Korea,New,Percentage,2.4,1.2,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Democratic People's Republic of Korea,New,Percentage,2.4,1.2,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Democratic People's Republic of Korea,New,Percentage,2.4,1.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Democratic People's Republic of Korea,New,Percentage,2.4,1.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Democratic People's Republic of Korea,New,Percentage,2.4,1.1,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Democratic People's Republic of Korea,New,Percentage,2.4,1.1,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Democratic People's Republic of Korea,New,Percentage,2.4,1.1,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Democratic People's Republic of Korea,New,Percentage,2.5,1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Democratic People's Republic of Korea,New,Percentage,2.5,0.97,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Democratic Republic of the Congo,New,Percentage,2,1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Democratic Republic of the Congo,New,Percentage,1.9,1.1,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Democratic Republic of the Congo,New,Percentage,1.8,1,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Democratic Republic of the Congo,New,Percentage,1.8,0.99,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Democratic Republic of the Congo,New,Percentage,1.7,0.94,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Democratic Republic of the Congo,New,Percentage,1.7,0.88,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Democratic Republic of the Congo,New,Percentage,1.6,0.81,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Democratic Republic of the Congo,New,Percentage,1.6,0.73,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Democratic Republic of the Congo,New,Percentage,1.6,0.67,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Denmark,New,Percentage,1.2,0.8,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Denmark,New,Percentage,1.3,0.85,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Denmark,New,Percentage,1.4,0.91,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Denmark,New,Percentage,1.5,0.95,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Denmark,New,Percentage,1.6,1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Denmark,New,Percentage,1.7,1.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Denmark,New,Percentage,1.9,1.1,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Denmark,New,Percentage,2,1.2,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Denmark,New,Percentage,2.2,1.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Djibouti,New,Percentage,4.4,2.7,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Djibouti,New,Percentage,4.2,2.6,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Djibouti,New,Percentage,4,2.4,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Djibouti,New,Percentage,3.8,2.2,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Djibouti,New,Percentage,3.6,2,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Djibouti,New,Percentage,3.4,1.8,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Djibouti,New,Percentage,3.3,1.6,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Djibouti,New,Percentage,3.2,1.4,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Djibouti,New,Percentage,3.1,1.2,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Dominica,New,Percentage,2.5,0.32,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Dominica,New,Percentage,2.5,0.33,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Dominica,New,Percentage,2.6,0.35,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Dominica,New,Percentage,2.6,0.38,8.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Dominica,New,Percentage,2.6,0.39,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Dominica,New,Percentage,2.6,0.39,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Dominica,New,Percentage,2.7,0.4,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Dominica,New,Percentage,2.7,0.4,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Dominica,New,Percentage,2.8,0.4,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Dominican Republic,New,Percentage,9.7,5.3,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Dominican Republic,New,Percentage,9.1,5.4,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Dominican Republic,New,Percentage,8.6,5.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Dominican Republic,New,Percentage,8.1,5.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Dominican Republic,New,Percentage,7.6,5.7,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Dominican Republic,New,Percentage,7.2,5.8,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Latvia,New,Percentage,9.9,8.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Latvia,New,Percentage,9.8,8.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Latvia,New,Percentage,9.8,8.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Latvia,New,Percentage,9.7,8.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Latvia,New,Percentage,9.7,8.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Latvia,New,Percentage,9.6,8.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Latvia,New,Percentage,9.6,8.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Latvia,New,Percentage,9.5,8.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lebanon,New,Percentage,1.6,1.1,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lebanon,New,Percentage,1.5,1.1,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lebanon,New,Percentage,1.5,1,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lebanon,New,Percentage,1.4,0.96,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Dominican Republic,New,Percentage,6.7,5.9,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Dominican Republic,New,Percentage,6.4,5.8,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Dominican Republic,New,Percentage,6,5.3,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ecuador,New,Percentage,4.7,4.2,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ecuador,New,Percentage,4.6,4.1,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ecuador,New,Percentage,4.5,4,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ecuador,New,Percentage,4.4,3.9,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ecuador,New,Percentage,4.2,3.8,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ecuador,New,Percentage,4.1,3.7,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ecuador,New,Percentage,4,3.6,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ecuador,New,Percentage,3.9,3.5,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Spain,Previously treated,Percentage,3.4,2.3,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Spain,Previously treated,Percentage,2.8,1.8,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Spain,Previously treated,Percentage,2.3,1.4,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sri Lanka,Previously treated,Percentage,2.7,2.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sri Lanka,Previously treated,Percentage,2.7,2.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sri Lanka,Previously treated,Percentage,2.8,2.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sri Lanka,Previously treated,Percentage,2.8,2.1,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sri Lanka,Previously treated,Percentage,2.8,2.1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sri Lanka,Previously treated,Percentage,2.9,2,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sri Lanka,Previously treated,Percentage,2.9,2,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lebanon,New,Percentage,1.3,0.92,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lebanon,New,Percentage,1.3,0.86,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lebanon,New,Percentage,1.2,0.79,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lebanon,New,Percentage,1.2,0.72,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lebanon,New,Percentage,1.1,0.67,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lesotho,New,Percentage,5.6,4.7,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lesotho,New,Percentage,5.2,4.5,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lesotho,New,Percentage,4.8,4.3,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lesotho,New,Percentage,4.5,4.1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lesotho,New,Percentage,4.2,3.8,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lesotho,New,Percentage,3.9,3.6,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ecuador,New,Percentage,3.8,3.4,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Egypt,New,Percentage,5.9,5.1,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Egypt,New,Percentage,4.9,4.2,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Egypt,New,Percentage,4,3.5,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Egypt,New,Percentage,3.1,2.7,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Egypt,New,Percentage,2.4,2.1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Egypt,New,Percentage,1.8,1.6,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Egypt,New,Percentage,1.3,1.1,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Egypt,New,Percentage,0.95,0.78,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Egypt,New,Percentage,0.66,0.52,0.83
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,El Salvador,New,Percentage,1.1,0.41,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sri Lanka,Previously treated,Percentage,3,1.9,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sri Lanka,Previously treated,Percentage,3.1,1.9,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sudan,Previously treated,Percentage,12,8.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sudan,Previously treated,Percentage,12,9.2,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sudan,Previously treated,Percentage,12,9.9,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sudan,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sudan,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sudan,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sudan,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sudan,Previously treated,Percentage,13,10,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sudan,Previously treated,Percentage,13,9.6,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lesotho,New,Percentage,3.6,3.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lesotho,New,Percentage,3.4,3,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lesotho,New,Percentage,3.1,2.7,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Liberia,New,Percentage,3.2,0.26,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Liberia,New,Percentage,3,0.25,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Liberia,New,Percentage,2.8,0.25,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Liberia,New,Percentage,2.7,0.24,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Liberia,New,Percentage,2.5,0.22,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Liberia,New,Percentage,2.4,0.22,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Liberia,New,Percentage,2.3,0.21,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Liberia,New,Percentage,2.2,0.19,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,El Salvador,New,Percentage,1.1,0.39,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,El Salvador,New,Percentage,1.1,0.37,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,El Salvador,New,Percentage,1.1,0.36,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,El Salvador,New,Percentage,1.2,0.35,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,El Salvador,New,Percentage,1.2,0.34,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,El Salvador,New,Percentage,1.2,0.33,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,El Salvador,New,Percentage,1.2,0.31,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,El Salvador,New,Percentage,1.2,0.29,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Equatorial Guinea,New,Percentage,3.9,0.33,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Equatorial Guinea,New,Percentage,3.6,0.31,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Equatorial Guinea,New,Percentage,3.4,0.29,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Suriname,Previously treated,Percentage,35,16,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Suriname,Previously treated,Percentage,33,16,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Suriname,Previously treated,Percentage,32,17,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Suriname,Previously treated,Percentage,30,17,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Suriname,Previously treated,Percentage,29,17,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Suriname,Previously treated,Percentage,28,15,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Suriname,Previously treated,Percentage,26,14,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Suriname,Previously treated,Percentage,25,12,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Suriname,Previously treated,Percentage,24,11,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sweden,Previously treated,Percentage,13,9.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Liberia,New,Percentage,2.1,0.18,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Libya,New,Percentage,1.7,0.73,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Libya,New,Percentage,1.6,0.75,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Libya,New,Percentage,1.5,0.77,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Libya,New,Percentage,1.4,0.78,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Libya,New,Percentage,1.3,0.79,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Libya,New,Percentage,1.2,0.78,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Libya,New,Percentage,1.2,0.75,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Libya,New,Percentage,1.1,0.72,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Libya,New,Percentage,1.1,0.67,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Lithuania,New,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Equatorial Guinea,New,Percentage,3.2,0.28,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Equatorial Guinea,New,Percentage,3.1,0.27,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Equatorial Guinea,New,Percentage,2.9,0.25,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Equatorial Guinea,New,Percentage,2.8,0.24,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Equatorial Guinea,New,Percentage,2.6,0.23,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Equatorial Guinea,New,Percentage,2.5,0.22,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Eritrea,New,Percentage,2.8,1.6,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Eritrea,New,Percentage,2.8,1.7,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Eritrea,New,Percentage,2.7,1.9,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Eritrea,New,Percentage,2.7,2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Eritrea,New,Percentage,2.7,2.1,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sweden,Previously treated,Percentage,14,9.8,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sweden,Previously treated,Percentage,14,9.9,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sweden,Previously treated,Percentage,15,10,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sweden,Previously treated,Percentage,16,10,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sweden,Previously treated,Percentage,16,11,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sweden,Previously treated,Percentage,17,11,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sweden,Previously treated,Percentage,18,11,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sweden,Previously treated,Percentage,19,11,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Switzerland,Previously treated,Percentage,18,12,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Switzerland,Previously treated,Percentage,19,12,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Switzerland,Previously treated,Percentage,20,13,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Republic of Tanzania,Previously treated,Percentage,8.4,7.5,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United States of America,Previously treated,Percentage,7,6.3,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United States of America,Previously treated,Percentage,6.9,6.2,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United States of America,Previously treated,Percentage,6.9,6.1,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United States of America,Previously treated,Percentage,6.8,5.9,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United States of America,Previously treated,Percentage,6.7,5.8,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United States of America,Previously treated,Percentage,6.6,5.7,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United States of America,Previously treated,Percentage,6.6,5.5,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United States of America,Previously treated,Percentage,6.5,5.3,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Eritrea,New,Percentage,2.6,2.1,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Eritrea,New,Percentage,2.6,2.1,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Eritrea,New,Percentage,2.6,2.1,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Eritrea,New,Percentage,2.6,2,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Estonia,New,Percentage,19,18,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Estonia,New,Percentage,20,18,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Estonia,New,Percentage,20,18,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Estonia,New,Percentage,20,18,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Estonia,New,Percentage,21,18,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Estonia,New,Percentage,21,19,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Estonia,New,Percentage,21,19,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Estonia,New,Percentage,22,19,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Lithuania,New,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Lithuania,New,Percentage,14,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Lithuania,New,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Lithuania,New,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Lithuania,New,Percentage,14,14,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Lithuania,New,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Lithuania,New,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Lithuania,New,Percentage,16,14,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Luxembourg,New,Percentage,1.1,0.38,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Luxembourg,New,Percentage,1.2,0.39,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Luxembourg,New,Percentage,1.2,0.4,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Senegal,Previously treated,Percentage,4.9,4.3,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Senegal,Previously treated,Percentage,4.4,3.8,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Senegal,Previously treated,Percentage,3.9,3.3,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Serbia,Previously treated,Percentage,6.2,3.9,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Serbia,Previously treated,Percentage,6.1,3.7,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Serbia,Previously treated,Percentage,6.1,3.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Serbia,Previously treated,Percentage,6.1,3.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Serbia,Previously treated,Percentage,6.1,2.9,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Serbia,Previously treated,Percentage,6.1,2.7,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Serbia,Previously treated,Percentage,6.1,2.6,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Luxembourg,New,Percentage,1.2,0.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Luxembourg,New,Percentage,1.2,0.39,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Luxembourg,New,Percentage,1.3,0.38,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Luxembourg,New,Percentage,1.3,0.37,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Luxembourg,New,Percentage,1.3,0.37,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Luxembourg,New,Percentage,1.3,0.37,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Madagascar,New,Percentage,0.8,0.3,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Madagascar,New,Percentage,0.83,0.31,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Madagascar,New,Percentage,0.86,0.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Madagascar,New,Percentage,0.89,0.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Madagascar,New,Percentage,0.92,0.3,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United States of America,Previously treated,Percentage,6.4,5.2,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uruguay,Previously treated,Percentage,3.6,2,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uruguay,Previously treated,Percentage,3.5,2,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uruguay,Previously treated,Percentage,3.5,1.9,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uruguay,Previously treated,Percentage,3.5,1.9,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uruguay,Previously treated,Percentage,3.4,1.8,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uruguay,Previously treated,Percentage,3.4,1.6,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uruguay,Previously treated,Percentage,3.4,1.5,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uruguay,Previously treated,Percentage,3.4,1.4,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uruguay,Previously treated,Percentage,3.4,1.3,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uzbekistan,Previously treated,Percentage,49,46,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uzbekistan,Previously treated,Percentage,46,44,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uzbekistan,Previously treated,Percentage,44,42,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uzbekistan,Previously treated,Percentage,41,40,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uzbekistan,Previously treated,Percentage,39,38,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uzbekistan,Previously treated,Percentage,36,35,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uzbekistan,Previously treated,Percentage,34,33,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uzbekistan,Previously treated,Percentage,32,31,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uzbekistan,Previously treated,Percentage,30,28,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Vanuatu,Previously treated,Percentage,12,0.7,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Vanuatu,Previously treated,Percentage,12,0.8,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Vanuatu,Previously treated,Percentage,12,0.92,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Vanuatu,Previously treated,Percentage,12,1,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Vanuatu,Previously treated,Percentage,12,1.1,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Vanuatu,Previously treated,Percentage,12,1.1,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Vanuatu,Previously treated,Percentage,12,1.2,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Vanuatu,Previously treated,Percentage,12,1.2,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Vanuatu,Previously treated,Percentage,12,1.1,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Venezuela (Bolivarian Republic of),Previously treated,Percentage,18,1.6,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Venezuela (Bolivarian Republic of),Previously treated,Percentage,17,1.8,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Venezuela (Bolivarian Republic of),Previously treated,Percentage,16,1.8,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Venezuela (Bolivarian Republic of),Previously treated,Percentage,16,1.7,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Venezuela (Bolivarian Republic of),Previously treated,Percentage,15,1.6,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Venezuela (Bolivarian Republic of),Previously treated,Percentage,14,1.6,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Venezuela (Bolivarian Republic of),Previously treated,Percentage,14,1.6,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Venezuela (Bolivarian Republic of),Previously treated,Percentage,13,1.5,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Venezuela (Bolivarian Republic of),Previously treated,Percentage,13,1.5,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Viet Nam,Previously treated,Percentage,17,17,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Viet Nam,Previously treated,Percentage,17,17,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Viet Nam,Previously treated,Percentage,17,17,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Viet Nam,Previously treated,Percentage,17,17,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Viet Nam,Previously treated,Percentage,17,17,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Viet Nam,Previously treated,Percentage,17,17,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Viet Nam,Previously treated,Percentage,17,17,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Viet Nam,Previously treated,Percentage,17,16,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Viet Nam,Previously treated,Percentage,17,16,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Wallis and Futuna,Previously treated,Percentage,24,1.4,76
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Wallis and Futuna,Previously treated,Percentage,23,1.4,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Wallis and Futuna,Previously treated,Percentage,22,1.4,70
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Wallis and Futuna,Previously treated,Percentage,21,1.5,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Wallis and Futuna,Previously treated,Percentage,20,1.6,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Wallis and Futuna,Previously treated,Percentage,19,1.5,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Wallis and Futuna,Previously treated,Percentage,18,1.5,62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Wallis and Futuna,Previously treated,Percentage,17,1.5,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Wallis and Futuna,Previously treated,Percentage,16,1.4,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Yemen,Previously treated,Percentage,17,9.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Yemen,Previously treated,Percentage,17,9.3,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Yemen,Previously treated,Percentage,18,8.9,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Yemen,Previously treated,Percentage,18,8.4,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Yemen,Previously treated,Percentage,18,7.7,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Yemen,Previously treated,Percentage,19,7.1,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Yemen,Previously treated,Percentage,19,6.6,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Yemen,Previously treated,Percentage,19,6.2,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Yemen,Previously treated,Percentage,20,5.7,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Zambia,Previously treated,Percentage,12,8.3,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Zambia,Previously treated,Percentage,12,7.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Zambia,Previously treated,Percentage,11,7.3,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Zambia,Previously treated,Percentage,11,6.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Zambia,Previously treated,Percentage,10,6.2,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Zambia,Previously treated,Percentage,10,5.7,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Zambia,Previously treated,Percentage,9.8,5.3,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Zambia,Previously treated,Percentage,9.4,4.9,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Zambia,Previously treated,Percentage,9.1,4.5,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Zimbabwe,Previously treated,Percentage,25,18,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Zimbabwe,Previously treated,Percentage,24,17,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Zimbabwe,Previously treated,Percentage,22,17,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Zimbabwe,Previously treated,Percentage,20,17,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Zimbabwe,Previously treated,Percentage,19,16,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Zimbabwe,Previously treated,Percentage,18,15,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Zimbabwe,Previously treated,Percentage,16,14,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Zimbabwe,Previously treated,Percentage,15,13,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Zimbabwe,Previously treated,Percentage,14,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Afghanistan,New,Percentage,2.6,1,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Afghanistan,New,Percentage,2.5,1.1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Afghanistan,New,Percentage,2.4,1.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Afghanistan,New,Percentage,2.3,1.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Afghanistan,New,Percentage,2.3,1.5,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Afghanistan,New,Percentage,2.2,1.6,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Afghanistan,New,Percentage,2.2,1.7,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Afghanistan,New,Percentage,2.1,1.9,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Afghanistan,New,Percentage,2.1,2,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Switzerland,Previously treated,Percentage,22,13,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Switzerland,Previously treated,Percentage,23,13,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Switzerland,Previously treated,Percentage,24,14,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Switzerland,Previously treated,Percentage,26,14,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Switzerland,Previously treated,Percentage,28,15,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Switzerland,Previously treated,Percentage,29,15,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Syrian Arab Republic,Previously treated,Percentage,25,20,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Syrian Arab Republic,Previously treated,Percentage,22,18,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Syrian Arab Republic,Previously treated,Percentage,19,16,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Syrian Arab Republic,Previously treated,Percentage,16,13,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Albania,New,Percentage,1.8,1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Albania,New,Percentage,1.7,1,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Albania,New,Percentage,1.7,1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Albania,New,Percentage,1.6,0.97,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Albania,New,Percentage,1.5,0.88,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Albania,New,Percentage,1.5,0.82,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Albania,New,Percentage,1.4,0.76,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Albania,New,Percentage,1.4,0.71,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Albania,New,Percentage,1.3,0.66,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Algeria,New,Percentage,1.7,0.55,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Algeria,New,Percentage,1.7,0.53,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Syrian Arab Republic,Previously treated,Percentage,14,11,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Syrian Arab Republic,Previously treated,Percentage,12,9.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Syrian Arab Republic,Previously treated,Percentage,10,7.7,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Syrian Arab Republic,Previously treated,Percentage,8.8,6.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Syrian Arab Republic,Previously treated,Percentage,7.5,5.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tajikistan,Previously treated,Percentage,49,47,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tajikistan,Previously treated,Percentage,47,45,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tajikistan,Previously treated,Percentage,45,43,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tajikistan,Previously treated,Percentage,42,41,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tajikistan,Previously treated,Percentage,40,39,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Algeria,New,Percentage,1.8,0.51,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Algeria,New,Percentage,1.8,0.48,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Algeria,New,Percentage,1.9,0.46,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Algeria,New,Percentage,1.9,0.43,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Algeria,New,Percentage,2,0.4,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Algeria,New,Percentage,2,0.38,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Algeria,New,Percentage,2.1,0.36,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,American Samoa,New,Percentage,2.2,0.21,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,American Samoa,New,Percentage,2.2,0.23,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,American Samoa,New,Percentage,2.1,0.25,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,American Samoa,New,Percentage,2.1,0.27,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tajikistan,Previously treated,Percentage,38,36,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tajikistan,Previously treated,Percentage,36,34,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tajikistan,Previously treated,Percentage,34,32,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tajikistan,Previously treated,Percentage,32,30,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Thailand,Previously treated,Percentage,16,15,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Thailand,Previously treated,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Thailand,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Thailand,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Thailand,Previously treated,Percentage,12,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Thailand,Previously treated,Percentage,11,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,American Samoa,New,Percentage,2.1,0.28,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,American Samoa,New,Percentage,2.1,0.3,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,American Samoa,New,Percentage,2.2,0.32,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,American Samoa,New,Percentage,2.2,0.33,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,American Samoa,New,Percentage,2.2,0.35,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Republic of Korea,New,Percentage,3.2,3.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Republic of Korea,New,Percentage,3.2,3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Republic of Korea,New,Percentage,3.1,3,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Republic of Korea,New,Percentage,3.1,2.9,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Republic of Korea,New,Percentage,3,2.9,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Republic of Korea,New,Percentage,3,2.8,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Thailand,Previously treated,Percentage,10,10,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Thailand,Previously treated,Percentage,9.7,9.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Thailand,Previously treated,Percentage,9,8.4,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Timor-Leste,Previously treated,Percentage,4.3,0.87,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Timor-Leste,Previously treated,Percentage,4.1,0.95,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Timor-Leste,Previously treated,Percentage,4,1.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Timor-Leste,Previously treated,Percentage,3.8,1.1,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Timor-Leste,Previously treated,Percentage,3.8,1.1,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Timor-Leste,Previously treated,Percentage,3.7,1.1,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Timor-Leste,Previously treated,Percentage,3.6,1,8.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Republic of Korea,New,Percentage,2.9,2.8,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Republic of Moldova,New,Percentage,27,26,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Republic of Moldova,New,Percentage,27,26,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Republic of Moldova,New,Percentage,27,26,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Romania,New,Percentage,2.9,2.7,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Timor-Leste,Previously treated,Percentage,3.6,1,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Timor-Leste,Previously treated,Percentage,3.6,0.96,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Togo,Previously treated,Percentage,6.8,4,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Togo,Previously treated,Percentage,6.1,3.9,8.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Togo,Previously treated,Percentage,5.5,3.9,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Togo,Previously treated,Percentage,5,3.7,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Togo,Previously treated,Percentage,4.5,3.5,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Togo,Previously treated,Percentage,4.1,3.2,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Togo,Previously treated,Percentage,3.8,2.7,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Togo,Previously treated,Percentage,3.4,2.3,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Togo,Previously treated,Percentage,3.1,1.9,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Romania,New,Percentage,2.8,2.6,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Romania,New,Percentage,2.7,2.6,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Romania,New,Percentage,2.6,2.5,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Romania,New,Percentage,2.6,2.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Romania,New,Percentage,2.5,2.3,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Romania,New,Percentage,2.4,2.2,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Romania,New,Percentage,2.3,2.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Romania,New,Percentage,2.3,2.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Russian Federation,New,Percentage,33,32,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Russian Federation,New,Percentage,33,33,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Russian Federation,New,Percentage,34,33,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tokelau,Previously treated,Percentage,15,0.96,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tokelau,Previously treated,Percentage,14,1,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tokelau,Previously treated,Percentage,14,0.96,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tokelau,Previously treated,Percentage,13,0.98,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tokelau,Previously treated,Percentage,13,0.86,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tokelau,Previously treated,Percentage,12,0.75,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tokelau,Previously treated,Percentage,12,0.53,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tokelau,Previously treated,Percentage,12,0.18,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tokelau,Previously treated,Percentage,12,0,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tonga,Previously treated,Percentage,24,1.6,78
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Russian Federation,New,Percentage,34,34,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Russian Federation,New,Percentage,35,34,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Russian Federation,New,Percentage,35,35,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Russian Federation,New,Percentage,36,35,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Russian Federation,New,Percentage,36,36,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Russian Federation,New,Percentage,37,36,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Rwanda,New,Percentage,2.1,1.8,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Rwanda,New,Percentage,2,1.8,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Rwanda,New,Percentage,1.8,1.7,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Rwanda,New,Percentage,1.7,1.5,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Rwanda,New,Percentage,1.6,1.4,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bahamas,New,Percentage,4.5,2,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bahamas,New,Percentage,4.1,1.7,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bahrain,New,Percentage,2.4,1.5,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bahrain,New,Percentage,2.3,1.5,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bahrain,New,Percentage,2.3,1.5,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bahrain,New,Percentage,2.3,1.5,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bahrain,New,Percentage,2.2,1.4,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bahrain,New,Percentage,2.2,1.3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bahrain,New,Percentage,2.1,1.3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bahrain,New,Percentage,2.1,1.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bahrain,New,Percentage,2.1,1.1,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tonga,Previously treated,Percentage,23,1.6,74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tonga,Previously treated,Percentage,22,1.7,72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tonga,Previously treated,Percentage,21,1.7,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tonga,Previously treated,Percentage,20,1.8,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tonga,Previously treated,Percentage,19,1.9,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tonga,Previously treated,Percentage,19,1.9,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tonga,Previously treated,Percentage,18,1.8,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tonga,Previously treated,Percentage,17,1.7,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Trinidad and Tobago,Previously treated,Percentage,8.3,1.6,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Trinidad and Tobago,Previously treated,Percentage,8,1.7,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bangladesh,New,Percentage,1.1,0.74,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bangladesh,New,Percentage,1.1,0.73,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bangladesh,New,Percentage,1.1,0.71,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bangladesh,New,Percentage,1.1,0.69,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bangladesh,New,Percentage,1.1,0.68,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bangladesh,New,Percentage,1.1,0.65,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bangladesh,New,Percentage,1.1,0.62,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bangladesh,New,Percentage,1.1,0.59,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bangladesh,New,Percentage,1.1,0.55,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Barbados,New,Percentage,2.2,0.35,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Barbados,New,Percentage,2.2,0.36,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Rwanda,New,Percentage,1.5,1.3,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Rwanda,New,Percentage,1.4,1.2,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Rwanda,New,Percentage,1.3,1.1,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Rwanda,New,Percentage,1.2,1,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Kitts and Nevis,New,Percentage,3.3,0.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Kitts and Nevis,New,Percentage,3.1,0.29,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Kitts and Nevis,New,Percentage,3,0.29,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Kitts and Nevis,New,Percentage,3,0.29,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Kitts and Nevis,New,Percentage,2.9,0.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Kitts and Nevis,New,Percentage,2.8,0.29,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Kitts and Nevis,New,Percentage,2.7,0.28,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Serbia,Previously treated,Percentage,6.1,2.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Serbia,Previously treated,Percentage,6.1,2.2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Seychelles,Previously treated,Percentage,10,0.74,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Seychelles,Previously treated,Percentage,10,0.79,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Seychelles,Previously treated,Percentage,9.6,0.84,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Seychelles,Previously treated,Percentage,9.3,0.89,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Seychelles,Previously treated,Percentage,9.1,0.93,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Seychelles,Previously treated,Percentage,8.9,0.92,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Seychelles,Previously treated,Percentage,8.7,0.96,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Seychelles,Previously treated,Percentage,8.6,0.96,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Estonia,New,Percentage,22,19,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Eswatini,New,Percentage,7.4,6.3,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Eswatini,New,Percentage,6.9,5.9,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Eswatini,New,Percentage,6.4,5.6,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Eswatini,New,Percentage,6,5.3,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Eswatini,New,Percentage,5.5,5,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Eswatini,New,Percentage,5.1,4.6,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Eswatini,New,Percentage,4.8,4.2,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Eswatini,New,Percentage,4.4,3.8,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Eswatini,New,Percentage,4.1,3.4,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ethiopia,New,Percentage,1,0.93,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Seychelles,Previously treated,Percentage,8.4,0.92,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sierra Leone,Previously treated,Percentage,23,1.7,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sierra Leone,Previously treated,Percentage,21,1.8,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sierra Leone,Previously treated,Percentage,20,1.8,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sierra Leone,Previously treated,Percentage,18,1.7,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sierra Leone,Previously treated,Percentage,17,1.6,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sierra Leone,Previously treated,Percentage,16,1.7,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sierra Leone,Previously treated,Percentage,15,1.4,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sierra Leone,Previously treated,Percentage,14,1.2,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sierra Leone,Previously treated,Percentage,13,1.1,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ethiopia,New,Percentage,1,0.95,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ethiopia,New,Percentage,1.1,0.98,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ethiopia,New,Percentage,1.1,1,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ethiopia,New,Percentage,1.1,1,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ethiopia,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ethiopia,New,Percentage,1.1,1.1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ethiopia,New,Percentage,1.1,1.1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ethiopia,New,Percentage,1.1,1.1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Fiji,New,Percentage,0.91,0.38,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Fiji,New,Percentage,0.93,0.42,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Fiji,New,Percentage,0.95,0.46,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Barbados,New,Percentage,2.1,0.36,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Barbados,New,Percentage,2.1,0.38,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Barbados,New,Percentage,2.1,0.38,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Barbados,New,Percentage,2.1,0.38,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Barbados,New,Percentage,2.1,0.38,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Barbados,New,Percentage,2.1,0.38,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Barbados,New,Percentage,2.1,0.36,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belarus,New,Percentage,36,36,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belarus,New,Percentage,37,36,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belarus,New,Percentage,37,36,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belarus,New,Percentage,37,37,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Singapore,Previously treated,Percentage,2.4,1.7,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Singapore,Previously treated,Percentage,2.5,1.7,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Singapore,Previously treated,Percentage,2.5,1.6,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Singapore,Previously treated,Percentage,2.5,1.6,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Singapore,Previously treated,Percentage,2.5,1.5,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Singapore,Previously treated,Percentage,2.6,1.5,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Singapore,Previously treated,Percentage,2.6,1.5,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Singapore,Previously treated,Percentage,2.6,1.4,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Singapore,Previously treated,Percentage,2.7,1.4,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sint Maarten (Dutch part),Previously treated,Percentage,21,1.3,69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belarus,New,Percentage,38,37,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belarus,New,Percentage,38,37,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belarus,New,Percentage,39,38,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belarus,New,Percentage,39,38,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belarus,New,Percentage,39,38,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belgium,New,Percentage,1.6,1.3,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belgium,New,Percentage,1.6,1.3,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belgium,New,Percentage,1.6,1.2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belgium,New,Percentage,1.6,1.2,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belgium,New,Percentage,1.6,1.2,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belgium,New,Percentage,1.6,1.1,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belgium,New,Percentage,1.6,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belgium,New,Percentage,1.6,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belgium,New,Percentage,1.6,1,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Belize,New,Percentage,1.2,0.28,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Belize,New,Percentage,1.2,0.28,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Belize,New,Percentage,1.1,0.29,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Belize,New,Percentage,1.1,0.27,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Belize,New,Percentage,1,0.27,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Belize,New,Percentage,1,0.27,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Belize,New,Percentage,0.99,0.27,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Belize,New,Percentage,0.96,0.27,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sint Maarten (Dutch part),Previously treated,Percentage,20,1.4,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sint Maarten (Dutch part),Previously treated,Percentage,19,1.5,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sint Maarten (Dutch part),Previously treated,Percentage,18,1.4,62
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sint Maarten (Dutch part),Previously treated,Percentage,17,1.4,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sint Maarten (Dutch part),Previously treated,Percentage,17,1.5,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sint Maarten (Dutch part),Previously treated,Percentage,16,1.6,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sint Maarten (Dutch part),Previously treated,Percentage,16,1.6,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sint Maarten (Dutch part),Previously treated,Percentage,15,1.6,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Slovakia,Previously treated,Percentage,8.7,5.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Kitts and Nevis,New,Percentage,2.7,0.26,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Kitts and Nevis,New,Percentage,2.6,0.25,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Lucia,New,Percentage,2.6,0.2,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Lucia,New,Percentage,2.6,0.21,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Lucia,New,Percentage,2.6,0.22,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Lucia,New,Percentage,2.6,0.23,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Lucia,New,Percentage,2.6,0.23,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Lucia,New,Percentage,2.6,0.23,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Lucia,New,Percentage,2.7,0.24,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Lucia,New,Percentage,2.7,0.24,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Lucia,New,Percentage,2.8,0.25,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Belize,New,Percentage,0.94,0.26,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Benin,New,Percentage,1.2,0.67,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Benin,New,Percentage,1.1,0.68,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Benin,New,Percentage,1.1,0.69,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Benin,New,Percentage,1,0.7,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Benin,New,Percentage,0.98,0.68,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Benin,New,Percentage,0.93,0.7,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Benin,New,Percentage,0.88,0.7,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Benin,New,Percentage,0.84,0.67,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Benin,New,Percentage,0.8,0.63,0.99
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bermuda,New,Percentage,2.2,0.23,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saint Vincent and the Grenadines,New,Percentage,2.1,0.18,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saint Vincent and the Grenadines,New,Percentage,2,0.18,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saint Vincent and the Grenadines,New,Percentage,2,0.19,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saint Vincent and the Grenadines,New,Percentage,2,0.2,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saint Vincent and the Grenadines,New,Percentage,1.9,0.2,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saint Vincent and the Grenadines,New,Percentage,1.9,0.21,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saint Vincent and the Grenadines,New,Percentage,1.9,0.22,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saint Vincent and the Grenadines,New,Percentage,1.9,0.21,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saint Vincent and the Grenadines,New,Percentage,1.9,0.21,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Samoa,New,Percentage,1.3,0.32,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bermuda,New,Percentage,2.2,0.24,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bermuda,New,Percentage,2.1,0.24,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bermuda,New,Percentage,2.1,0.24,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bermuda,New,Percentage,2.1,0.24,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bermuda,New,Percentage,2.1,0.23,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bermuda,New,Percentage,2.1,0.24,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bermuda,New,Percentage,2.1,0.23,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bermuda,New,Percentage,2.1,0.22,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bhutan,New,Percentage,14,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bhutan,New,Percentage,14,12,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bhutan,New,Percentage,14,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Slovakia,Previously treated,Percentage,9.3,6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Slovakia,Previously treated,Percentage,9.9,6.3,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Slovakia,Previously treated,Percentage,11,6.6,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Slovakia,Previously treated,Percentage,11,6.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Slovakia,Previously treated,Percentage,12,6.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Slovakia,Previously treated,Percentage,13,7.2,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Slovakia,Previously treated,Percentage,14,7.5,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Slovakia,Previously treated,Percentage,15,7.8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Slovenia,Previously treated,Percentage,2.5,0.86,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Slovenia,Previously treated,Percentage,2.7,0.89,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Samoa,New,Percentage,1.3,0.33,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Samoa,New,Percentage,1.3,0.33,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Samoa,New,Percentage,1.4,0.34,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Samoa,New,Percentage,1.4,0.34,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Samoa,New,Percentage,1.4,0.35,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Samoa,New,Percentage,1.4,0.35,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Samoa,New,Percentage,1.5,0.34,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Samoa,New,Percentage,1.5,0.32,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,San Marino,New,Percentage,1.8,0.27,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,San Marino,New,Percentage,1.9,0.29,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,San Marino,New,Percentage,1.9,0.31,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bhutan,New,Percentage,13,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bhutan,New,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bhutan,New,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bhutan,New,Percentage,13,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bhutan,New,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bhutan,New,Percentage,12,10,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bolivia (Plurinational State of),New,Percentage,1.7,1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bolivia (Plurinational State of),New,Percentage,1.7,1.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bolivia (Plurinational State of),New,Percentage,1.7,1.2,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bolivia (Plurinational State of),New,Percentage,1.6,1.2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bolivia (Plurinational State of),New,Percentage,1.6,1.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,San Marino,New,Percentage,2,0.34,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,San Marino,New,Percentage,2,0.35,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,San Marino,New,Percentage,2.1,0.36,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,San Marino,New,Percentage,2.2,0.39,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,San Marino,New,Percentage,2.2,0.4,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,San Marino,New,Percentage,2.3,0.41,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sao Tome and Principe,New,Percentage,5,0.35,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sao Tome and Principe,New,Percentage,4.8,0.36,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sao Tome and Principe,New,Percentage,4.6,0.37,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sao Tome and Principe,New,Percentage,4.4,0.39,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sao Tome and Principe,New,Percentage,4.2,0.4,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Slovenia,Previously treated,Percentage,2.9,0.92,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Slovenia,Previously treated,Percentage,3.1,0.95,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Slovenia,Previously treated,Percentage,3.3,0.96,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Slovenia,Previously treated,Percentage,3.5,0.97,8.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Slovenia,Previously treated,Percentage,3.7,0.96,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Slovenia,Previously treated,Percentage,4,0.95,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Slovenia,Previously treated,Percentage,4.3,1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Solomon Islands,Previously treated,Percentage,3.7,0.52,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Solomon Islands,Previously treated,Percentage,3.7,0.55,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Solomon Islands,Previously treated,Percentage,3.8,0.59,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bolivia (Plurinational State of),New,Percentage,1.6,1.3,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bolivia (Plurinational State of),New,Percentage,1.6,1.4,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bolivia (Plurinational State of),New,Percentage,1.6,1.4,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bolivia (Plurinational State of),New,Percentage,1.5,1.3,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bosnia and Herzegovina,New,Percentage,0.29,0.19,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bosnia and Herzegovina,New,Percentage,0.28,0.18,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bosnia and Herzegovina,New,Percentage,0.27,0.17,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bosnia and Herzegovina,New,Percentage,0.27,0.16,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bosnia and Herzegovina,New,Percentage,0.26,0.15,0.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bosnia and Herzegovina,New,Percentage,0.25,0.14,0.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sao Tome and Principe,New,Percentage,4.1,0.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sao Tome and Principe,New,Percentage,3.9,0.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sao Tome and Principe,New,Percentage,3.8,0.41,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sao Tome and Principe,New,Percentage,3.7,0.4,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Saudi Arabia,New,Percentage,1.9,1.6,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Saudi Arabia,New,Percentage,1.8,1.5,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Saudi Arabia,New,Percentage,1.7,1.4,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Saudi Arabia,New,Percentage,1.6,1.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Saudi Arabia,New,Percentage,1.5,1.2,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Saudi Arabia,New,Percentage,1.4,1.1,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Saudi Arabia,New,Percentage,1.3,0.98,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bosnia and Herzegovina,New,Percentage,0.25,0.14,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bosnia and Herzegovina,New,Percentage,0.24,0.13,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bosnia and Herzegovina,New,Percentage,0.23,0.12,0.41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Somalia,New,Percentage,3.8,3.4,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Somalia,New,Percentage,3.5,3.2,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Somalia,New,Percentage,3.3,2.9,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,South Africa,New,Percentage,2.4,2.2,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,South Africa,New,Percentage,2.5,2.3,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,South Africa,New,Percentage,2.6,2.5,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,South Africa,New,Percentage,2.7,2.5,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,South Africa,New,Percentage,2.7,2.7,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Germany,Previously treated,Percentage,24,19,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Germany,Previously treated,Percentage,26,19,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Germany,Previously treated,Percentage,27,20,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ghana,Previously treated,Percentage,27,22,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ghana,Previously treated,Percentage,21,18,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ghana,Previously treated,Percentage,16,14,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ghana,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ghana,Previously treated,Percentage,9.4,8.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ghana,Previously treated,Percentage,7,6.3,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ghana,Previously treated,Percentage,5.2,4.5,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ghana,Previously treated,Percentage,3.8,3.2,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Saudi Arabia,New,Percentage,1.3,0.9,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Saudi Arabia,New,Percentage,1.2,0.82,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Senegal,New,Percentage,1,0.56,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Senegal,New,Percentage,0.98,0.54,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Senegal,New,Percentage,0.95,0.51,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Senegal,New,Percentage,0.92,0.48,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Senegal,New,Percentage,0.89,0.44,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Senegal,New,Percentage,0.87,0.4,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Senegal,New,Percentage,0.85,0.36,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Senegal,New,Percentage,0.83,0.33,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Senegal,New,Percentage,0.81,0.3,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Solomon Islands,Previously treated,Percentage,3.8,0.63,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Solomon Islands,Previously treated,Percentage,3.9,0.69,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Solomon Islands,Previously treated,Percentage,4,0.73,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Solomon Islands,Previously treated,Percentage,4.2,0.76,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Madagascar,New,Percentage,1,0.28,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Madagascar,New,Percentage,1,0.27,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Madagascar,New,Percentage,1.1,0.27,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malawi,New,Percentage,1.9,1.2,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malawi,New,Percentage,1.9,1.3,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malawi,New,Percentage,2,1.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malawi,New,Percentage,2,1.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,South Africa,New,Percentage,2.8,2.8,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,South Africa,New,Percentage,2.9,2.9,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,South Africa,New,Percentage,3,3,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,South Africa,New,Percentage,3.1,3.1,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,South Sudan,New,Percentage,2,0.14,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,South Sudan,New,Percentage,2,0.14,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,South Sudan,New,Percentage,1.9,0.15,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,South Sudan,New,Percentage,1.8,0.15,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,South Sudan,New,Percentage,1.8,0.15,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,South Sudan,New,Percentage,1.7,0.15,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,South Sudan,New,Percentage,1.7,0.15,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ghana,Previously treated,Percentage,2.8,2.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Greece,Previously treated,Percentage,15,7.6,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Greece,Previously treated,Percentage,14,6.8,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Greece,Previously treated,Percentage,13,5.9,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Greece,Previously treated,Percentage,13,5.2,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Greece,Previously treated,Percentage,12,4.5,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Greece,Previously treated,Percentage,11,3.7,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Greece,Previously treated,Percentage,11,3.1,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Greece,Previously treated,Percentage,10,2.6,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Greece,Previously treated,Percentage,9.5,2.2,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Greenland,Previously treated,Percentage,2.1,0.81,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Serbia,New,Percentage,0.85,0.54,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Serbia,New,Percentage,0.87,0.52,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Serbia,New,Percentage,0.88,0.51,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Serbia,New,Percentage,0.9,0.49,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Serbia,New,Percentage,0.91,0.47,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Serbia,New,Percentage,0.93,0.45,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Serbia,New,Percentage,0.95,0.43,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Serbia,New,Percentage,0.97,0.41,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Serbia,New,Percentage,0.99,0.4,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Seychelles,New,Percentage,1.2,0.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Seychelles,New,Percentage,1.2,0.21,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Greenland,Previously treated,Percentage,2.3,0.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Greenland,Previously treated,Percentage,2.5,0.97,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Greenland,Previously treated,Percentage,2.7,1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Greenland,Previously treated,Percentage,2.9,1.1,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Greenland,Previously treated,Percentage,3.1,1.1,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Greenland,Previously treated,Percentage,3.4,1.1,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Greenland,Previously treated,Percentage,3.7,1.2,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Greenland,Previously treated,Percentage,4,1.2,9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Grenada,Previously treated,Percentage,16,1.3,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Grenada,Previously treated,Percentage,15,1.3,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Trinidad and Tobago,Previously treated,Percentage,7.7,1.7,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Trinidad and Tobago,Previously treated,Percentage,7.4,1.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Trinidad and Tobago,Previously treated,Percentage,7.2,1.8,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Trinidad and Tobago,Previously treated,Percentage,7,1.7,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Trinidad and Tobago,Previously treated,Percentage,6.8,1.7,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Trinidad and Tobago,Previously treated,Percentage,6.7,1.6,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Trinidad and Tobago,Previously treated,Percentage,6.7,1.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tunisia,Previously treated,Percentage,13,8.5,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tunisia,Previously treated,Percentage,14,10,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tunisia,Previously treated,Percentage,16,12,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Grenada,Previously treated,Percentage,15,1.3,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Grenada,Previously treated,Percentage,14,1.3,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Grenada,Previously treated,Percentage,14,1.4,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Grenada,Previously treated,Percentage,13,1.4,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Grenada,Previously treated,Percentage,13,1.4,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Grenada,Previously treated,Percentage,13,1.4,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Grenada,Previously treated,Percentage,13,1.4,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guam,Previously treated,Percentage,9.2,1.5,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guam,Previously treated,Percentage,9,1.5,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guam,Previously treated,Percentage,8.8,1.5,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Seychelles,New,Percentage,1.1,0.23,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Seychelles,New,Percentage,1.1,0.24,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Seychelles,New,Percentage,1.1,0.26,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Seychelles,New,Percentage,1.1,0.26,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Seychelles,New,Percentage,1.1,0.26,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Seychelles,New,Percentage,1.1,0.27,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Seychelles,New,Percentage,1.1,0.28,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sierra Leone,New,Percentage,1.6,0.19,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sierra Leone,New,Percentage,1.5,0.19,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sierra Leone,New,Percentage,1.5,0.19,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sierra Leone,New,Percentage,1.4,0.19,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guam,Previously treated,Percentage,8.6,1.6,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guam,Previously treated,Percentage,8.4,1.7,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guam,Previously treated,Percentage,8.3,1.5,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guam,Previously treated,Percentage,8.2,1.4,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guam,Previously treated,Percentage,8.2,1.3,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guam,Previously treated,Percentage,8.2,1.3,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guatemala,Previously treated,Percentage,14,12,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guatemala,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guatemala,Previously treated,Percentage,12,10,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guatemala,Previously treated,Percentage,11,9.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malawi,New,Percentage,2.1,1.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malawi,New,Percentage,2.1,1.5,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malawi,New,Percentage,2.2,1.5,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malawi,New,Percentage,2.2,1.5,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malawi,New,Percentage,2.3,1.4,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malaysia,New,Percentage,1.4,1.2,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malaysia,New,Percentage,1.3,1.2,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malaysia,New,Percentage,1.3,1.1,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malaysia,New,Percentage,1.2,1.1,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malaysia,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malaysia,New,Percentage,1,0.95,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tunisia,Previously treated,Percentage,17,13,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tunisia,Previously treated,Percentage,19,14,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tunisia,Previously treated,Percentage,21,15,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tunisia,Previously treated,Percentage,23,15,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tunisia,Previously treated,Percentage,26,15,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tunisia,Previously treated,Percentage,28,16,42
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Trkiye,Previously treated,Percentage,18,17,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Trkiye,Previously treated,Percentage,17,16,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Trkiye,Previously treated,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Trkiye,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Trkiye,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sierra Leone,New,Percentage,1.4,0.18,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sierra Leone,New,Percentage,1.3,0.17,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sierra Leone,New,Percentage,1.3,0.18,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sierra Leone,New,Percentage,1.3,0.18,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sierra Leone,New,Percentage,1.2,0.18,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Singapore,New,Percentage,1.2,1,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Singapore,New,Percentage,1.2,1.1,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Singapore,New,Percentage,1.3,1.2,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Singapore,New,Percentage,1.4,1.2,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Singapore,New,Percentage,1.5,1.3,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Singapore,New,Percentage,1.6,1.3,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Singapore,New,Percentage,1.7,1.4,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Singapore,New,Percentage,1.8,1.5,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Singapore,New,Percentage,2,1.6,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sint Maarten (Dutch part),New,Percentage,3.7,0.32,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sint Maarten (Dutch part),New,Percentage,3.7,0.34,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sint Maarten (Dutch part),New,Percentage,3.8,0.35,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sint Maarten (Dutch part),New,Percentage,3.8,0.35,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sint Maarten (Dutch part),New,Percentage,3.8,0.37,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sint Maarten (Dutch part),New,Percentage,3.9,0.38,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sint Maarten (Dutch part),New,Percentage,3.9,0.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sint Maarten (Dutch part),New,Percentage,4,0.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malaysia,New,Percentage,0.98,0.89,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malaysia,New,Percentage,0.92,0.81,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malaysia,New,Percentage,0.87,0.74,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Maldives,New,Percentage,0.94,0.16,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Maldives,New,Percentage,0.91,0.16,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Maldives,New,Percentage,0.89,0.17,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Maldives,New,Percentage,0.87,0.17,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Maldives,New,Percentage,0.86,0.17,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Maldives,New,Percentage,0.84,0.17,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Maldives,New,Percentage,0.83,0.18,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Maldives,New,Percentage,0.82,0.19,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Trkiye,Previously treated,Percentage,12,10,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Trkiye,Previously treated,Percentage,11,9.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Trkiye,Previously treated,Percentage,9.6,8.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Trkiye,Previously treated,Percentage,8.7,7.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Turkmenistan,Previously treated,Percentage,47,41,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Turkmenistan,Previously treated,Percentage,48,43,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Turkmenistan,Previously treated,Percentage,49,45,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Turkmenistan,Previously treated,Percentage,49,46,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Turkmenistan,Previously treated,Percentage,50,47,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Turkmenistan,Previously treated,Percentage,51,48,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Maldives,New,Percentage,0.82,0.19,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mali,New,Percentage,1,0.43,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mali,New,Percentage,1,0.45,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mali,New,Percentage,1,0.47,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mali,New,Percentage,0.98,0.48,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mali,New,Percentage,0.96,0.47,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mali,New,Percentage,0.95,0.46,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mali,New,Percentage,0.94,0.44,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mali,New,Percentage,0.93,0.43,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mali,New,Percentage,0.92,0.42,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malta,New,Percentage,1,0.34,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malta,New,Percentage,1,0.35,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Turkmenistan,Previously treated,Percentage,51,48,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Turkmenistan,Previously treated,Percentage,52,48,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Turkmenistan,Previously treated,Percentage,53,48,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Turks and Caicos Islands,Previously treated,Percentage,21,1.6,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Turks and Caicos Islands,Previously treated,Percentage,20,1.6,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Turks and Caicos Islands,Previously treated,Percentage,19,1.7,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Turks and Caicos Islands,Previously treated,Percentage,18,1.8,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,New Caledonia,New,Percentage,0.93,0.31,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,New Caledonia,New,Percentage,0.95,0.31,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,New Caledonia,New,Percentage,0.96,0.31,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guatemala,Previously treated,Percentage,11,8.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guatemala,Previously treated,Percentage,10,8.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guatemala,Previously treated,Percentage,9.3,7.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guatemala,Previously treated,Percentage,8.7,7.1,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guatemala,Previously treated,Percentage,8.1,6.5,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guinea,Previously treated,Percentage,53,46,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guinea,Previously treated,Percentage,50,44,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guinea,Previously treated,Percentage,46,42,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guinea,Previously treated,Percentage,43,40,47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guinea,Previously treated,Percentage,40,37,43
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,New Caledonia,New,Percentage,0.98,0.31,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,New Caledonia,New,Percentage,1,0.31,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,New Zealand,New,Percentage,1.2,0.61,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,New Zealand,New,Percentage,1.3,0.62,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,New Zealand,New,Percentage,1.4,0.62,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,New Zealand,New,Percentage,1.4,0.61,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,New Zealand,New,Percentage,1.5,0.6,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,New Zealand,New,Percentage,1.6,0.6,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,New Zealand,New,Percentage,1.7,0.59,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,New Zealand,New,Percentage,1.8,0.58,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,New Zealand,New,Percentage,1.9,0.57,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malta,New,Percentage,1,0.35,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malta,New,Percentage,1.1,0.36,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malta,New,Percentage,1.1,0.37,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malta,New,Percentage,1.1,0.37,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malta,New,Percentage,1.2,0.37,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malta,New,Percentage,1.2,0.37,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malta,New,Percentage,1.3,0.37,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Marshall Islands,New,Percentage,1.4,0.67,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Marshall Islands,New,Percentage,1.4,0.65,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Marshall Islands,New,Percentage,1.4,0.62,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Marshall Islands,New,Percentage,1.4,0.59,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Marshall Islands,New,Percentage,1.4,0.58,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Marshall Islands,New,Percentage,1.4,0.54,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Marshall Islands,New,Percentage,1.4,0.51,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Marshall Islands,New,Percentage,1.4,0.48,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Marshall Islands,New,Percentage,1.4,0.46,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mauritania,New,Percentage,1.6,0.15,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mauritania,New,Percentage,1.6,0.15,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mauritania,New,Percentage,1.5,0.15,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mauritania,New,Percentage,1.5,0.16,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mauritania,New,Percentage,1.4,0.16,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mauritania,New,Percentage,1.4,0.16,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nicaragua,New,Percentage,1.3,0.72,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nicaragua,New,Percentage,1.3,0.77,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nicaragua,New,Percentage,1.3,0.79,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nicaragua,New,Percentage,1.3,0.82,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nicaragua,New,Percentage,1.3,0.81,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nicaragua,New,Percentage,1.3,0.81,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nicaragua,New,Percentage,1.3,0.78,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nicaragua,New,Percentage,1.4,0.78,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nicaragua,New,Percentage,1.4,0.75,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Niger,New,Percentage,3.4,1.3,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Niger,New,Percentage,3.3,1.4,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Niger,New,Percentage,3.2,1.5,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Niger,New,Percentage,3.1,1.6,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Niger,New,Percentage,3,1.7,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Niger,New,Percentage,2.9,1.7,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Niger,New,Percentage,2.9,1.6,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Niger,New,Percentage,2.8,1.6,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Niger,New,Percentage,2.7,1.5,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nigeria,New,Percentage,4.6,3.9,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nigeria,New,Percentage,4,3.5,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nigeria,New,Percentage,3.5,3.1,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nigeria,New,Percentage,3.1,2.8,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nigeria,New,Percentage,2.7,2.5,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nigeria,New,Percentage,2.4,2.2,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nigeria,New,Percentage,2.1,2,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nigeria,New,Percentage,1.8,1.8,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nigeria,New,Percentage,1.6,1.5,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Niue,New,Percentage,2,0.15,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Niue,New,Percentage,2,0.15,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Niue,New,Percentage,2,0.16,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Niue,New,Percentage,2,0.17,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Niue,New,Percentage,2,0.18,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Niue,New,Percentage,2,0.19,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Niue,New,Percentage,2,0.19,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Niue,New,Percentage,2,0.2,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sint Maarten (Dutch part),New,Percentage,4,0.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Slovakia,New,Percentage,1.8,1.2,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Slovakia,New,Percentage,1.8,1.2,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Slovakia,New,Percentage,1.9,1.2,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Slovakia,New,Percentage,2,1.2,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Slovakia,New,Percentage,2.1,1.2,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Slovakia,New,Percentage,2.2,1.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Slovakia,New,Percentage,2.3,1.3,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Slovakia,New,Percentage,2.4,1.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Slovakia,New,Percentage,2.5,1.3,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Slovenia,New,Percentage,0.43,0.2,0.74
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Niue,New,Percentage,2.1,0.21,6.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,North Macedonia,New,Percentage,1.2,0.82,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,North Macedonia,New,Percentage,1.2,0.8,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,North Macedonia,New,Percentage,1.2,0.75,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,North Macedonia,New,Percentage,1.1,0.71,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,North Macedonia,New,Percentage,1.1,0.67,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,North Macedonia,New,Percentage,1.1,0.62,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,North Macedonia,New,Percentage,1.1,0.57,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,North Macedonia,New,Percentage,1,0.53,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,North Macedonia,New,Percentage,1,0.49,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Northern Mariana Islands,New,Percentage,2.8,1.4,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Slovenia,New,Percentage,0.44,0.2,0.78
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Slovenia,New,Percentage,0.45,0.19,0.82
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Slovenia,New,Percentage,0.46,0.2,0.87
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Slovenia,New,Percentage,0.47,0.19,0.93
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Slovenia,New,Percentage,0.48,0.19,0.99
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Slovenia,New,Percentage,0.49,0.19,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Slovenia,New,Percentage,0.5,0.19,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Slovenia,New,Percentage,0.51,0.18,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Solomon Islands,New,Percentage,1.5,0.26,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Solomon Islands,New,Percentage,1.5,0.28,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Solomon Islands,New,Percentage,1.5,0.3,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mauritania,New,Percentage,1.3,0.16,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mauritania,New,Percentage,1.3,0.16,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mauritania,New,Percentage,1.3,0.16,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mauritius,New,Percentage,0.97,0.56,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mauritius,New,Percentage,0.99,0.58,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mauritius,New,Percentage,1,0.6,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mauritius,New,Percentage,1,0.61,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mauritius,New,Percentage,1,0.61,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mauritius,New,Percentage,1.1,0.6,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mauritius,New,Percentage,1.1,0.59,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mauritius,New,Percentage,1.1,0.59,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Northern Mariana Islands,New,Percentage,2.7,1.4,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Northern Mariana Islands,New,Percentage,2.7,1.3,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Northern Mariana Islands,New,Percentage,2.6,1.2,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Northern Mariana Islands,New,Percentage,2.6,1.2,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Northern Mariana Islands,New,Percentage,2.5,1.1,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Northern Mariana Islands,New,Percentage,2.5,1,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Northern Mariana Islands,New,Percentage,2.4,0.94,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Northern Mariana Islands,New,Percentage,2.4,0.88,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Norway,New,Percentage,3.8,3.1,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Norway,New,Percentage,4.1,3.3,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,South Sudan,New,Percentage,1.7,0.14,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,South Sudan,New,Percentage,1.6,0.14,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Spain,New,Percentage,4,2.8,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Spain,New,Percentage,3.9,2.7,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Spain,New,Percentage,3.8,2.6,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Spain,New,Percentage,3.8,2.3,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Spain,New,Percentage,3.8,2.2,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Spain,New,Percentage,3.7,2,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Spain,New,Percentage,3.7,1.7,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Spain,New,Percentage,3.7,1.5,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Spain,New,Percentage,3.7,1.4,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mauritius,New,Percentage,1.2,0.58,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mexico,New,Percentage,2.5,1.5,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mexico,New,Percentage,2.5,1.4,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mexico,New,Percentage,2.5,1.3,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mexico,New,Percentage,2.5,1.2,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mexico,New,Percentage,2.5,1.1,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mexico,New,Percentage,2.5,0.96,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mexico,New,Percentage,2.5,0.88,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mexico,New,Percentage,2.5,0.8,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mexico,New,Percentage,2.5,0.73,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Micronesia (Federated States of),New,Percentage,0.89,0.13,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Micronesia (Federated States of),New,Percentage,0.88,0.13,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Micronesia (Federated States of),New,Percentage,0.86,0.13,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Micronesia (Federated States of),New,Percentage,0.85,0.14,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Micronesia (Federated States of),New,Percentage,0.85,0.15,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Micronesia (Federated States of),New,Percentage,0.84,0.16,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Micronesia (Federated States of),New,Percentage,0.83,0.16,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Micronesia (Federated States of),New,Percentage,0.83,0.16,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Micronesia (Federated States of),New,Percentage,0.83,0.15,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Monaco,New,Percentage,2.6,0.25,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Monaco,New,Percentage,2.5,0.26,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Solomon Islands,New,Percentage,1.5,0.31,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Solomon Islands,New,Percentage,1.5,0.31,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Solomon Islands,New,Percentage,1.5,0.32,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Solomon Islands,New,Percentage,1.5,0.31,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Solomon Islands,New,Percentage,1.5,0.3,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Solomon Islands,New,Percentage,1.5,0.31,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Somalia,New,Percentage,6.1,4.9,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Somalia,New,Percentage,5.6,4.7,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Somalia,New,Percentage,5.2,4.4,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Somalia,New,Percentage,4.8,4.2,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Somalia,New,Percentage,4.5,3.9,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Norway,New,Percentage,4.4,3.4,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Norway,New,Percentage,4.8,3.6,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Norway,New,Percentage,5.1,3.8,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Norway,New,Percentage,5.5,4,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Norway,New,Percentage,5.9,4.2,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Norway,New,Percentage,6.4,4.5,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Norway,New,Percentage,6.8,4.7,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.9,0.45,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.7,0.45,8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.6,0.42,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.4,0.39,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.3,0.37,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.2,0.37,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2.1,0.36,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"occupied Palestinian territory, including east Jerusalem",New,Percentage,2,0.35,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"occupied Palestinian territory, including east Jerusalem",New,Percentage,1.9,0.31,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Oman,New,Percentage,1.5,1.1,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Oman,New,Percentage,1.5,1.1,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Oman,New,Percentage,1.5,1.1,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Monaco,New,Percentage,2.4,0.25,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Monaco,New,Percentage,2.4,0.26,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Monaco,New,Percentage,2.3,0.27,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Monaco,New,Percentage,2.2,0.28,8.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Monaco,New,Percentage,2.2,0.28,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Monaco,New,Percentage,2.1,0.28,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Monaco,New,Percentage,2.1,0.28,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mongolia,New,Percentage,4.8,4.1,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mongolia,New,Percentage,5,4.4,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mongolia,New,Percentage,5.2,4.6,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mongolia,New,Percentage,5.4,4.9,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Oman,New,Percentage,1.5,1.1,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Oman,New,Percentage,1.5,1.1,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Oman,New,Percentage,1.5,1,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Oman,New,Percentage,1.5,1,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Oman,New,Percentage,1.5,0.97,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Oman,New,Percentage,1.5,0.94,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Pakistan,New,Percentage,3.7,3.3,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Pakistan,New,Percentage,3.4,3.1,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Pakistan,New,Percentage,3.2,3,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Pakistan,New,Percentage,3,2.8,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Pakistan,New,Percentage,2.8,2.7,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Pakistan,New,Percentage,2.6,2.5,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sri Lanka,New,Percentage,0.46,0.18,0.93
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sri Lanka,New,Percentage,0.46,0.17,0.94
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sri Lanka,New,Percentage,0.47,0.16,0.97
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sri Lanka,New,Percentage,0.47,0.16,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sri Lanka,New,Percentage,0.48,0.15,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sri Lanka,New,Percentage,0.48,0.14,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sri Lanka,New,Percentage,0.49,0.14,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sri Lanka,New,Percentage,0.5,0.13,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sri Lanka,New,Percentage,0.51,0.12,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sudan,New,Percentage,2.9,1.7,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sudan,New,Percentage,2.9,1.8,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Pakistan,New,Percentage,2.4,2.3,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Pakistan,New,Percentage,2.3,2.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Pakistan,New,Percentage,2.1,1.9,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Palau,New,Percentage,2.7,0.71,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Palau,New,Percentage,2.7,0.7,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Palau,New,Percentage,2.7,0.71,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Palau,New,Percentage,2.6,0.71,5.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Palau,New,Percentage,2.6,0.7,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Palau,New,Percentage,2.5,0.71,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Palau,New,Percentage,2.5,0.69,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Palau,New,Percentage,2.5,0.68,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mongolia,New,Percentage,5.6,5.2,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mongolia,New,Percentage,5.9,5.4,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mongolia,New,Percentage,6.1,5.6,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mongolia,New,Percentage,6.4,5.8,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mongolia,New,Percentage,6.7,5.9,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Montenegro,New,Percentage,0.63,0.25,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Montenegro,New,Percentage,0.61,0.24,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Montenegro,New,Percentage,0.6,0.23,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Montenegro,New,Percentage,0.58,0.22,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Montenegro,New,Percentage,0.57,0.21,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Montenegro,New,Percentage,0.56,0.2,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Palau,New,Percentage,2.5,0.66,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Panama,New,Percentage,4,2.1,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Panama,New,Percentage,4,2.1,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Panama,New,Percentage,4,2.3,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Panama,New,Percentage,4,2.4,6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Panama,New,Percentage,4.1,2.5,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Panama,New,Percentage,4.1,2.5,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Panama,New,Percentage,4.2,2.4,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Panama,New,Percentage,4.2,2.3,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Panama,New,Percentage,4.3,2.3,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Papua New Guinea,New,Percentage,3.9,3,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Montenegro,New,Percentage,0.55,0.19,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Montenegro,New,Percentage,0.54,0.18,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Montenegro,New,Percentage,0.53,0.17,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Montserrat,New,Percentage,2.9,0.2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Montserrat,New,Percentage,2.9,0.21,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Montserrat,New,Percentage,2.8,0.22,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Montserrat,New,Percentage,2.8,0.21,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Montserrat,New,Percentage,2.7,0.2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Montserrat,New,Percentage,2.7,0.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Montserrat,New,Percentage,2.7,0.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Montserrat,New,Percentage,2.7,0.19,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Papua New Guinea,New,Percentage,4,3.2,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Papua New Guinea,New,Percentage,4.2,3.4,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Papua New Guinea,New,Percentage,4.3,3.6,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Papua New Guinea,New,Percentage,4.4,3.8,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Papua New Guinea,New,Percentage,4.5,4,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Papua New Guinea,New,Percentage,4.6,4.2,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Papua New Guinea,New,Percentage,4.8,4.4,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Papua New Guinea,New,Percentage,4.9,4.5,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Paraguay,New,Percentage,0.8,0.56,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Paraguay,New,Percentage,0.74,0.52,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Paraguay,New,Percentage,0.69,0.49,0.94
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Montserrat,New,Percentage,2.7,0.19,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Morocco,New,Percentage,0.97,0.53,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Morocco,New,Percentage,0.99,0.51,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Morocco,New,Percentage,1,0.49,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Morocco,New,Percentage,1,0.47,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Morocco,New,Percentage,1.1,0.46,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Morocco,New,Percentage,1.1,0.45,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Morocco,New,Percentage,1.1,0.44,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Morocco,New,Percentage,1.2,0.42,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Morocco,New,Percentage,1.2,0.4,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mozambique,New,Percentage,3.4,2.9,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Paraguay,New,Percentage,0.64,0.45,0.87
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Paraguay,New,Percentage,0.59,0.41,0.81
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Paraguay,New,Percentage,0.55,0.37,0.76
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Paraguay,New,Percentage,0.51,0.34,0.72
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Paraguay,New,Percentage,0.47,0.31,0.68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Paraguay,New,Percentage,0.43,0.28,0.64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Peru,New,Percentage,5.6,5.5,5.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Peru,New,Percentage,5.8,5.6,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Peru,New,Percentage,5.9,5.8,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Peru,New,Percentage,6.1,6,6.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Peru,New,Percentage,6.3,6.1,6.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mozambique,New,Percentage,3.3,2.9,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mozambique,New,Percentage,3.3,2.9,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mozambique,New,Percentage,3.2,2.9,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mozambique,New,Percentage,3.2,3,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mozambique,New,Percentage,3.1,3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mozambique,New,Percentage,3.1,3,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mozambique,New,Percentage,3,2.9,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mozambique,New,Percentage,3,2.9,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Myanmar,New,Percentage,5.3,5,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Myanmar,New,Percentage,5.1,4.9,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Myanmar,New,Percentage,4.9,4.7,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Peru,New,Percentage,6.5,6.3,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Peru,New,Percentage,6.7,6.4,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Peru,New,Percentage,6.8,6.6,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Peru,New,Percentage,7,6.8,7.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Philippines,New,Percentage,2.9,2.5,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Philippines,New,Percentage,2.8,2.4,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Philippines,New,Percentage,2.7,2.4,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Philippines,New,Percentage,2.6,2.3,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Philippines,New,Percentage,2.6,2.2,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Philippines,New,Percentage,2.5,2.1,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Philippines,New,Percentage,2.4,2,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Myanmar,New,Percentage,4.7,4.5,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Myanmar,New,Percentage,4.5,4.3,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Myanmar,New,Percentage,4.2,4.1,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Myanmar,New,Percentage,3.9,3.8,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Myanmar,New,Percentage,3.6,3.5,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Myanmar,New,Percentage,3.4,3.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Namibia,New,Percentage,5,4.6,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Namibia,New,Percentage,4.9,4.5,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Namibia,New,Percentage,4.8,4.5,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Namibia,New,Percentage,4.7,4.4,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Namibia,New,Percentage,4.5,4.3,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Namibia,New,Percentage,4.4,4.2,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Namibia,New,Percentage,4.3,4.1,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Namibia,New,Percentage,4.2,4,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Namibia,New,Percentage,4.1,3.8,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nauru,New,Percentage,1.2,0.17,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nauru,New,Percentage,1.3,0.19,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nauru,New,Percentage,1.3,0.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nauru,New,Percentage,1.3,0.21,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nauru,New,Percentage,1.3,0.22,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nauru,New,Percentage,1.3,0.24,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nauru,New,Percentage,1.4,0.25,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Philippines,New,Percentage,2.4,1.9,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Philippines,New,Percentage,2.3,1.9,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Poland,New,Percentage,1,0.92,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Poland,New,Percentage,1,0.95,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Poland,New,Percentage,1.1,0.99,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Poland,New,Percentage,1.1,1,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Poland,New,Percentage,1.2,1.1,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Poland,New,Percentage,1.3,1.1,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Poland,New,Percentage,1.3,1.1,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Poland,New,Percentage,1.4,1.2,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Poland,New,Percentage,1.4,1.2,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nauru,New,Percentage,1.4,0.25,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nauru,New,Percentage,1.4,0.26,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nepal,New,Percentage,3.2,2.8,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nepal,New,Percentage,3.3,2.9,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nepal,New,Percentage,3.4,3,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nepal,New,Percentage,3.5,3.1,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nepal,New,Percentage,3.6,3.2,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nepal,New,Percentage,3.7,3.3,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nepal,New,Percentage,3.8,3.4,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nepal,New,Percentage,3.9,3.5,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nepal,New,Percentage,4,3.6,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Netherlands (Kingdom of the),New,Percentage,1.8,1.5,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Netherlands (Kingdom of the),New,Percentage,1.9,1.6,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Netherlands (Kingdom of the),New,Percentage,2,1.6,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Netherlands (Kingdom of the),New,Percentage,2.1,1.7,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Netherlands (Kingdom of the),New,Percentage,2.2,1.7,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Netherlands (Kingdom of the),New,Percentage,2.3,1.8,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Netherlands (Kingdom of the),New,Percentage,2.4,1.8,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Netherlands (Kingdom of the),New,Percentage,2.5,1.9,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Netherlands (Kingdom of the),New,Percentage,2.6,2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,New Caledonia,New,Percentage,0.9,0.24,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,New Caledonia,New,Percentage,0.91,0.27,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Portugal,New,Percentage,1.1,0.79,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Portugal,New,Percentage,1.1,0.74,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Portugal,New,Percentage,1.1,0.69,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Portugal,New,Percentage,1,0.64,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Portugal,New,Percentage,0.99,0.6,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Portugal,New,Percentage,0.96,0.56,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Portugal,New,Percentage,0.93,0.52,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Portugal,New,Percentage,0.9,0.48,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Portugal,New,Percentage,0.87,0.44,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Puerto Rico,New,Percentage,1.9,1.1,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Puerto Rico,New,Percentage,1.9,1.1,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Puerto Rico,New,Percentage,2,1.1,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Puerto Rico,New,Percentage,2,1.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Puerto Rico,New,Percentage,2,1.1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Puerto Rico,New,Percentage,2.1,1,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Puerto Rico,New,Percentage,2.1,1,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Puerto Rico,New,Percentage,2.2,1,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Puerto Rico,New,Percentage,2.2,0.96,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Qatar,New,Percentage,1.5,1.2,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Qatar,New,Percentage,1.6,1.2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Qatar,New,Percentage,1.6,1.2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Qatar,New,Percentage,1.7,1.3,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sudan,New,Percentage,2.8,1.8,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sudan,New,Percentage,2.7,1.7,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sudan,New,Percentage,2.7,1.6,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sudan,New,Percentage,2.6,1.5,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sudan,New,Percentage,2.6,1.4,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sudan,New,Percentage,2.6,1.3,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sudan,New,Percentage,2.6,1.1,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Suriname,New,Percentage,9.8,5.3,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Suriname,New,Percentage,9.7,5.7,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Suriname,New,Percentage,9.7,6.1,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Suriname,New,Percentage,9.7,6.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Suriname,New,Percentage,9.7,7.1,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Suriname,New,Percentage,9.8,7.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Suriname,New,Percentage,9.8,7.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Suriname,New,Percentage,9.9,7.3,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Suriname,New,Percentage,9.9,7,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Sweden,New,Percentage,2.7,2.3,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Sweden,New,Percentage,2.9,2.4,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Sweden,New,Percentage,3,2.5,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Sweden,New,Percentage,3.1,2.6,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Sweden,New,Percentage,3.3,2.7,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Sweden,New,Percentage,3.4,2.8,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Sweden,New,Percentage,3.6,2.8,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Sweden,New,Percentage,3.7,2.9,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Sweden,New,Percentage,3.9,3,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Switzerland,New,Percentage,1.8,1.3,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Switzerland,New,Percentage,1.9,1.3,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Switzerland,New,Percentage,2,1.3,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Switzerland,New,Percentage,2.1,1.4,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Switzerland,New,Percentage,2.2,1.4,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Switzerland,New,Percentage,2.3,1.4,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Switzerland,New,Percentage,2.4,1.5,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Switzerland,New,Percentage,2.5,1.5,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Switzerland,New,Percentage,2.6,1.5,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Syrian Arab Republic,New,Percentage,2.6,2.1,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Syrian Arab Republic,New,Percentage,2.4,1.9,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Syrian Arab Republic,New,Percentage,2.2,1.8,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Syrian Arab Republic,New,Percentage,2.1,1.6,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Syrian Arab Republic,New,Percentage,1.9,1.5,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Syrian Arab Republic,New,Percentage,1.7,1.4,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Syrian Arab Republic,New,Percentage,1.6,1.2,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Syrian Arab Republic,New,Percentage,1.5,1.1,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Syrian Arab Republic,New,Percentage,1.4,1,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tajikistan,New,Percentage,18,17,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tajikistan,New,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tajikistan,New,Percentage,20,19,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tajikistan,New,Percentage,21,20,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tajikistan,New,Percentage,22,21,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tajikistan,New,Percentage,23,22,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tajikistan,New,Percentage,24,23,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tajikistan,New,Percentage,25,24,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tajikistan,New,Percentage,26,25,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Thailand,New,Percentage,1.9,1.7,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Thailand,New,Percentage,1.9,1.8,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Thailand,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Thailand,New,Percentage,1.9,1.8,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Timor-Leste,New,Percentage,0.75,0.25,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Timor-Leste,New,Percentage,0.74,0.27,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Timor-Leste,New,Percentage,0.73,0.29,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Timor-Leste,New,Percentage,0.72,0.3,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Timor-Leste,New,Percentage,0.72,0.31,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Timor-Leste,New,Percentage,0.71,0.32,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Timor-Leste,New,Percentage,0.71,0.32,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Timor-Leste,New,Percentage,0.71,0.32,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Timor-Leste,New,Percentage,0.71,0.31,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Togo,New,Percentage,1.4,0.76,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Togo,New,Percentage,1.2,0.72,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Togo,New,Percentage,1,0.67,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Togo,New,Percentage,0.92,0.63,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Togo,New,Percentage,0.81,0.6,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Togo,New,Percentage,0.72,0.55,0.91
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Togo,New,Percentage,0.63,0.5,0.79
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Togo,New,Percentage,0.56,0.43,0.71
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Togo,New,Percentage,0.5,0.36,0.64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tokelau,New,Percentage,2,0.7,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tokelau,New,Percentage,2,0.75,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tokelau,New,Percentage,2,0.78,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tokelau,New,Percentage,2.1,0.8,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tokelau,New,Percentage,2.1,0.82,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tokelau,New,Percentage,2.1,0.82,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tokelau,New,Percentage,2.1,0.8,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tokelau,New,Percentage,2.2,0.77,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tokelau,New,Percentage,2.2,0.73,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tonga,New,Percentage,1.2,0.15,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tonga,New,Percentage,1.2,0.16,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tonga,New,Percentage,1.2,0.15,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tonga,New,Percentage,1.2,0.16,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tonga,New,Percentage,1.2,0.17,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tonga,New,Percentage,1.2,0.18,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tonga,New,Percentage,1.3,0.19,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tonga,New,Percentage,1.3,0.19,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tonga,New,Percentage,1.3,0.19,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Trinidad and Tobago,New,Percentage,1.1,0.24,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Trinidad and Tobago,New,Percentage,1.1,0.26,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Trinidad and Tobago,New,Percentage,1,0.28,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Trinidad and Tobago,New,Percentage,1,0.29,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Trinidad and Tobago,New,Percentage,1,0.28,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Trinidad and Tobago,New,Percentage,1,0.3,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Trinidad and Tobago,New,Percentage,1.1,0.31,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Trinidad and Tobago,New,Percentage,1.1,0.31,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Trinidad and Tobago,New,Percentage,1.1,0.28,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tunisia,New,Percentage,0.89,0.61,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tunisia,New,Percentage,0.92,0.66,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tunisia,New,Percentage,0.96,0.7,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tunisia,New,Percentage,1,0.74,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tunisia,New,Percentage,1,0.76,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tunisia,New,Percentage,1.1,0.79,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tunisia,New,Percentage,1.1,0.79,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tunisia,New,Percentage,1.2,0.79,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tunisia,New,Percentage,1.2,0.77,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Trkiye,New,Percentage,3.4,3.2,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Trkiye,New,Percentage,3.3,3.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Trkiye,New,Percentage,3.1,3,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Trkiye,New,Percentage,3,2.9,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Trkiye,New,Percentage,2.9,2.7,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Trkiye,New,Percentage,2.8,2.6,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Trkiye,New,Percentage,2.7,2.5,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Trkiye,New,Percentage,2.6,2.3,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Trkiye,New,Percentage,2.5,2.2,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Turkmenistan,New,Percentage,19,17,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Turkmenistan,New,Percentage,21,19,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Turkmenistan,New,Percentage,22,20,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Turkmenistan,New,Percentage,24,22,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Turkmenistan,New,Percentage,26,24,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Turkmenistan,New,Percentage,27,26,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Turkmenistan,New,Percentage,29,27,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Turkmenistan,New,Percentage,31,29,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Turkmenistan,New,Percentage,33,30,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Turks and Caicos Islands,New,Percentage,3.3,0.33,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Turks and Caicos Islands,New,Percentage,3.2,0.34,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Turks and Caicos Islands,New,Percentage,3.1,0.34,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Turks and Caicos Islands,New,Percentage,3,0.35,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Turks and Caicos Islands,New,Percentage,3,0.36,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Turks and Caicos Islands,New,Percentage,2.9,0.38,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Turks and Caicos Islands,New,Percentage,2.8,0.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Turks and Caicos Islands,New,Percentage,2.8,0.41,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Turks and Caicos Islands,New,Percentage,2.7,0.39,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Tuvalu,New,Percentage,1.8,0.32,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Tuvalu,New,Percentage,1.8,0.34,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Tuvalu,New,Percentage,1.8,0.35,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Tuvalu,New,Percentage,1.8,0.36,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Tuvalu,New,Percentage,1.8,0.38,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Tuvalu,New,Percentage,1.8,0.38,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Tuvalu,New,Percentage,1.8,0.39,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Tuvalu,New,Percentage,1.8,0.39,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Tuvalu,New,Percentage,1.8,0.38,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uganda,New,Percentage,1.1,0.93,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uganda,New,Percentage,1.1,0.95,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uganda,New,Percentage,1.1,0.97,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mali,Previously treated,Percentage,9.9,7.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mali,Previously treated,Percentage,9,7.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mali,Previously treated,Percentage,8.2,6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Malta,Previously treated,Percentage,8,0.75,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Malta,Previously treated,Percentage,8.2,0.81,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Malta,Previously treated,Percentage,8.5,0.9,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Malta,Previously treated,Percentage,8.9,0.98,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Malta,Previously treated,Percentage,9.3,0.97,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Malta,Previously treated,Percentage,9.7,1,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Malta,Previously treated,Percentage,10,1,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Malta,Previously treated,Percentage,11,1,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Malta,Previously treated,Percentage,11,1,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Marshall Islands,Previously treated,Percentage,7.3,1.5,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Marshall Islands,Previously treated,Percentage,7.7,1.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Marshall Islands,Previously treated,Percentage,8.1,1.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Marshall Islands,Previously treated,Percentage,8.6,2,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Marshall Islands,Previously treated,Percentage,9.1,2.3,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Marshall Islands,Previously treated,Percentage,9.7,2.6,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Marshall Islands,Previously treated,Percentage,10,2.8,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Marshall Islands,Previously treated,Percentage,11,2.8,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Marshall Islands,Previously treated,Percentage,12,2.8,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mauritania,Previously treated,Percentage,34,21,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mauritania,Previously treated,Percentage,36,24,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mauritania,Previously treated,Percentage,39,28,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mauritania,Previously treated,Percentage,41,33,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mauritania,Previously treated,Percentage,44,37,50
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mauritania,Previously treated,Percentage,46,41,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mauritania,Previously treated,Percentage,49,43,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mauritania,Previously treated,Percentage,52,44,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mauritania,Previously treated,Percentage,54,45,65
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mauritius,Previously treated,Percentage,6.4,1.9,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mauritius,Previously treated,Percentage,6,1.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mauritius,Previously treated,Percentage,5.7,1.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mauritius,Previously treated,Percentage,5.4,1.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mauritius,Previously treated,Percentage,5.2,1.7,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mauritius,Previously treated,Percentage,5,1.6,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mauritius,Previously treated,Percentage,4.8,1.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mauritius,Previously treated,Percentage,4.7,1.2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mauritius,Previously treated,Percentage,4.5,1.1,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mexico,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mexico,Previously treated,Percentage,13,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mexico,Previously treated,Percentage,13,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mexico,Previously treated,Percentage,13,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mexico,Previously treated,Percentage,14,12,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mexico,Previously treated,Percentage,14,12,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mexico,Previously treated,Percentage,14,12,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mexico,Previously treated,Percentage,15,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mexico,Previously treated,Percentage,15,12,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Micronesia (Federated States of),Previously treated,Percentage,12,0.59,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Micronesia (Federated States of),Previously treated,Percentage,11,0.68,46
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Micronesia (Federated States of),Previously treated,Percentage,10,0.69,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Micronesia (Federated States of),Previously treated,Percentage,9.9,0.74,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Micronesia (Federated States of),Previously treated,Percentage,9.5,0.77,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Micronesia (Federated States of),Previously treated,Percentage,9.1,0.73,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Micronesia (Federated States of),Previously treated,Percentage,8.8,0.69,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Micronesia (Federated States of),Previously treated,Percentage,8.5,0.69,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Micronesia (Federated States of),Previously treated,Percentage,8.3,0.64,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Monaco,Previously treated,Percentage,20,1.7,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Monaco,Previously treated,Percentage,19,1.8,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Monaco,Previously treated,Percentage,19,1.9,61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Monaco,Previously treated,Percentage,18,1.9,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Monaco,Previously treated,Percentage,17,1.9,58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Monaco,Previously treated,Percentage,17,1.9,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Monaco,Previously treated,Percentage,16,1.7,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Monaco,Previously treated,Percentage,16,1.6,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Monaco,Previously treated,Percentage,15,1.5,55
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mongolia,Previously treated,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mongolia,Previously treated,Percentage,17,16,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mongolia,Previously treated,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mongolia,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mongolia,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mongolia,Previously treated,Percentage,11,9.8,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mongolia,Previously treated,Percentage,9.9,8.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mongolia,Previously treated,Percentage,8.9,7.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mongolia,Previously treated,Percentage,8,6.7,9.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Montenegro,Previously treated,Percentage,8.8,4.5,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Montenegro,Previously treated,Percentage,8.2,4.2,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Montenegro,Previously treated,Percentage,7.7,3.8,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Montenegro,Previously treated,Percentage,7.3,3.4,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Montenegro,Previously treated,Percentage,6.8,3.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Montenegro,Previously treated,Percentage,6.5,2.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Montenegro,Previously treated,Percentage,6.1,2.6,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Montenegro,Previously treated,Percentage,5.8,2.3,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Montenegro,Previously treated,Percentage,5.4,2,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Montserrat,Previously treated,Percentage,18,1.2,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Montserrat,Previously treated,Percentage,17,1.3,59
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Montserrat,Previously treated,Percentage,16,1.4,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Montserrat,Previously treated,Percentage,16,1.4,53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Montserrat,Previously treated,Percentage,15,1.5,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Montserrat,Previously treated,Percentage,14,1.5,51
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Montserrat,Previously treated,Percentage,14,1.5,49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Montserrat,Previously treated,Percentage,14,1.4,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Montserrat,Previously treated,Percentage,13,1.3,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Morocco,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Morocco,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Morocco,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Morocco,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Morocco,Previously treated,Percentage,10,9.6,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Morocco,Previously treated,Percentage,9.8,9.1,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Morocco,Previously treated,Percentage,9.2,8.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Morocco,Previously treated,Percentage,8.7,7.8,9.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Morocco,Previously treated,Percentage,8.2,7.2,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Mozambique,Previously treated,Percentage,13,11,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Mozambique,Previously treated,Percentage,13,11,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Mozambique,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Mozambique,Previously treated,Percentage,13,11,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Mozambique,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Mozambique,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Mozambique,Previously treated,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Mozambique,Previously treated,Percentage,13,12,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Mozambique,Previously treated,Percentage,12,11,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Myanmar,Previously treated,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Myanmar,Previously treated,Percentage,19,18,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Myanmar,Previously treated,Percentage,19,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Myanmar,Previously treated,Percentage,19,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Myanmar,Previously treated,Percentage,19,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Myanmar,Previously treated,Percentage,18,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Myanmar,Previously treated,Percentage,18,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Myanmar,Previously treated,Percentage,18,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Myanmar,Previously treated,Percentage,18,18,19
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Namibia,Previously treated,Percentage,12,11,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Namibia,Previously treated,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Namibia,Previously treated,Percentage,10,9.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Namibia,Previously treated,Percentage,9.4,8.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Namibia,Previously treated,Percentage,8.6,7.9,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Namibia,Previously treated,Percentage,7.9,7.1,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Namibia,Previously treated,Percentage,7.3,6.5,8.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Namibia,Previously treated,Percentage,6.7,5.9,7.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Namibia,Previously treated,Percentage,6.1,5.3,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nauru,Previously treated,Percentage,11,0.73,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nauru,Previously treated,Percentage,11,0.84,40
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nauru,Previously treated,Percentage,11,0.9,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nauru,Previously treated,Percentage,11,0.94,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nauru,Previously treated,Percentage,10,0.96,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nauru,Previously treated,Percentage,10,0.99,35
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nauru,Previously treated,Percentage,11,1,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nauru,Previously treated,Percentage,11,0.95,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nauru,Previously treated,Percentage,11,0.92,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Nepal,Previously treated,Percentage,12,8.1,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Nepal,Previously treated,Percentage,11,7.6,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Nepal,Previously treated,Percentage,11,7.2,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Nepal,Previously treated,Percentage,10,6.8,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Nepal,Previously treated,Percentage,10,6.4,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Nepal,Previously treated,Percentage,9.7,6,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Nepal,Previously treated,Percentage,9.4,5.6,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Nepal,Previously treated,Percentage,9.1,5.3,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Nepal,Previously treated,Percentage,8.8,4.9,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Netherlands (Kingdom of the),Previously treated,Percentage,12,8.1,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Netherlands (Kingdom of the),Previously treated,Percentage,12,8.6,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Netherlands (Kingdom of the),Previously treated,Percentage,14,9.1,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Netherlands (Kingdom of the),Previously treated,Percentage,15,9.6,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Netherlands (Kingdom of the),Previously treated,Percentage,16,10,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Netherlands (Kingdom of the),Previously treated,Percentage,17,11,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Netherlands (Kingdom of the),Previously treated,Percentage,18,11,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Netherlands (Kingdom of the),Previously treated,Percentage,20,12,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Netherlands (Kingdom of the),Previously treated,Percentage,21,12,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,New Caledonia,Previously treated,Percentage,7.5,0.61,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,New Caledonia,Previously treated,Percentage,7.6,0.7,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,New Caledonia,Previously treated,Percentage,7.7,0.73,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,New Caledonia,Previously treated,Percentage,7.9,0.8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,New Caledonia,Previously treated,Percentage,8.1,0.86,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,New Caledonia,Previously treated,Percentage,8.4,0.95,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,New Caledonia,Previously treated,Percentage,8.7,1,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,New Caledonia,Previously treated,Percentage,9.1,1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,New Caledonia,Previously treated,Percentage,9.5,1.1,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,New Zealand,Previously treated,Percentage,14,4.4,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,New Zealand,Previously treated,Percentage,15,4.4,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,New Zealand,Previously treated,Percentage,16,4.3,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,New Zealand,Previously treated,Percentage,17,4.1,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,New Zealand,Previously treated,Percentage,18,3.8,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,New Zealand,Previously treated,Percentage,19,3.7,45
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,New Zealand,Previously treated,Percentage,20,3.6,48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,New Zealand,Previously treated,Percentage,21,3.6,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,New Zealand,Previously treated,Percentage,23,3.5,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Fiji,New,Percentage,1,0.55,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Fiji,New,Percentage,1.1,0.54,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Fiji,New,Percentage,1.1,0.53,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Fiji,New,Percentage,1.1,0.52,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Finland,New,Percentage,2.4,1.8,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Finland,New,Percentage,2.5,1.9,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Finland,New,Percentage,2.7,2.1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Finland,New,Percentage,2.9,2.2,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Finland,New,Percentage,3.2,2.3,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Finland,New,Percentage,3.4,2.4,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Finland,New,Percentage,3.7,2.5,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Finland,New,Percentage,4,2.6,5.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Finland,New,Percentage,4.3,2.7,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,France,New,Percentage,0.75,0.48,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,France,New,Percentage,0.74,0.45,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,France,New,Percentage,0.73,0.42,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,France,New,Percentage,0.71,0.4,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,France,New,Percentage,0.7,0.37,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,France,New,Percentage,0.69,0.35,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,France,New,Percentage,0.68,0.32,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,France,New,Percentage,0.66,0.31,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,France,New,Percentage,0.65,0.29,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,French Polynesia,New,Percentage,2.9,1.6,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,French Polynesia,New,Percentage,3.2,1.9,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,French Polynesia,New,Percentage,3.6,2.2,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,French Polynesia,New,Percentage,4,2.5,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,French Polynesia,New,Percentage,4.4,2.8,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,French Polynesia,New,Percentage,4.9,3,7.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,French Polynesia,New,Percentage,5.5,3.2,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,French Polynesia,New,Percentage,6.2,3.4,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,French Polynesia,New,Percentage,6.9,3.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Gabon,New,Percentage,5.9,2.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Gabon,New,Percentage,5.5,2.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Gabon,New,Percentage,5.1,2.4,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Gabon,New,Percentage,4.8,2.5,8.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Gabon,New,Percentage,4.5,2.7,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Gabon,New,Percentage,4.3,2.9,6.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Gabon,New,Percentage,4,3,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Gabon,New,Percentage,3.8,3.1,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Gabon,New,Percentage,3.6,3,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Gambia,New,Percentage,0.76,0.41,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Gambia,New,Percentage,0.76,0.41,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Gambia,New,Percentage,0.76,0.43,1.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Gambia,New,Percentage,0.76,0.43,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Gambia,New,Percentage,0.76,0.43,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Gambia,New,Percentage,0.76,0.43,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Gambia,New,Percentage,0.76,0.43,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Gambia,New,Percentage,0.76,0.43,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Gambia,New,Percentage,0.76,0.44,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Georgia,New,Percentage,12,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Georgia,New,Percentage,12,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Georgia,New,Percentage,12,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Georgia,New,Percentage,11,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Georgia,New,Percentage,11,11,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Georgia,New,Percentage,11,10,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Georgia,New,Percentage,11,9.9,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Georgia,New,Percentage,10,9.4,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Georgia,New,Percentage,9.9,8.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Germany,New,Percentage,1.9,1.5,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Germany,New,Percentage,1.9,1.5,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Germany,New,Percentage,2,1.5,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Germany,New,Percentage,2,1.5,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Germany,New,Percentage,2,1.5,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Germany,New,Percentage,2,1.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Germany,New,Percentage,2.1,1.4,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Germany,New,Percentage,2.1,1.4,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Germany,New,Percentage,2.1,1.4,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ghana,New,Percentage,2.3,1.9,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ghana,New,Percentage,2.2,1.9,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ghana,New,Percentage,2.1,1.9,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ghana,New,Percentage,2.1,1.9,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ghana,New,Percentage,2,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ghana,New,Percentage,1.9,1.8,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ghana,New,Percentage,1.8,1.7,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ghana,New,Percentage,1.8,1.6,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ghana,New,Percentage,1.7,1.6,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Greece,New,Percentage,3,1.7,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Greece,New,Percentage,2.8,1.6,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Greece,New,Percentage,2.7,1.5,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Greece,New,Percentage,2.5,1.3,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Greece,New,Percentage,2.4,1.2,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Greece,New,Percentage,2.3,1.1,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Greece,New,Percentage,2.2,0.98,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Greece,New,Percentage,2.1,0.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Greece,New,Percentage,2,0.81,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Greenland,New,Percentage,1.2,0.8,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Greenland,New,Percentage,1.3,0.85,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Greenland,New,Percentage,1.4,0.91,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Greenland,New,Percentage,1.5,0.95,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Greenland,New,Percentage,1.6,1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Greenland,New,Percentage,1.7,1.1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Greenland,New,Percentage,1.9,1.1,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Greenland,New,Percentage,2,1.2,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Greenland,New,Percentage,2.2,1.2,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Grenada,New,Percentage,3.3,0.44,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Grenada,New,Percentage,3.2,0.46,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Grenada,New,Percentage,3.1,0.47,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Grenada,New,Percentage,3.1,0.47,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Grenada,New,Percentage,3,0.49,9.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Grenada,New,Percentage,3,0.49,9.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Grenada,New,Percentage,3,0.49,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Grenada,New,Percentage,2.9,0.49,9.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Grenada,New,Percentage,2.9,0.49,9.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guam,New,Percentage,2.4,1.3,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guam,New,Percentage,2.5,1.4,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guam,New,Percentage,2.5,1.4,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guam,New,Percentage,2.5,1.4,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guam,New,Percentage,2.5,1.4,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guam,New,Percentage,2.5,1.4,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guam,New,Percentage,2.5,1.3,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guam,New,Percentage,2.6,1.3,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guam,New,Percentage,2.6,1.2,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guatemala,New,Percentage,2.5,2.1,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guatemala,New,Percentage,2.4,2,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guatemala,New,Percentage,2.3,2,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guatemala,New,Percentage,2.2,1.9,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guatemala,New,Percentage,2.2,1.8,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guatemala,New,Percentage,2.1,1.8,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guatemala,New,Percentage,2,1.7,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guatemala,New,Percentage,1.9,1.6,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guatemala,New,Percentage,1.9,1.5,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guinea,New,Percentage,1.6,0.2,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guinea,New,Percentage,1.5,0.21,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guinea,New,Percentage,1.4,0.21,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guinea,New,Percentage,1.4,0.19,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guinea,New,Percentage,1.3,0.19,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guinea,New,Percentage,1.3,0.19,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guinea,New,Percentage,1.3,0.19,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guinea,New,Percentage,1.2,0.18,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guinea,New,Percentage,1.2,0.17,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guinea-Bissau,New,Percentage,2,0.87,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guinea-Bissau,New,Percentage,2,0.93,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guinea-Bissau,New,Percentage,1.9,0.98,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guinea-Bissau,New,Percentage,1.8,1,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guinea-Bissau,New,Percentage,1.8,1.1,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guinea-Bissau,New,Percentage,1.7,1.1,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guinea-Bissau,New,Percentage,1.7,1.1,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guinea-Bissau,New,Percentage,1.6,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guinea-Bissau,New,Percentage,1.6,0.99,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guyana,New,Percentage,2.5,1.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guyana,New,Percentage,2.5,1.3,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guyana,New,Percentage,2.4,1.3,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guyana,New,Percentage,2.4,1.3,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guyana,New,Percentage,2.3,1.3,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guyana,New,Percentage,2.3,1.2,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guyana,New,Percentage,2.3,1.2,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guyana,New,Percentage,2.2,1.1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guyana,New,Percentage,2.2,1.1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Haiti,New,Percentage,3.7,0.45,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Haiti,New,Percentage,3.6,0.45,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Haiti,New,Percentage,3.5,0.47,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Haiti,New,Percentage,3.4,0.49,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Haiti,New,Percentage,3.3,0.49,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Haiti,New,Percentage,3.2,0.49,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Haiti,New,Percentage,3.2,0.49,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Haiti,New,Percentage,3.1,0.48,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Haiti,New,Percentage,3,0.46,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Honduras,New,Percentage,1.8,0.75,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Honduras,New,Percentage,1.8,0.69,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Honduras,New,Percentage,1.7,0.64,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Honduras,New,Percentage,1.7,0.59,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Honduras,New,Percentage,1.7,0.54,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Honduras,New,Percentage,1.7,0.5,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Honduras,New,Percentage,1.7,0.47,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Honduras,New,Percentage,1.7,0.44,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Honduras,New,Percentage,1.7,0.41,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Hungary,New,Percentage,3.6,2.8,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Hungary,New,Percentage,3.6,2.8,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Hungary,New,Percentage,3.7,2.9,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Hungary,New,Percentage,3.7,2.9,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Hungary,New,Percentage,3.8,2.9,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Hungary,New,Percentage,3.8,2.8,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Hungary,New,Percentage,3.8,2.8,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Hungary,New,Percentage,3.9,2.7,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Hungary,New,Percentage,3.9,2.7,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iceland,New,Percentage,1.1,0.24,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iceland,New,Percentage,1.1,0.24,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iceland,New,Percentage,1.1,0.22,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iceland,New,Percentage,1.1,0.21,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iceland,New,Percentage,1.1,0.2,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iceland,New,Percentage,1.1,0.19,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iceland,New,Percentage,1.1,0.18,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iceland,New,Percentage,1.1,0.18,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iceland,New,Percentage,1.1,0.17,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,India,New,Percentage,2.8,2.3,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,India,New,Percentage,2.8,2.4,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,India,New,Percentage,2.7,2.4,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,India,New,Percentage,2.7,2.5,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,India,New,Percentage,2.6,2.5,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,India,New,Percentage,2.6,2.5,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,India,New,Percentage,2.5,2.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,India,New,Percentage,2.5,2.3,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,India,New,Percentage,2.5,2.2,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Indonesia,New,Percentage,2.5,1.6,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Indonesia,New,Percentage,2.4,1.7,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Indonesia,New,Percentage,2.4,1.7,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Indonesia,New,Percentage,2.3,1.8,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Indonesia,New,Percentage,2.3,1.8,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Indonesia,New,Percentage,2.2,1.9,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Indonesia,New,Percentage,2.2,1.9,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guinea,Previously treated,Percentage,37,34,39
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guinea,Previously treated,Percentage,34,31,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guinea,Previously treated,Percentage,31,28,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guinea,Previously treated,Percentage,28,25,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guinea-Bissau,Previously treated,Percentage,52,27,77
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guinea-Bissau,Previously treated,Percentage,51,28,73
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guinea-Bissau,Previously treated,Percentage,50,29,71
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guinea-Bissau,Previously treated,Percentage,49,29,68
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guinea-Bissau,Previously treated,Percentage,48,29,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guinea-Bissau,Previously treated,Percentage,47,29,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guinea-Bissau,Previously treated,Percentage,46,30,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guinea-Bissau,Previously treated,Percentage,45,28,63
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guinea-Bissau,Previously treated,Percentage,44,26,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Guyana,Previously treated,Percentage,11,4.9,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Guyana,Previously treated,Percentage,9.7,5,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Guyana,Previously treated,Percentage,8.9,5.1,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Guyana,Previously treated,Percentage,8.1,5.1,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Guyana,Previously treated,Percentage,7.5,4.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Guyana,Previously treated,Percentage,6.9,4.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Guyana,Previously treated,Percentage,6.5,3.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Guyana,Previously treated,Percentage,6,2.8,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Guyana,Previously treated,Percentage,5.7,2.3,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Haiti,Previously treated,Percentage,22,1.3,67
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Haiti,Previously treated,Percentage,21,1.4,66
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Haiti,Previously treated,Percentage,20,1.6,64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Haiti,Previously treated,Percentage,19,1.6,60
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Haiti,Previously treated,Percentage,18,1.5,57
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Haiti,Previously treated,Percentage,17,1.6,56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Haiti,Previously treated,Percentage,17,1.5,54
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Haiti,Previously treated,Percentage,16,1.4,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Haiti,Previously treated,Percentage,15,1.3,52
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Honduras,Previously treated,Percentage,6.4,4.6,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Honduras,Previously treated,Percentage,5.8,4.2,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Honduras,Previously treated,Percentage,5.3,3.8,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Honduras,Previously treated,Percentage,4.8,3.3,6.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Honduras,Previously treated,Percentage,4.3,3,5.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Honduras,Previously treated,Percentage,3.9,2.6,5.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Honduras,Previously treated,Percentage,3.6,2.3,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Honduras,Previously treated,Percentage,3.3,2.1,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Honduras,Previously treated,Percentage,3,1.8,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Hungary,Previously treated,Percentage,11,7.3,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Hungary,Previously treated,Percentage,12,7.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Hungary,Previously treated,Percentage,13,7.7,18
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Hungary,Previously treated,Percentage,13,7.8,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Hungary,Previously treated,Percentage,14,7.6,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Hungary,Previously treated,Percentage,14,7.7,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Hungary,Previously treated,Percentage,15,7.8,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Hungary,Previously treated,Percentage,16,7.9,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Hungary,Previously treated,Percentage,16,7.9,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iceland,Previously treated,Percentage,10,1.4,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iceland,Previously treated,Percentage,10,1.4,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iceland,Previously treated,Percentage,11,1.4,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iceland,Previously treated,Percentage,11,1.4,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iceland,Previously treated,Percentage,11,1.4,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iceland,Previously treated,Percentage,11,1.5,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iceland,Previously treated,Percentage,12,1.5,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iceland,Previously treated,Percentage,12,1.4,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iceland,Previously treated,Percentage,13,1.3,37
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,India,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,India,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,India,Previously treated,Percentage,14,13,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,India,Previously treated,Percentage,14,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,India,Previously treated,Percentage,14,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,India,Previously treated,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,India,Previously treated,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,India,Previously treated,Percentage,13,13,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,India,Previously treated,Percentage,13,12,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Indonesia,Previously treated,Percentage,26,25,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Indonesia,Previously treated,Percentage,25,25,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Indonesia,Previously treated,Percentage,24,24,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Indonesia,Previously treated,Percentage,24,23,24
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Indonesia,Previously treated,Percentage,23,22,23
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Indonesia,Previously treated,Percentage,22,21,22
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Indonesia,Previously treated,Percentage,21,21,21
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Indonesia,Previously treated,Percentage,20,20,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Indonesia,Previously treated,Percentage,19,19,20
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iran (Islamic Republic of),Previously treated,Percentage,9.7,7.4,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iran (Islamic Republic of),Previously treated,Percentage,9.1,7.2,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iran (Islamic Republic of),Previously treated,Percentage,8.5,6.9,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iran (Islamic Republic of),Previously treated,Percentage,7.9,6.4,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iran (Islamic Republic of),Previously treated,Percentage,7.4,6,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iran (Islamic Republic of),Previously treated,Percentage,6.9,5.3,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iran (Islamic Republic of),Previously treated,Percentage,6.4,4.8,8.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iran (Islamic Republic of),Previously treated,Percentage,6,4.3,7.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iran (Islamic Republic of),Previously treated,Percentage,5.6,3.8,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Iraq,Previously treated,Percentage,26,22,30
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Iraq,Previously treated,Percentage,27,24,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Iraq,Previously treated,Percentage,29,26,32
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Iraq,Previously treated,Percentage,31,28,33
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Iraq,Previously treated,Percentage,32,30,34
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Iraq,Previously treated,Percentage,34,32,36
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Iraq,Previously treated,Percentage,36,33,38
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Iraq,Previously treated,Percentage,38,34,41
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Iraq,Previously treated,Percentage,39,36,44
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ireland,Previously treated,Percentage,5,2.4,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ireland,Previously treated,Percentage,5.3,2.5,8.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ireland,Previously treated,Percentage,5.7,2.6,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ireland,Previously treated,Percentage,6,2.6,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ireland,Previously treated,Percentage,6.4,2.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ireland,Previously treated,Percentage,6.8,2.6,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ireland,Previously treated,Percentage,7.2,2.6,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ireland,Previously treated,Percentage,7.7,2.6,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ireland,Previously treated,Percentage,8.2,2.5,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Israel,Previously treated,Percentage,19,10,31
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Israel,Previously treated,Percentage,18,8.9,29
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Israel,Previously treated,Percentage,16,7.7,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Israel,Previously treated,Percentage,14,6.6,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Botswana,New,Percentage,3.4,2.8,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Botswana,New,Percentage,3.5,2.9,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Botswana,New,Percentage,3.6,2.9,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Botswana,New,Percentage,3.7,2.9,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Botswana,New,Percentage,3.8,3,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Botswana,New,Percentage,3.9,3,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Botswana,New,Percentage,3.9,3,4.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Madagascar,New,Percentage,0.96,0.29,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uganda,New,Percentage,1.1,0.99,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uganda,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,New Caledonia,New,Percentage,0.91,0.28,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,New Caledonia,New,Percentage,0.92,0.3,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Somalia,New,Percentage,4.1,3.7,4.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Qatar,New,Percentage,1.7,1.3,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Qatar,New,Percentage,1.8,1.3,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Qatar,New,Percentage,1.8,1.3,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Qatar,New,Percentage,1.9,1.3,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Qatar,New,Percentage,2,1.4,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Republic of Korea,New,Percentage,3.3,3.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Republic of Korea,New,Percentage,3.3,3.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Fiji,New,Percentage,0.97,0.5,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Fiji,New,Percentage,1,0.53,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Botswana,New,Percentage,4,3.1,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Botswana,New,Percentage,4.1,3.1,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Brazil,New,Percentage,1.5,0.89,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Brazil,New,Percentage,1.5,0.83,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Brazil,New,Percentage,1.5,0.79,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Brazil,New,Percentage,1.6,0.74,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Brazil,New,Percentage,1.6,0.68,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Brazil,New,Percentage,1.6,0.63,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Brazil,New,Percentage,1.6,0.58,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Brazil,New,Percentage,1.6,0.55,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Brazil,New,Percentage,1.6,0.51,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,British Virgin Islands,New,Percentage,4.2,0.43,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,British Virgin Islands,New,Percentage,4.1,0.45,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,British Virgin Islands,New,Percentage,4,0.47,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,British Virgin Islands,New,Percentage,3.9,0.49,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,British Virgin Islands,New,Percentage,3.8,0.48,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,British Virgin Islands,New,Percentage,3.7,0.49,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,British Virgin Islands,New,Percentage,3.7,0.49,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,British Virgin Islands,New,Percentage,3.6,0.49,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,British Virgin Islands,New,Percentage,3.6,0.48,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Brunei Darussalam,New,Percentage,0.26,0.11,0.47
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Brunei Darussalam,New,Percentage,0.27,0.12,0.48
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Brunei Darussalam,New,Percentage,0.28,0.12,0.49
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Brunei Darussalam,New,Percentage,0.29,0.12,0.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Brunei Darussalam,New,Percentage,0.3,0.13,0.53
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Brunei Darussalam,New,Percentage,0.31,0.13,0.56
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Brunei Darussalam,New,Percentage,0.32,0.13,0.58
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Brunei Darussalam,New,Percentage,0.33,0.13,0.61
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Brunei Darussalam,New,Percentage,0.34,0.12,0.64
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Bulgaria,New,Percentage,2.5,1.9,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Bulgaria,New,Percentage,2.4,1.8,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Bulgaria,New,Percentage,2.3,1.7,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Bulgaria,New,Percentage,2.2,1.6,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Bulgaria,New,Percentage,2.2,1.4,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Bulgaria,New,Percentage,2.1,1.3,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Bulgaria,New,Percentage,2,1.3,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Bulgaria,New,Percentage,2,1.2,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Bulgaria,New,Percentage,1.9,1.1,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Burkina Faso,New,Percentage,2,1.3,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Burkina Faso,New,Percentage,1.8,1.3,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Burkina Faso,New,Percentage,1.7,1.2,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Burkina Faso,New,Percentage,1.5,1.2,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Burkina Faso,New,Percentage,1.4,1.1,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Burkina Faso,New,Percentage,1.3,1,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Burkina Faso,New,Percentage,1.2,0.89,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Burkina Faso,New,Percentage,1.1,0.77,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Burkina Faso,New,Percentage,0.98,0.67,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Burundi,New,Percentage,2.2,0.96,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Burundi,New,Percentage,2.1,1,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Burundi,New,Percentage,2,1.1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Burundi,New,Percentage,1.9,1.1,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Burundi,New,Percentage,1.9,1.1,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Burundi,New,Percentage,1.8,1.2,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Burundi,New,Percentage,1.7,1.2,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Burundi,New,Percentage,1.7,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Burundi,New,Percentage,1.6,1.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cabo Verde,New,Percentage,0.94,0.1,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cabo Verde,New,Percentage,0.9,0.11,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cabo Verde,New,Percentage,0.86,0.11,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cabo Verde,New,Percentage,0.83,0.11,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cabo Verde,New,Percentage,0.8,0.11,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cabo Verde,New,Percentage,0.77,0.11,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cabo Verde,New,Percentage,0.75,0.11,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cabo Verde,New,Percentage,0.73,0.11,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cabo Verde,New,Percentage,0.71,0.11,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cambodia,New,Percentage,1.6,0.91,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cambodia,New,Percentage,1.6,0.89,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cambodia,New,Percentage,1.6,0.86,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cambodia,New,Percentage,1.5,0.84,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cambodia,New,Percentage,1.5,0.81,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cambodia,New,Percentage,1.5,0.79,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cambodia,New,Percentage,1.5,0.77,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cambodia,New,Percentage,1.5,0.73,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cambodia,New,Percentage,1.5,0.71,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cameroon,New,Percentage,1.9,1.1,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cameroon,New,Percentage,1.8,1.1,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cameroon,New,Percentage,1.7,1,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cameroon,New,Percentage,1.6,0.98,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cameroon,New,Percentage,1.5,0.91,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cameroon,New,Percentage,1.4,0.83,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cameroon,New,Percentage,1.4,0.74,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cameroon,New,Percentage,1.3,0.67,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cameroon,New,Percentage,1.3,0.59,2.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Canada,New,Percentage,1.1,0.87,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Canada,New,Percentage,1.1,0.85,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Canada,New,Percentage,1.1,0.83,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Canada,New,Percentage,1.1,0.81,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Canada,New,Percentage,1.1,0.79,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Canada,New,Percentage,1.1,0.76,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Canada,New,Percentage,1.1,0.74,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Canada,New,Percentage,1.1,0.71,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Canada,New,Percentage,1.1,0.68,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cayman Islands,New,Percentage,1.4,0.21,5.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cayman Islands,New,Percentage,1.4,0.22,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cayman Islands,New,Percentage,1.4,0.22,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cayman Islands,New,Percentage,1.4,0.22,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cayman Islands,New,Percentage,1.4,0.22,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cayman Islands,New,Percentage,1.3,0.21,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cayman Islands,New,Percentage,1.3,0.21,5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Cayman Islands,New,Percentage,1.3,0.21,4.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Cayman Islands,New,Percentage,1.3,0.2,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Central African Republic,New,Percentage,1,0.18,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Central African Republic,New,Percentage,1.1,0.19,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Central African Republic,New,Percentage,1.1,0.19,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Central African Republic,New,Percentage,1.1,0.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Central African Republic,New,Percentage,1.2,0.21,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Central African Republic,New,Percentage,1.2,0.22,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Central African Republic,New,Percentage,1.3,0.23,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Central African Republic,New,Percentage,1.3,0.23,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Central African Republic,New,Percentage,1.4,0.22,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Chad,New,Percentage,1.9,0.87,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Chad,New,Percentage,1.9,0.95,3.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Chad,New,Percentage,1.8,1,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Chad,New,Percentage,1.7,1.1,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Chad,New,Percentage,1.6,1.2,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Chad,New,Percentage,1.6,1.3,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Chad,New,Percentage,1.5,1.3,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Chad,New,Percentage,1.5,1.2,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Chad,New,Percentage,1.5,1.1,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Chile,New,Percentage,1.8,1.5,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Chile,New,Percentage,1.8,1.6,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Chile,New,Percentage,1.9,1.7,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Chile,New,Percentage,2,1.8,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Chile,New,Percentage,2,1.8,2.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Chile,New,Percentage,2.1,1.9,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Chile,New,Percentage,2.2,1.9,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Chile,New,Percentage,2.2,1.9,2.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Chile,New,Percentage,2.3,2,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,China,New,Percentage,5.2,5,5.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,China,New,Percentage,4.9,4.7,5.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,China,New,Percentage,4.5,4.4,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,China,New,Percentage,4.2,4.1,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,China,New,Percentage,3.9,3.8,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,China,New,Percentage,3.7,3.6,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,China,New,Percentage,3.4,3.4,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,China,New,Percentage,3.2,3.1,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,China,New,Percentage,2.9,2.9,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"China, Hong Kong SAR",New,Percentage,0.96,0.86,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"China, Hong Kong SAR",New,Percentage,0.96,0.86,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"China, Hong Kong SAR",New,Percentage,0.96,0.85,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"China, Hong Kong SAR",New,Percentage,0.96,0.84,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"China, Hong Kong SAR",New,Percentage,0.97,0.84,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"China, Hong Kong SAR",New,Percentage,0.97,0.83,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"China, Hong Kong SAR",New,Percentage,0.97,0.82,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"China, Hong Kong SAR",New,Percentage,0.97,0.81,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"China, Hong Kong SAR",New,Percentage,0.97,0.8,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,"China, Macao SAR",New,Percentage,2.2,1.7,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,"China, Macao SAR",New,Percentage,2.2,1.7,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,"China, Macao SAR",New,Percentage,2.2,1.7,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,"China, Macao SAR",New,Percentage,2.2,1.6,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,"China, Macao SAR",New,Percentage,2.2,1.6,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,"China, Macao SAR",New,Percentage,2.2,1.6,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,"China, Macao SAR",New,Percentage,2.2,1.5,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,"China, Macao SAR",New,Percentage,2.2,1.5,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,"China, Macao SAR",New,Percentage,2.2,1.5,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Colombia,New,Percentage,3.5,1.7,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Colombia,New,Percentage,3.7,1.6,7.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Colombia,New,Percentage,3.9,1.6,8.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Colombia,New,Percentage,4.1,1.5,9.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Colombia,New,Percentage,4.3,1.5,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Colombia,New,Percentage,4.6,1.5,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Colombia,New,Percentage,4.8,1.5,12
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Colombia,New,Percentage,5.1,1.5,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Colombia,New,Percentage,5.4,1.4,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Comoros,New,Percentage,1.4,0.24,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Comoros,New,Percentage,1.3,0.26,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Comoros,New,Percentage,1.3,0.27,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Comoros,New,Percentage,1.3,0.28,3.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Comoros,New,Percentage,1.2,0.28,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Comoros,New,Percentage,1.2,0.3,3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Comoros,New,Percentage,1.2,0.3,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Comoros,New,Percentage,1.2,0.28,2.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Comoros,New,Percentage,1.2,0.26,2.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Congo,New,Percentage,3.1,0.38,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Congo,New,Percentage,2.9,0.38,11
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Congo,New,Percentage,2.8,0.38,10
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Congo,New,Percentage,2.7,0.37,9.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Congo,New,Percentage,2.6,0.37,9.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Congo,New,Percentage,2.5,0.35,8.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Congo,New,Percentage,2.4,0.34,8.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Congo,New,Percentage,2.3,0.33,8.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Congo,New,Percentage,2.2,0.32,8.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Cook Islands,New,Percentage,2.1,0.27,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Cook Islands,New,Percentage,2.1,0.29,7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Cook Islands,New,Percentage,2.2,0.29,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Cook Islands,New,Percentage,2.3,0.29,7.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Cook Islands,New,Percentage,2.4,0.31,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Cook Islands,New,Percentage,2.4,0.32,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Cook Islands,New,Percentage,2.5,0.32,8.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uganda,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uganda,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uganda,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uganda,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Ukraine,New,Percentage,24,24,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Ukraine,New,Percentage,25,24,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Ukraine,New,Percentage,25,25,25
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Ukraine,New,Percentage,26,25,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Ukraine,New,Percentage,26,26,26
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Ukraine,New,Percentage,27,26,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Ukraine,New,Percentage,27,27,27
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Ukraine,New,Percentage,27,27,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Ukraine,New,Percentage,28,27,28
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Arab Emirates,New,Percentage,1.2,0.16,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Arab Emirates,New,Percentage,1.2,0.16,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Arab Emirates,New,Percentage,1.2,0.17,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Arab Emirates,New,Percentage,1.2,0.18,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Arab Emirates,New,Percentage,1.3,0.19,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Arab Emirates,New,Percentage,1.3,0.2,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Arab Emirates,New,Percentage,1.3,0.21,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Arab Emirates,New,Percentage,1.4,0.21,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Arab Emirates,New,Percentage,1.4,0.22,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.5,1.4,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.5,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.6,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.6,1.4,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.6,1.5,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.7,1.5,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.7,1.5,1.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.7,1.5,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Kingdom of Great Britain and Northern Ireland,New,Percentage,1.8,1.5,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United Republic of Tanzania,New,Percentage,1.5,1.2,2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United Republic of Tanzania,New,Percentage,1.4,1.1,1.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United Republic of Tanzania,New,Percentage,1.4,1.1,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United Republic of Tanzania,New,Percentage,1.3,1.1,1.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United Republic of Tanzania,New,Percentage,1.2,1.1,1.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United Republic of Tanzania,New,Percentage,1.1,1,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United Republic of Tanzania,New,Percentage,1.1,0.98,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United Republic of Tanzania,New,Percentage,1,0.93,1.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United Republic of Tanzania,New,Percentage,0.94,0.87,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,United States of America,New,Percentage,1.6,1.5,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,United States of America,New,Percentage,1.6,1.5,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,United States of America,New,Percentage,1.5,1.5,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,United States of America,New,Percentage,1.5,1.4,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,United States of America,New,Percentage,1.5,1.4,1.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,United States of America,New,Percentage,1.5,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,United States of America,New,Percentage,1.5,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,United States of America,New,Percentage,1.5,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,United States of America,New,Percentage,1.5,1.4,1.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uruguay,New,Percentage,0.48,0.3,0.69
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uruguay,New,Percentage,0.51,0.32,0.71
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uruguay,New,Percentage,0.53,0.33,0.73
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uruguay,New,Percentage,0.56,0.36,0.77
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uruguay,New,Percentage,0.59,0.37,0.82
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uruguay,New,Percentage,0.62,0.37,0.89
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uruguay,New,Percentage,0.65,0.38,0.96
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uruguay,New,Percentage,0.69,0.38,1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uruguay,New,Percentage,0.73,0.38,1.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Uzbekistan,New,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Uzbekistan,New,Percentage,15,14,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Uzbekistan,New,Percentage,15,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Uzbekistan,New,Percentage,15,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Uzbekistan,New,Percentage,15,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Uzbekistan,New,Percentage,16,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Uzbekistan,New,Percentage,16,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Uzbekistan,New,Percentage,16,15,16
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Uzbekistan,New,Percentage,16,15,17
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Vanuatu,New,Percentage,1.9,0.67,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Vanuatu,New,Percentage,1.9,0.71,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Vanuatu,New,Percentage,1.9,0.76,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Vanuatu,New,Percentage,2,0.81,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Vanuatu,New,Percentage,2.1,0.88,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Vanuatu,New,Percentage,2.1,0.88,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Vanuatu,New,Percentage,2.2,0.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Vanuatu,New,Percentage,2.3,0.91,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Vanuatu,New,Percentage,2.4,0.91,4.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Venezuela (Bolivarian Republic of),New,Percentage,4.4,0.67,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Venezuela (Bolivarian Republic of),New,Percentage,4.3,0.68,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Venezuela (Bolivarian Republic of),New,Percentage,4.3,0.68,15
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Venezuela (Bolivarian Republic of),New,Percentage,4.2,0.71,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Venezuela (Bolivarian Republic of),New,Percentage,4.2,0.72,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Venezuela (Bolivarian Republic of),New,Percentage,4.1,0.73,14
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Venezuela (Bolivarian Republic of),New,Percentage,4.1,0.72,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Venezuela (Bolivarian Republic of),New,Percentage,4.1,0.69,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Venezuela (Bolivarian Republic of),New,Percentage,4,0.68,13
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Viet Nam,New,Percentage,3.6,3.3,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Viet Nam,New,Percentage,3.7,3.5,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Viet Nam,New,Percentage,3.8,3.6,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Viet Nam,New,Percentage,3.9,3.7,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Viet Nam,New,Percentage,4,3.9,4.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Viet Nam,New,Percentage,4.1,4,4.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Viet Nam,New,Percentage,4.2,4.1,4.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Viet Nam,New,Percentage,4.3,4.2,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Viet Nam,New,Percentage,4.4,4.3,4.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Wallis and Futuna,New,Percentage,1.7,0.15,7.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Wallis and Futuna,New,Percentage,1.7,0.15,7.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Wallis and Futuna,New,Percentage,1.7,0.17,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Wallis and Futuna,New,Percentage,1.7,0.18,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Wallis and Futuna,New,Percentage,1.7,0.18,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Wallis and Futuna,New,Percentage,1.7,0.21,6.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Wallis and Futuna,New,Percentage,1.7,0.22,6.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Wallis and Futuna,New,Percentage,1.7,0.22,6.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Wallis and Futuna,New,Percentage,1.8,0.21,7.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Yemen,New,Percentage,2.2,1.3,3.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Yemen,New,Percentage,2.2,1.2,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Yemen,New,Percentage,2.1,1.1,3.5
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Yemen,New,Percentage,2.1,1.1,3.6
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Yemen,New,Percentage,2,1,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Yemen,New,Percentage,2,0.94,3.8
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Yemen,New,Percentage,2,0.87,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Yemen,New,Percentage,2,0.81,3.9
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Yemen,New,Percentage,1.9,0.75,4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Zambia,New,Percentage,1.9,1.5,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Zambia,New,Percentage,1.9,1.4,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Zambia,New,Percentage,1.9,1.4,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Zambia,New,Percentage,1.9,1.4,2.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2015,Zimbabwe,New,Percentage,5.3,4.6,6.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2016,Zimbabwe,New,Percentage,4.6,4.1,5.2
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2017,Zimbabwe,New,Percentage,4,3.6,4.4
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2018,Zimbabwe,New,Percentage,3.4,3.2,3.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2019,Zimbabwe,New,Percentage,3,2.8,3.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2020,Zimbabwe,New,Percentage,2.6,2.4,2.7
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2021,Zimbabwe,New,Percentage,2.2,2.1,2.3
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2022,Zimbabwe,New,Percentage,1.9,1.8,2.1
8B98E3538B643F,TB_e_rr_prct,Estimated percentage of TB cases with rifampicin resistance,2023,Zimbabwe,New,Percentage,1.6,1.5,1.8
